<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Apoptosis</journal-id><journal-id journal-id-type="iso-abbrev">Apoptosis</journal-id><journal-id journal-id-type="pmc-domain-id">365</journal-id><journal-id journal-id-type="pmc-domain">springeropen</journal-id><journal-title-group><journal-title>Apoptosis</journal-title></journal-title-group><issn pub-type="ppub">1360-8185</issn><issn pub-type="epub">1573-675X</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>Springer</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12474643</article-id><article-id pub-id-type="pmcid-ver">PMC12474643.1</article-id><article-id pub-id-type="pmcaid">12474643</article-id><article-id pub-id-type="pmcaiid">12474643</article-id><article-id pub-id-type="pmid">40721981</article-id><article-id pub-id-type="doi">10.1007/s10495-025-02155-4</article-id><article-id pub-id-type="publisher-id">2155</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Mitochondrial bioenergetics and networks in melanoma: an update</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Giannitti</surname><given-names initials="G">Gaia</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Paganoni</surname><given-names initials="AJJ">Alyssa Julia Jennifer</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Marchesi</surname><given-names initials="S">Sara</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Garavaglia</surname><given-names initials="R">Riccardo</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Fontana</surname><given-names initials="F">Fabrizio</given-names></name><address><email>fabrizio.fontana@unimi.it</email></address><xref ref-type="aff" rid="Aff1"/></contrib><aff id="Aff1"><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00wjc7c48</institution-id><institution-id institution-id-type="GRID">grid.4708.b</institution-id><institution-id institution-id-type="ISNI">0000 0004 1757 2822</institution-id><institution>Department of Pharmacological and Biomolecular Sciences &#8220;Rodolfo Paoletti&#8221;, </institution><institution>Universit&#224; Degli Studi di Milano, </institution></institution-wrap>Milan, Italy </aff></contrib-group><pub-date pub-type="epub"><day>28</day><month>7</month><year>2025</year></pub-date><pub-date pub-type="ppub"><year>2025</year></pub-date><volume>30</volume><issue>9-10</issue><issue-id pub-id-type="pmc-issue-id">497685</issue-id><fpage>2042</fpage><lpage>2056</lpage><history><date date-type="accepted"><day>14</day><month>7</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>28</day><month>07</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>28</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-28 13:25:37.627"><day>28</day><month>09</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article&#8217;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#8217;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="10495_2025_Article_2155.pdf"/><abstract id="Abs1"><p id="Par1">Melanoma&#160;is the most aggressive and deadly form of skin cancer. However, advances in the understanding of its biology have led to the development of several new therapeutic approaches. One of these novel treatment strategies is based on the targeting of the mitochondrial bioenergetic and networks responsible for tumor initiation and progression. Indeed, it has recently emerged that changes in mitochondrial metabolism, dynamics, redox homeostasis, and apoptosis are strictly associated with tumor growth, metastasis, and drug resistance. In this review, we summarize current evidence about the multiple biological functions exerted by mitochondria in melanoma, also focusing on the role of these organelles as promising targets for pharmacological intervention.</p></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Melanoma</kwd><kwd>Mitochondrial metabolism</kwd><kwd>Mitochondrial dynamics</kwd><kwd>Redox homeostasis</kwd><kwd>Apoptosis</kwd><kwd>Cancer therapy</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">https://doi.org/10.13039/501100003407</institution-id><institution>Ministero dell&#8217;Istruzione, dell&#8217;Universit&#224; e della Ricerca</institution></institution-wrap></funding-source><award-id>Progetto di Eccellenza</award-id><principal-award-recipient><name name-style="western"><surname>Fontana</surname><given-names>Fabrizio</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">https://doi.org/10.13039/100012352</institution-id><institution>Universit&#224; degli Studi di Milano</institution></institution-wrap></funding-source><award-id>PSR2023</award-id><principal-award-recipient><name name-style="western"><surname>Fontana</surname><given-names>Fabrizio</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; Springer Science+Business Media, LLC, part of Springer Nature 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par2">Melanoma is the deadliest form of skin cancer [<xref ref-type="bibr" rid="CR1">1</xref>]. Although it can be effectively treated with surgical removal when detected early at the primary site, its prognosis significantly worsens at advanced stages [<xref ref-type="bibr" rid="CR2">2</xref>]. Current treatments for metastatic melanoma&#8212;such as BRAF and mitogen-activated protein kinase kinase (MEK) inhibitors, as well as immune checkpoint blockade&#8212;show inconsistent response rates, and most patients eventually develop resistance to these therapies [<xref ref-type="bibr" rid="CR2">2</xref>]. This highlights an urgent need to uncover the biological mechanisms driving melanoma aggressive behavior. In this regard, recent research has been focused on the study of the metabolic features of melanoma cells. In particular, alterations in mitochondrial bioenergetics and networks have been linked to cancer metastasis and drug resistance [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR4">4</xref>]. In the present article, we provide an overview of the different roles played by mitochondria in melanoma development and evolution. Specifically, the function of these organelles in determining metabolic plasticity and redox homeostasis is discussed, together with their ability to regulate apoptosis. The molecular bases of mitochondrial dynamics and quality control are also summarized, with particular emphasis on their involvement in the determination of melanoma cell state and fate. Finally, we explore how targeting mitochondria could be exploited for therapeutic benefit.</p></sec><sec id="Sec2"><title>Mitochondrial metabolism in melanoma</title><p id="Par3">As extensively reviewed in [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR6">6</xref>], melanoma exhibits profound metabolic reprogramming involving glycolysis, fatty acid &#946;-oxidation (FAO), and amino acid catabolism through oxidative deamination and transamination. Regardless of the carbon source, intermediates from these pathways feed into the tricarboxylic acid (TCA) cycle, generating substrates for the electron transport chain (ETC) to fuel oxidative phosphorylation (OXPHOS) [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR4">4</xref>]. Notably, both the TCA cycle and OXPHOS are dysregulated in melanoma.</p><p id="Par4">The TCA cycle, located in the mitochondrial matrix, serves as a central hub for catabolic and anabolic processes [<xref ref-type="bibr" rid="CR7">7</xref>]. Among its enzymes, isocitrate dehydrogenase 2 (IDH2) has emerged as a key player in melanomagenesis. Indeed, recent studies have identified sporadic mutations in <italic toggle="yes">IDH</italic> genes in melanoma, suggesting they may confer a growth advantage, mainly in BRAF-mutant tumors [<xref ref-type="bibr" rid="CR8">8</xref>&#8211;<xref ref-type="bibr" rid="CR10">10</xref>]. In particular, IDH2 and the cytosolic isozyme IDH1 appear to be relevant under hypoxic conditions, where they drive a reversal of TCA flux through reductive carboxylation, shifting lipid biosynthesis from glucose to glutamine dependence [<xref ref-type="bibr" rid="CR11">11</xref>&#8211;<xref ref-type="bibr" rid="CR13">13</xref>]. Similarly, other enzymes regulating the TCA cycle, such as pyruvate dehydrogenase subunit 1 (PDHA1) and oxoglutarate dehydrogenase (OGDH), are found to be hyperactivated in melanoma, highlighting the importance of citrate metabolism in shaping the tumor metabolic landscape [<xref ref-type="bibr" rid="CR14">14</xref>]. Despite these observations, recent research has shown that high amounts of citric acid inhibit the growth of different tumor types, mainly by disrupting ATP production, inactivating the insulin-like growth factor 1 receptor (IGF-1R)/Akt pathway and stimulating cell death via downregulation of the anti-apoptotic proteins B-cell lymphoma-extra large (Bcl-xL) and myeloid cell leukemia-1 (Mcl-1) [<xref ref-type="bibr" rid="CR15">15</xref>]; in melanoma, elevated doses of this metabolite have been demonstrated to suppress cell proliferation and promote UV-induced apoptosis by blockade of the glycogen synthase kinase-3 beta (GSK3&#946;)/&#946;-catenin pathway [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR17">17</xref>]. Overall, these seemingly contradictory effects suggest a dose-dependent role for citrate, making it a potential therapeutic target and/or agent in melanoma.</p><p id="Par5">Mitochondria are the primary cellular consumers of oxygen, which is mainly utilized in adenosine triphosphate (ATP) production via OXPHOS [<xref ref-type="bibr" rid="CR18">18</xref>]. Under hypoxic conditions, cells switch from OXPHOS to glycolysis to maintain energy homeostasis [<xref ref-type="bibr" rid="CR18">18</xref>]. In 1956, Otto Warburg described a hallmark of cancer metabolism: the tendency of tumor cells to favor glycolysis over OXPHOS even in the presence of oxygen&#8212;a phenomenon known as &#8220;aerobic glycolysis&#8221; or the &#8220;Warburg effect&#8221; [<xref ref-type="bibr" rid="CR18">18</xref>]. Like many cancers, melanoma demonstrates this metabolic phenotype [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR19">19</xref>&#8211;<xref ref-type="bibr" rid="CR21">21</xref>]. In particular, in melanoma cells aerobic glycolysis is driven by oncogenic activation and loss of tumor suppressors. For example, BRAF mutations, present in nearly 60% of melanomas, enhance glycolytic flux via stabilization of hypoxia-inducible factor 1&#945; (HIF1&#945;) and simultaneous inhibition of mitochondrial respiration through suppression of the microphthalmia-associated transcription factor (MITF)/peroxisome proliferator-activated receptor-&#947; coactivator 1&#945; (PGC-1&#945;) pathway [<xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR23">23</xref>]. Similarly, mutations in phosphate and tensin homolog (PTEN)&#8212;which occur in 40&#8211;60% of melanomas&#8212;lead to persistent Akt activation, upregulating glucose uptake and consumption through increased expression of glucose transporter type 1 (GLUT1), hexokinase 2 (HK2), phosphofructokinase 1 (PFK-1) and lactate dehydrogenase A (LDH-A) [<xref ref-type="bibr" rid="CR24">24</xref>]. However, growing evidence suggests that OXPHOS remains active and even upregulated during melanoma progression, despite the Warburg effect [<xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR26">26</xref>]. Rather than adhering strictly to one metabolic strategy, melanoma cells display a hybrid phenotype that allows flexibility in response to fluctuating nutrient and oxygen availability. When glucose is scarce, cells rely more on mitochondrial respiration; under hypoxia, they shift toward glycolysis, resulting in uncoupled OXPHOS activity [<xref ref-type="bibr" rid="CR11">11</xref>]. This metabolic heterogeneity is spatially reflected within tumors: cells in poorly vascularized cores primarily depend on glycolysis, while those at better-perfused peripheries favor OXPHOS [<xref ref-type="bibr" rid="CR26">26</xref>]. Intriguingly, these distinct cellular populations may cooperate metabolically: glycolysis-derived lactate from hypoxic cells can be taken up by neighboring cells to fuel their mitochondria [<xref ref-type="bibr" rid="CR26">26</xref>]. Adding further complexity, melanoma-associated fibroblasts (MAFs) also contribute to tumor metabolism by entering a catabolic state and secreting metabolites that support the anabolic needs of cancer cells [<xref ref-type="bibr" rid="CR27">27</xref>&#8211;<xref ref-type="bibr" rid="CR29">29</xref>]. This dynamic interplay of metabolic pathways&#8212;termed &#8220;metabolic plasticity&#8221;&#8212;is illustrated in Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>.<fig id="Fig1" position="float" orientation="portrait"><label>Fig. 1</label><caption><p>Melanoma is characterized by metabolic plasticity. In 1956, Otto Warburg reported that, in contrast to non-malignant cells, cancer cells display a glycolytic phenotype characterized by high lactate production and low oxygen consumption even in normoxic conditions. However, in the last years it has clearly emerged that melanoma cells have a hybrid phenotype, in which mitochondrial respiration is still functional, allowing high flexibility and plasticity</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e323" position="float" orientation="portrait" xlink:href="10495_2025_2155_Fig1_HTML.jpg"/></fig></p><p id="Par6">As noted earlier, melanoma cells exhibit a remarkable ability to reprogram their metabolism in response to a wide range of both intracellular and extracellular stimuli. In this scenario, both glutaminolysis and FAO play a pivotal role in sustaining the activity of the TCA cycle and OXPHOS. Focusing on the first, melanoma cells often exhibit a strong dependency on glutamine, a phenomenon commonly referred to as "glutamine addiction". This is largely driven by cataplerotic reactions involving glutamate and asparagine, which serve to replenish TCA cycle intermediates while also supporting the synthesis of nucleotides, amino acids, and other macromolecules [<xref ref-type="bibr" rid="CR30">30</xref>]. Notably, this reliance on glutamine metabolism becomes even more pronounced during the development of resistance to targeted therapies, indicating a metabolic shift that supports cell survival upon drug-induced stress [<xref ref-type="bibr" rid="CR31">31</xref>]. Turning to FAO, this pathway similarly contributes to melanoma cell proliferation, particularly under conditions of glucose deprivation; in particular, it provides an alternative energy source that helps maintain ATP production and redox balance [<xref ref-type="bibr" rid="CR32">32</xref>]. Beyond its role in energy metabolism, FAO has also been implicated in enhancing the migratory capacity of melanoma cells, especially those that are resistant to anoikis, a form of programmed cell death triggered by detachment from the extracellular matrix [<xref ref-type="bibr" rid="CR33">33</xref>, <xref ref-type="bibr" rid="CR34">34</xref>]. Moreover, FAO modulates the response of BRAF-mutant melanoma cells to MAPK pathway inhibitors, thereby contributing to therapeutic resistance and disease progression [<xref ref-type="bibr" rid="CR35">35</xref>]. Taken together, this evidence points to a dual dependency in melanoma metabolism, where both glutamine and fatty acid catabolism is crucial for energy production and survival under stress. Clinically, this opens the door to combination strategies (<italic toggle="yes">i.e.</italic> BRAF or MAPK inhibitors with metabolic inhibitors targeting glutaminase or FAO enzymes) that may prevent or delay drug resistance, improve treatment efficacy, and potentially impair metastatic spread.</p><p id="Par7">Within melanoma microenvironment, metabolic plasticity also orchestrates the interactions between cancer cells and immune components. Specifically, the upregulation of glycolysis in melanoma cells produces a glucose-deprived microenvironment, contributing to the functional exhaustion of CD4&#8201;+&#8201;T lymphocytes [<xref ref-type="bibr" rid="CR36">36</xref>, <xref ref-type="bibr" rid="CR37">37</xref>]. Additionally, the accumulation of lactate is associated with a marked reduction in both the number and activity of cytotoxic CD8&#8201;+&#8201;T cells and natural killer (NK) cells as well as with the polarization of macrophages toward an immunosuppressive, pro-tumoral M2-like phenotype characterized by increased vascular endothelial growth factor (VEGF) expression [<xref ref-type="bibr" rid="CR38">38</xref>, <xref ref-type="bibr" rid="CR39">39</xref>]. However, tumor cells with high OXPHOS levels have also been shown to correlate with resistance to anti-PD-1 immunotherapy; indeed, they seem to promote the development of a hypoxic stroma, culminating in the dedifferentiation and impaired activation of T cells [<xref ref-type="bibr" rid="CR40">40</xref>]. These immunosuppressive effects highlight how tumor-derived mitochondrial alterations can hinder antitumor immunity. Consequently, strategies aimed at targeting metabolic reprogramming may enhance the effectiveness of immunotherapeutic approaches in melanoma.</p></sec><sec id="Sec3"><title>Mitochondrial dynamics and quality control in melanoma</title><p id="Par8">Mitochondrial dynamics encompass biogenesis, fission, fusion, and mitophagy&#8212;processes essential for maintaining mitochondrial quality control and overall cellular health [<xref ref-type="bibr" rid="CR30">30</xref>]. These mechanisms play critical roles in melanoma initiation and progression (Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>).<fig id="Fig2" position="float" orientation="portrait"><label>Fig. 2</label><caption><p>Mitochondrial dynamics are dysregulated during melanoma development and progression. Mitochondria are highly dynamic organelles undergoing continuous processes of biogenesis, fission, fusion, and mitophagy. In melanoma, PGC-1&#945;-driven mitochondrial biogenesis is activated in proliferative tumors, cancer stem cells, and after BRAF or MAPK pharmacological inhibition, while being suppressed during metastasis. Drp1, the main regulator of mitochondrial fission, is upregulated upon Ras-induced malignant transformation, while being inactivated by MAPK inhibitors. Mfn1-related mitochondrial fusion correlates with a senescence-associated secretory phenotype; on the other hand, Mfn2 is degraded in cancer cells undergoing ER stress, leading to mitophagy. Regarding the latter, it seems to be non-canonical, with Parkin being absent in NRAS-mutant malignancies and BNIP3 being overexpressed in hypoxic conditions</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e381" position="float" orientation="portrait" xlink:href="10495_2025_2155_Fig2_HTML.jpg"/></fig></p><p id="Par9">PGC-1&#945; is a key transcriptional coactivator regulating mitochondrial biogenesis [<xref ref-type="bibr" rid="CR41">41</xref>]. Upon nuclear translocation, it activates nuclear respiratory factors (Nrf1 and Nrf2) and mitochondrial transcription factor A (TFAM), promoting mitochondrial protein synthesis and organelle proliferation. PGC-1&#945; also interacts with various nuclear receptors&#8212;peroxisome proliferator-activated receptors (PPARs), estrogen-related receptors &#945; (ERRs), hepatic nuclear factors (HNFs), liver X receptors (LXRs), farnesoid X receptor (FXR), retinoic acid receptor (RAR&#945;), and the glucocorticoid receptor&#8212;to influence cellular energy metabolism beyond the mitochondria [<xref ref-type="bibr" rid="CR42">42</xref>]. Remarkably,&#160;Vazquez et al. have recently reported that PGC-1&#945; is overexpressed in a subset of melanomas displaying MITF activation, where it correlates with improved tolerance to the damaging effects of reactive oxygen species (ROS) and increased ability to survive under conditions of oxidative stress [<xref ref-type="bibr" rid="CR43">43</xref>]. Intriguingly, PGC-1&#945; expression also displays high intratumor heterogeneity, with cellular populations with low levels of this protein displaying a pro-metastatic gene program and subgroups with high PGC-1&#945; activity driving a proliferating phenotype [<xref ref-type="bibr" rid="CR44">44</xref>&#8211;<xref ref-type="bibr" rid="CR46">46</xref>]. In line with these reports, this transcriptional coactivator has been found to be upregulated in the melanoma stem cell niche, highlighting the cruciality of mitochondrial content in determining tumor relapse [<xref ref-type="bibr" rid="CR47">47</xref>]. Finally, increased MITF/PGC-1&#945;-driven OXPHOS has been observed after treatment with BRAF and mitogen-activated protein kinase (MAPK) inhibitors [<xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR48">48</xref>&#8211;<xref ref-type="bibr" rid="CR50">50</xref>]. Collectively, these observations highlight the ability of mitochondrial biogenesis to redirect melanoma metabolic phenotypes and confer a significant survival advantage to cancer cells; thus, understanding the context-dependent role of this process should be considered of primary importance in developing effective targeted therapies.</p><p id="Par10">Mitochondrial shape, tightly controlled by the balance of fission and fusion, reflects and regulates metabolic activity and apoptosis [<xref ref-type="bibr" rid="CR51">51</xref>]. Fission is mediated by Drp1, which relocates to the mitochondrial outer membrane (MOM) and interacts with fission-1 (Fis1) and mitochondrial fission factor (Mff). Fusion involves mitofusin 1/2 (Mfn1/2) on the MOM and optic atrophy 1 (OPA1) on the inner membrane [<xref ref-type="bibr" rid="CR51">51</xref>]. Notably, mitochondrial morphology transitions regulate melanin synthesis via ROS generation in melanocytes [<xref ref-type="bibr" rid="CR52">52</xref>, <xref ref-type="bibr" rid="CR53">53</xref>]. In melanoma, Drp1-dependent mitochondrial division is required for RAS-induced malignant transformation [<xref ref-type="bibr" rid="CR54">54</xref>]. In addition, it is inhibited by MAPK pathway inhibitors, leading to mitochondrial superfusion and enhanced oxidative capacity [<xref ref-type="bibr" rid="CR55">55</xref>, <xref ref-type="bibr" rid="CR56">56</xref>]. On the other hand, Mfn1 knockdown suppresses melanoma senescence-associated secretory phenotype (SASP), delaying tumor growth after chemotherapy and promoting immune cell recruitment [<xref ref-type="bibr" rid="CR57">57</xref>]. In light of these considerations, any disruption of the balance between fusion and fission can profoundly affect the development, progression, and treatment of melanoma. Therefore, the design of drugs selectively targeting mitochondrial shape represents a promising avenue for melanoma therapy; as discussed later in this manuscript, this can be realized either by re-establishing fusion/fission homeostasis to block cell proliferation, migration, and drug resistance, or by altering fusion/fission balance to induce apoptosis.</p><p id="Par11">Mitophagy, a selective form of autophagy, clears damaged mitochondria to maintain cellular homeostasis [<xref ref-type="bibr" rid="CR58">58</xref>]. The PTEN-induced kinase 1 (PINK1)/parkin pathway is the best-characterized mitophagic mechanism: under stress, PINK1 accumulates on mitochondrial surface, recruits and phosphorylates parkin, and triggers ubiquitination of MOM proteins, leading to mitophagosome formation via the microtubule-associated protein light chain 3 (LC3)-mediated interactions with adaptor proteins, such as p62 [<xref ref-type="bibr" rid="CR58">58</xref>]. Of note, parkin protein is expressed in melanocytes but not in melanoma cells, and its expression decreases upon melanocyte transformation by NRAS mutation; downregulation of parkin in melanocytes stimulates their proliferation, while its re-expression in melanoma leads to cell cycle arrest [<xref ref-type="bibr" rid="CR59">59</xref>]. This has raised the hypothesis that parkin might function as tumor suppressor in melanoma. Furthermore, it seems to suggest that in this tumor the mitophagic flux might be PINK1/parkin-independent. In this regard, Vara&#8208;P&#233;rez and colleagues have demonstrated that Bcl-2-interacting protein 3 (BNIP3), which can recruit LC3 irrespective of PINK1/parkin cascade initiation, is activated in response to hypoxia [<xref ref-type="bibr" rid="CR60">60</xref>]; this results in mitophagy induction, which alleviates ROS-associated mitochondrial dysfunction and enhances OXPHOS, while parallelly inhibiting glycolysis via impairment of HIF-1&#945; stability [<xref ref-type="bibr" rid="CR60">60</xref>, <xref ref-type="bibr" rid="CR61">61</xref>]. Likewise, Wang and coworkers have shown that, under endoplasmic reticulum (ER) stress, the unfolded protein response (UPR) induces the transcription of mitochondrial E3 ubiquitin-protein ligase (MARCH5) to promote the ubiquitination and degradation of Mfn2, resulting in the activation of non-canonical pro-survival mitophagy [<xref ref-type="bibr" rid="CR62">62</xref>]. Despite still scanty, these preliminary studies highlight that mitochondrial biogenesis, dynamics, and mitophagy are all implicated in melanoma onset and evolution. Importantly, the three mitochondrial processes are interrelated, indicating that their dynamic interplay might hide great potential as therapeutic target. Based on these premises, further research is encouraged to dissect the complex function of mitophagy in melanomagenesis.</p><p id="Par12">As discussed above, mitochondrial integrity is preserved via mitochondrial biogenesis, activated in response to context-specific cellular demands, and mitophagy, triggered by mitochondrial dysfunction [<xref ref-type="bibr" rid="CR41">41</xref>]. If mitochondrial damage prevention and repair fail, cells can exchange copies of mtDNA, which encodes the peptides essential for OXPHOS [<xref ref-type="bibr" rid="CR63">63</xref>, <xref ref-type="bibr" rid="CR64">64</xref>]. Intriguingly, mitochondrial transfer from the endothelium to melanoma has been found to promote cancer cell proliferation via Nrf2/HO-1 pathway and to induce M2 macrophage polarization [<xref ref-type="bibr" rid="CR65">65</xref>]. Moreover, human melanoma cells can attract bone marrow-derived mesenchymal stem cells (MSCs) to the primary tumor site, stimulating mitochondrial biogenesis in the latter through PGC-1&#945; upregulation; mitochondria are then taken up by tumor cells via direct contact with MSCs [<xref ref-type="bibr" rid="CR66">66</xref>]. Likewise, MSCs in mouse melanoma microenvironment can directly transmit mtDNA to mitochondria-deprived cancer cells, conferring respiration rates similar to those of their parental counterpart [<xref ref-type="bibr" rid="CR67">67</xref>]. Of course, further studies are required to validate the role of mitochondrial trafficking in the clinical setting.</p><p id="Par13">Mitochondria-derived vesicles (MDVs) are&#160;a type of extracellular vesicles (EVs) that originate from mitochondria.&#160;They are formed from mitochondrial sub-compartments and released into the cytosol, and can also be incorporated into larger EVs and excreted from the cell.&#160;MDVs are deeply implicated in mitochondrial quality control, intercellular communication, and potentially in various diseases.&#160;In this regard, it should be noted that functional mitochondria are actively transported by melanoma EVs and lipidosomes, influencing both donor and recipient cells and significantly impacting tumor growth and dissemination [<xref ref-type="bibr" rid="CR68">68</xref>, <xref ref-type="bibr" rid="CR69">69</xref>]. Moreover, it has been recently reported that adipocyte-derived EVs containing mitochondrial proteins involved in FAO are transferred to melanoma, thus fueling cancer metastasis; interestingly, this might in part explain why obese melanoma patients have a poorer prognosis than non-obese subjects [<xref ref-type="bibr" rid="CR70">70</xref>]. Although still preliminary, this evidence suggests that pharmacologically blocking MDV formation or altering EV content might prevent tumor progression. Furthermore, MDV protein signatures could serve as novel diagnostic or prognostic markers for melanoma.</p><p id="Par14">It is now well-established that some malignancies, including thyroid, renal, and colorectal carcinoma, accumulate loss-of-function mtDNA mutations and adopt an oncocytic phenotype characterized by high mitochondrial content [<xref ref-type="bibr" rid="CR71">71</xref>]. In contrast, such mutations have been found to suppress metastasis and enhance immunotherapy response in melanoma, suggesting that functional mitochondria are required for the progression of this tumor [<xref ref-type="bibr" rid="CR72">72</xref>, <xref ref-type="bibr" rid="CR73">73</xref>]. In this setting, analysis of mtDNA heteroplasmy, commonly observed in inherited mitochondrial diseases, could offer interesting insights into tumor selection for functional mitochondrial genomes [<xref ref-type="bibr" rid="CR74">74</xref>]. Remarkably, advanced multi-omics techniques, such as DOGMA-seq and PHAGE-ATAC, enable simultaneous profiling of mtDNA, RNA, and protein content at single-cell resolution, facilitating exploration of mtDNA influence on melanoma heterogeneity and treatment outcomes [<xref ref-type="bibr" rid="CR75">75</xref>].</p><p id="Par15">Mitochondria contain 13 proteins encoded by mtDNA and more than 1000 proteins encoded by nuclear DNA [<xref ref-type="bibr" rid="CR76">76</xref>]. Within the mitochondrial matrix, ATP-dependent proteases, such as mitochondrial Lon peptidase 1 (LONP1) and caseinolytic protease X and protease P complex (CLPXP), maintain mitochondrial homeostasis by eliminating damaged or misfolded proteins [<xref ref-type="bibr" rid="CR76">76</xref>, <xref ref-type="bibr" rid="CR77">77</xref>]. Interestingly, clinical studies indicate that LONP1 overexpression is a poor prognosis marker in melanoma; in particular, functional experiments have revealed that it promotes tumor growth and metastasis and protects against senescence [<xref ref-type="bibr" rid="CR78">78</xref>]. On the other hand, high levels of ClpP correlate with a shorter survival of patients with uveal melanoma [<xref ref-type="bibr" rid="CR79">79</xref>]. Although the molecular mechanisms underlying the pro-tumor activity of mitochondrial proteases still need to be clarified, the above findings not only demonstrate the relevance of these molecules for cellular and organismal viability but also identify them as crucial regulators of melanomagenesis.</p><p id="Par16">As shown in the previous paragraphs of this chapter, mitochondria dynamically adapt to the changing environment by adjusting their nucleic acid and protein contents. Additionally, the mitochondrial components are modulated in terms of activity and interactions. In this context, multi-omics approaches offer comprehensive insight into mitochondrial regulation in melanoma [<xref ref-type="bibr" rid="CR75">75</xref>]. Genomics identifies mutations in both mtDNA and nuclear-encoded mitochondrial genes; transcriptomics tracks mitochondrial gene expression changes, while ribosome profiling and mePROD assess mitochondrial protein synthesis and import; PTM profiling reveals regulatory modifications, complexome profiling maps protein supercomplexes, and N-terminomics measures mitochondrial protease activity [<xref ref-type="bibr" rid="CR75">75</xref>]. The major advantage of these techniques is that they can examine thousands of cellular macromolecules at once. Thus, multi-omics approaches not only offer a more holistic view of melanoma mitochondrial networks but also hold promise for diagnostic applications by linking metabolic phenotypes to molecular signatures.</p></sec><sec id="Sec4"><title>Mitochondrial redox homeostasis in melanoma</title><p id="Par17">ROS are widely recognized as key drivers of melanomagenesis, due to their ability to damage DNA and induce genetic and epigenetic alterations associated with cancer development [<xref ref-type="bibr" rid="CR80">80</xref>]. Beyond genomic instability, oxidative stress promotes metabolic reprogramming&#8212;particularly enhancing glucose metabolism&#8212;and contributes to immunosuppression, thereby accelerating melanoma progression [<xref ref-type="bibr" rid="CR80">80</xref>]. While the exact sources of ROS overproduction in melanoma remain unclear, UV radiation, melanin biosynthesis, and NADPH oxidase (NOX) activity have been identified as primary contributors to redox imbalance [<xref ref-type="bibr" rid="CR80">80</xref>, <xref ref-type="bibr" rid="CR81">81</xref>]. Importantly, mitochondria also play a significant role in ROS generation in melanoma cells (Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>).<fig id="Fig3" position="float" orientation="portrait"><label>Fig. 3</label><caption><p>Mitochondrial ROS regulate several tumorigenic processes in melanoma. Mitochondrial ROS have been found to exert a pleiotropic role in melanoma. First, they inhibit prolyl hydroxylases, leading to HIF-1&#945; stabilization and contributing to Myc and Met activation. Then, they activate the Akt and ERK pathways, resulting in TGF-&#946; and IL-13 release and subsequent M2 TAM polarization. Finally, they control the autophagic flux, determining cell survival or death</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e563" position="float" orientation="portrait" xlink:href="10495_2025_2155_Fig3_HTML.jpg"/></fig></p><p id="Par18">The relationship between mitochondrial ROS and HIF-1&#945; has been largely investigated in melanoma. In particular, mitochondrial oxidative stress has been found to stabilize HIF-1&#945; protein by inhibiting prolyl hydroxylases [<xref ref-type="bibr" rid="CR82">82</xref>]. This interplay has been confirmed in a Myc-dependent mouse model of melanoma, where different antioxidants, including N-acetylcysteine and vitamin C, could successfully suppress tumor growth [<xref ref-type="bibr" rid="CR83">83</xref>]. Other studies have shown that ROS-mediated stabilization of HIF-1&#945; can lead to activation of the proto-oncogene Met, which promotes the aggressiveness of early-stage tumors, partially through vasculogenic mimicry [<xref ref-type="bibr" rid="CR84">84</xref>]. Of note, HIF-1&#945; upregulation correlates with melanoma poor prognosis, contributing to cancer progression not only by inducing a variety of other pro-tumor pathways, such as the RAS/RAF/MEK/extracellular signal-regulated&#160;kinase (ERK), phosphatidylinositol 3-kinase (PI3K)/Akt/mechanistic target of rapamycin (mTOR), Janus kinase (JAK)/signal transducer and activator of transcription (STAT), Wnt/&#946;-catenin, Notch and nuclear factor kappa-light-chain-enhancer of activated B cells (NF-&#954;B) cascade, but also by regulating the levels of different oncogenic miRNAs [<xref ref-type="bibr" rid="CR85">85</xref>]; whether ROS from mitochondria are involved in the control of this intricate molecular network remains to be elucidated.</p><p id="Par19">In addition to modulating transcriptional programs, mitochondrial ROS facilitate the release of inflammatory cytokines, such as transforming growth factor beta (TGF-&#946;) and interleukin 13 (IL-13), from melanoma cells. In particular, both the ERK and Akt pathways appear to positively regulate the induction of this inflammatory state [<xref ref-type="bibr" rid="CR86">86</xref>]. This results in the activation and M2 polarization of tumor-associated macrophages (TAMs), determining the establishment of an immunosuppressive microenvironment that facilitates cancer growth and metastasis [<xref ref-type="bibr" rid="CR65">65</xref>]. These findings support the dual role of ROS in cancer: while acute exposure can stimulate innate and adaptive immune responses, chronic ROS generation may lead to T-cell exhaustion and reduced responsiveness to immunotherapy [<xref ref-type="bibr" rid="CR87">87</xref>]. Thereby, carefully modulating oxidative stress could boost anti-tumor immunity and improve the efficacy of current melanoma treatments.</p><p id="Par20">ROS also play a critical role in regulating cellular stress responses, particularly through the activation of autophagy&#8212;a major pathway for maintaining cellular homeostasis [<xref ref-type="bibr" rid="CR88">88</xref>]. In melanoma, mitochondrial ROS generated during hypoxia or ER stress can induce pro-survival autophagy, facilitating the rapid clearance of damaged components through lysosomal degradation [<xref ref-type="bibr" rid="CR89">89</xref>, <xref ref-type="bibr" rid="CR90">90</xref>]. However, excessive or sustained autophagy can shift from a protective mechanism to a cytotoxic one, leading to cell death due to over-degradation of cellular structures [<xref ref-type="bibr" rid="CR89">89</xref>, <xref ref-type="bibr" rid="CR90">90</xref>]. As explored later in this review, emerging anti-melanoma therapies are increasingly focused on targeting autophagy as a means of controlling tumor growth.</p></sec><sec id="Sec5"><title>Mitochondrial apoptosis in melanoma</title><p id="Par21">Apoptosis, or programmed cell death, is a fundamental biological process essential for embryonic development, tissue homeostasis, and the removal of damaged or abnormal cells [<xref ref-type="bibr" rid="CR91">91</xref>, <xref ref-type="bibr" rid="CR92">92</xref>]. There are two primary apoptotic pathways: the extrinsic pathway, initiated by the binding of death ligands to membrane-located death receptors, and the intrinsic (mitochondrial) pathway, triggered by internal stress signals, such as nutrient deprivation, DNA damage, oxidative stress, or infection [<xref ref-type="bibr" rid="CR91">91</xref>, <xref ref-type="bibr" rid="CR92">92</xref>]. The intrinsic pathway is tightly regulated by the Bcl-2 family of proteins, which includes both anti-apoptotic members (Bcl-2A1, Bcl-xL, Mcl-1) and pro-apoptotic effectors (Bcl2-Associated X protein&#8212;Bax&#8212;and Bcl-2 homologous antagonist/killer&#8212;Bak). The balance between these opposing groups determines mitochondrial outer membrane permeabilization (MOMP). When pro-apoptotic signals prevail, cytochrome c is released from mitochondria into the cytoplasm, where it associates with apoptotic protease-activating factor-1 (APAF-1) to form the apoptosome, leading to caspase-9 activation and subsequent execution of apoptosis [<xref ref-type="bibr" rid="CR91">91</xref>&#8211;<xref ref-type="bibr" rid="CR93">93</xref>]. In melanoma, several members of the Bcl-2 family are dysregulated, contributing to therapy resistance and disease progression. For example, Bcl-2 is more highly expressed in melanocytes than in many other cell types, and its relative <italic toggle="yes">BCL2A1</italic> is amplified in 30&#8211;40% of melanomas. This amplification enhances resistance to cytotoxic chemotherapy and targeted agents [<xref ref-type="bibr" rid="CR94">94</xref>&#8211;<xref ref-type="bibr" rid="CR96">96</xref>]. Similarly, Bcl-xL is frequently overexpressed in metastatic melanoma and is associated not only with resistance to apoptosis and drug treatment but also with cancer cell stemness, angiogenesis, and immune evasion; indeed, it has been recently reported that it promotes melanoma cell phenotypic plasticity as well as the release of different pro-angiogenic and inflammatory factors from cancer cells, including VEGF, IL-1&#946; e IL-8 [<xref ref-type="bibr" rid="CR97">97</xref>&#8211;<xref ref-type="bibr" rid="CR103">103</xref>]. Another key anti-apoptotic protein, Mcl-1, plays a particularly important role in BRAF-mutant melanomas; in these tumors, MAPK pathway hyperactivation drives both increased <italic toggle="yes">MCL1</italic> transcription and stabilization of Mcl-1 protein through phosphorylation at threonine 163, preventing its degradation [<xref ref-type="bibr" rid="CR104">104</xref>&#8211;<xref ref-type="bibr" rid="CR108">108</xref>]. As illustrated in Fig.&#160;<xref rid="Fig4" ref-type="fig">4</xref>, the central role of Bcl-2 family proteins in regulating cell death and survival in melanoma makes them promising targets for novel therapies. In particular, inhibitors of Bcl-2, Bcl-xL, or Mcl-1 may help to overcome drug resistance in tumors that have relapsed following conventional treatment.<fig id="Fig4" position="float" orientation="portrait"><label>Fig. 4</label><caption><p>Mitochondrial apoptosis is reduced in melanoma. Melanoma is characterized by the upregulation of different anti-apoptotic proteins belonging to the Bcl-2 mitochondrial family, including Bcl-2A1, Bcl-xL and Mcl-1. Targeting these proteins with ad hoc drugs might result in improved therapeutic outcomes</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e663" position="float" orientation="portrait" xlink:href="10495_2025_2155_Fig4_HTML.jpg"/></fig></p></sec><sec id="Sec6"><title>Mitochondria in melanoma therapy</title><p id="Par22">Based on the above evidence, many new anticancer therapies are currently targeting mitochondria in the attempt to eradicate melanoma (Table&#160;<xref rid="Tab1" ref-type="table">1</xref>).<table-wrap id="Tab1" position="float" orientation="portrait"><label>Table&#160;1</label><caption><p>Mitochondrial inhibitors in melanoma therapy</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Drug</th><th align="left" colspan="1" rowspan="1">Mechanism of action</th><th align="left" colspan="1" rowspan="1">Clinical development</th><th align="left" colspan="1" rowspan="1">References</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">CPI613</td><td align="left" colspan="1" rowspan="1">PDHA1 and OGDH inhibition</td><td align="left" colspan="1" rowspan="1">Preclinical studies</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR14">14</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">BAY 87-2243, IACS-010759, metformin, and phenformin</td><td align="left" colspan="1" rowspan="1">OXPHOS inhibition</td><td align="left" colspan="1" rowspan="1">Preclinical studies; phase I/II trial (metformin)</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR109">109</xref>&#8211;<xref ref-type="bibr" rid="CR120">120</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Mensacarcin, cryptolepine, deguelin, tocotrienols, and limonoids</td><td align="left" colspan="1" rowspan="1">OXPHOS inhibition</td><td align="left" colspan="1" rowspan="1">Preclinical studies</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR122">122</xref>&#8211;<xref ref-type="bibr" rid="CR126">126</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Mdivi-1</td><td align="left" colspan="1" rowspan="1">Drp1 inhibition</td><td align="left" colspan="1" rowspan="1">Preclinical studies</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR127">127</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">ONC201, ONC206, and ONC212</td><td align="left" colspan="1" rowspan="1">ClpP agonism</td><td align="left" colspan="1" rowspan="1">Preclinical studies</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR130">130</xref>&#8211;<xref ref-type="bibr" rid="CR132">132</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Tigecycline, doxycycline, and azithromycin</td><td align="left" colspan="1" rowspan="1">Mitochondrial translation inhibition</td><td align="left" colspan="1" rowspan="1">Preclinical studies</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR131">131</xref>, <xref ref-type="bibr" rid="CR133">133</xref>&#8211;<xref ref-type="bibr" rid="CR138">138</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Elesclomol, simvastatin, resveratrol, curcumin, tocotrienols, and chalcone derivatives</td><td align="left" colspan="1" rowspan="1">ROS induction</td><td align="left" colspan="1" rowspan="1">Preclinical studies</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR141">141</xref>&#8211;<xref ref-type="bibr" rid="CR145">145</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">SAR405, 3-MA, and chloroquine</td><td align="left" colspan="1" rowspan="1">Pro-survival autophagy inhibition</td><td align="left" colspan="1" rowspan="1">Preclinical studies</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR147">147</xref>&#8211;<xref ref-type="bibr" rid="CR149">149</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Everolimus, GSK621, and trehalose</td><td align="left" colspan="1" rowspan="1">Pro-death autophagy induction</td><td align="left" colspan="1" rowspan="1">Preclinical studies; phase II trial (Everolimus)</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR150">150</xref>&#8211;<xref ref-type="bibr" rid="CR153">153</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Antisense oligonucleotides</td><td align="left" colspan="1" rowspan="1">Bcl-2 and Bcl-xL inhibition</td><td align="left" colspan="1" rowspan="1">Preclinical studies</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR154">154</xref>, <xref ref-type="bibr" rid="CR155">155</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">A-1331852, GX15-070 (Obatoclax), ABT-263 (Navitoclax), and ABT-737</td><td align="left" colspan="1" rowspan="1">BH3 mimicry</td><td align="left" colspan="1" rowspan="1">Preclinical studies; phase I/II trial (Navitoclax)</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR156">156</xref>&#8211;<xref ref-type="bibr" rid="CR159">159</xref>, <xref ref-type="bibr" rid="CR162">162</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">SC-2001, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="S63845">S63845</ext-link> and <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="S64315">S64315</ext-link> (MIK655)</td><td align="left" colspan="1" rowspan="1">Mcl-1 inhibition</td><td align="left" colspan="1" rowspan="1">Preclinical studies</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR160">160</xref>, <xref ref-type="bibr" rid="CR161">161</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Paraptosis inducers</td><td align="left" colspan="1" rowspan="1">Ca<sup>2+</sup> overload-dependent mitochondrial swelling</td><td align="left" colspan="1" rowspan="1">Preclinical studies</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR163">163</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Ferroptosis inducers</td><td align="left" colspan="1" rowspan="1">Intracellular iron accumulation and lipid peroxidation</td><td align="left" colspan="1" rowspan="1">Preclinical studies</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR164">164</xref>]</td></tr></tbody></table></table-wrap></p><p id="Par23">Both TCA and OXPHOS have been exploited for melanoma treatment. In particular, CPI613, a lipoic acid analog that inhibits PDHA1 and OGDH, has been shown to dramatically attenuate the progression of melanoma and improve the therapeutic efficacy of anti-PD-1 against this tumor [<xref ref-type="bibr" rid="CR14">14</xref>]. On the other hand, several inhibitors of the OXPHOS complex I, such as BAY 87&#8211;2243, IACS-010759, metformin and phenformin, have been observed to be potent melanoma suppressors [<xref ref-type="bibr" rid="CR109">109</xref>&#8211;<xref ref-type="bibr" rid="CR113">113</xref>]. Of note, these chemicals also display strong synergism when administered in combination with both targeted and immunotherapies, due to their ability to specifically target the metabolic signatures associated with BRAF and MAPK inhibitor resistance on the one side, and to alleviate the hypoxia responsible for CD8&#8201;+&#8201;T cell dysfunction of the other side [<xref ref-type="bibr" rid="CR110">110</xref>, <xref ref-type="bibr" rid="CR114">114</xref>&#8211;<xref ref-type="bibr" rid="CR120">120</xref>] (ClinicalTrials.gov,&#160;<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04114136">NCT04114136</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03311308">NCT03311308</ext-link>). However, their use remains limited because of their high toxicity; indeed, due their broad and unspecific activity, they commonly cause fatigue, nausea, vomiting, diarrhea, lactic acidosis, elevated blood lactate, and peripheral neuropathy [<xref ref-type="bibr" rid="CR121">121</xref>]. In this regard, it should be noted that several mitochondria-targeting natural compounds free of side effects are now under study for melanoma therapy; among them, mensacarcin, cryptolepine, deguelin, tocotrienols, and limonoids have demonstrated great anticancer potential [<xref ref-type="bibr" rid="CR122">122</xref>&#8211;<xref ref-type="bibr" rid="CR126">126</xref>].</p><p id="Par24">Drp1 has been recently proposed as a promising target for melanoma management. Indeed, Akita et al. have found that mitochondrial division inhibitor-1 (mdivi-1), a specific Drp1 inactivator, sensitizes melanoma cells to apoptosis induced by the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), by causing robust mitochondrial hyperfusion and eliciting both the ER and oxidative stress responses. Importantly, mdivi-1 cytotoxic effects are minimal in normal melanocytes and fibroblasts, suggesting the possibility to exploit melanoma cell susceptibility to mitochondrial breakdown to improve therapy outcomes [<xref ref-type="bibr" rid="CR127">127</xref>].</p><p id="Par25">Mitochondrial UPR (mtUPR) occurs when an excess of unfolded or misfolded proteins accumulates in the mitochondrial matrix, eventually culminating into mitochondrial dysfunction [<xref ref-type="bibr" rid="CR128">128</xref>]. Activation of this pathway by imipridones, a class of ClpP agonists, leads to the eradication of different tumor types, including both solid (<italic toggle="yes">i.e.</italic> glioblastoma and breast, endometrial and prostate carcinoma) and hematological (<italic toggle="yes">i.e.</italic> multiple myeloma and acute myeloid leukemia) malignancies [<xref ref-type="bibr" rid="CR129">129</xref>]. In melanoma, ONC201, ONC206, and ONC212 displayed potent anti-tumor effects in vivo, a broad therapeutic window and a favorable pharmacokinetic profile [<xref ref-type="bibr" rid="CR130">130</xref>&#8211;<xref ref-type="bibr" rid="CR132">132</xref>]. Based on these findings, these chemicals warrant further development as anti-melanoma drug candidates.</p><p id="Par26">Inhibition of mitochondrial translation is rapidly emerging as a novel anti-tumor strategy. In melanoma, several antibiotics, such as tigecycline, doxycycline, and azithromycin, have been shown to suppress OXPHOS capacity by reducing the levels of ETC complexes [<xref ref-type="bibr" rid="CR131">131</xref>, <xref ref-type="bibr" rid="CR133">133</xref>&#8211;<xref ref-type="bibr" rid="CR137">137</xref>]. Remarkably, these molecules could selectively eradicate the cancer stem cell niche, known to greatly rely on oxidative metabolism for its own maintenance and propagation [<xref ref-type="bibr" rid="CR138">138</xref>]. However, it should be noted the antibiotic exposure appears to be associated with an increased incidence of cancer; as a direct consequence of antibiotic misuse, it is highly likely that microbiota dysfunction may enhance cancer risk and limit the efficacy of chemotherapy, radiotherapy, and immunotherapy [<xref ref-type="bibr" rid="CR139">139</xref>, <xref ref-type="bibr" rid="CR140">140</xref>]. In this setting, further studies are required to elucidate the correlation between antibiotic usage and melanoma development.</p><p id="Par27">Given their crucial role in determining cancer cell survival or death, ROS levels can be pharmacologically modulated for melanoma eradication [<xref ref-type="bibr" rid="CR80">80</xref>]. While the anti-tumor benefits of antioxidants still need to be elucidated, several reports have pointed out that ROS inducers can successfully suppress melanoma growth. Among these molecules, we can count several synthetic drugs, particularly elesclomol and simvastatin, and nutraceuticals, including resveratrol, curcumin, tocotrienols, and chalcone derivatives [<xref ref-type="bibr" rid="CR141">141</xref>&#8211;<xref ref-type="bibr" rid="CR145">145</xref>]. These chemicals mainly act through ROS-mediated DNA damage, cell cycle arrest, apoptosis, Akt inactivation, and induction of a senescent phenotype [<xref ref-type="bibr" rid="CR80">80</xref>, <xref ref-type="bibr" rid="CR141">141</xref>&#8211;<xref ref-type="bibr" rid="CR145">145</xref>]. Notably, increased ROS-induced melanoma cell death has also been reported after ATP depletion caused by the inactivation of glycolytic enzymes as well as by chemotherapy, radiation therapy, and immunotherapy [<xref ref-type="bibr" rid="CR80">80</xref>]; these observations highlight the great potential of ROS manipulation in anticancer combinatorial treatments. Although more efforts are needed to enhance the selectivity of anticancer ROS-related drugs, the main mechanisms involved in melanoma cellular stress responses are continuously being unveiled and most of them concern the redox balance.</p><p id="Par28">As previously illustrated, autophagy is a critical process in melanoma, involving autophagosome formation and its subsequent fusion with lysosomes for cargo degradation; from a molecular point of view, its regulation is based on mTOR-dependent and independent pathways, such as adenosine monophosphate-activated&#160;protein kinase (AMPK), MAPK, ER, and oxidative stress [<xref ref-type="bibr" rid="CR90">90</xref>, <xref ref-type="bibr" rid="CR146">146</xref>]. In this setting, pro-survival autophagy inhibitors, able to block autophagosome or autolysosome generation, and pro-death autophagy inducers, modulating mTOR-related and unrelated autophagic mechanisms, have proved to be useful against melanoma [<xref ref-type="bibr" rid="CR90">90</xref>, <xref ref-type="bibr" rid="CR146">146</xref>]. Well-known members of the first pharmacological class are SAR405, 3-methyladenine (3-MA), and chloroquine, while Everolimus, GSK621, and trehalose belong to the second one [<xref ref-type="bibr" rid="CR147">147</xref>&#8211;<xref ref-type="bibr" rid="CR153">153</xref>]. However, clinical translation remains challenging due to the non-specific nature of these agents and the involvement of autophagic proteins in various biological processes [<xref ref-type="bibr" rid="CR90">90</xref>]. In this context, future therapies may focus on the transient modulation of autophagy rather than on its complete and irreversible blockage or induction. Whether autophagy should be up or downregulated in melanoma is still under debate, particularly given its metabolic state-dependent effects on cancer cells.</p><p id="Par29">Because of its relevance in the evasion of apoptosis, different strategies have been evaluated to inhibit the Bcl-2 protein family in melanoma. These include antisense oligonucleotides targeting Bcl-2 and Bcl-xL mRNAs and small molecules, such as the BH3 mimetics A-1331852, GX15-070 (Obatoclax), ABT-263 (Navitoclax), and ABT-737 [<xref ref-type="bibr" rid="CR154">154</xref>&#8211;<xref ref-type="bibr" rid="CR159">159</xref>]. Importantly, combinations of BH3 mimetics with Mcl-1 inhibitors, namely SC-2001, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="S63845">S63845</ext-link>, and <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="S64315">S64315</ext-link> (MIK655), are even more effective at eradicating melanoma in vitro and in vivo [<xref ref-type="bibr" rid="CR160">160</xref>, <xref ref-type="bibr" rid="CR161">161</xref>]. Furthermore, combining these drugs with either BRAF or MEK inhibitors resensitizes melanoma cells to the latter and enhances xenograft tumor growth inhibition [<xref ref-type="bibr" rid="CR162">162</xref>]. In this regard, a phase I/II trial study using Navitoclax in combination with dabrafenib and trametinib is recruiting unresectable or metastatic patients with BRAF mutant melanoma (ClinicalTrials.gov,&#160;<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01989585">NCT01989585</ext-link>). Alternative treatment options are based on the induction of non-apoptotic cell death mechanisms, including paraptosis, characterized by calcium (Ca<sup>2+</sup>) overload-dependent mitochondrial swelling, and ferroptosis, caused by intracellular iron accumulation and lipid peroxidation; nonetheless, they have only been tested in preclinical models till now [<xref ref-type="bibr" rid="CR163">163</xref>, <xref ref-type="bibr" rid="CR164">164</xref>].</p><p id="Par30">While promising, mitochondria-targeted therapies still face challenges in selectivity, often leading to side effects in healthy tissues. Nanotechnology presents an innovative solution to this issue, by enhancing drug delivery precision, reducing off-target effects, and improving mitochondrial targeting [<xref ref-type="bibr" rid="CR165">165</xref>]. Nanocarriers, such as liposomes and polymeric/inorganic nanoparticles, have been designed to cross cell membranes and deliver therapeutic agents directly to mitochondria; the modification of these vectors&#8212;in terms of structure, charge, and size&#8212;facilitates their accumulation within the mitochondrial matrix [<xref ref-type="bibr" rid="CR165">165</xref>]. This approach, powered by advancements in materials science, bioengineering, and molecular biology, holds the promise of unlocking new frontiers in melanoma treatment.</p></sec><sec id="Sec7"><title>Conclusion and future perspectives</title><p id="Par31">In recent years, advancements in melanoma research have underscored the pivotal role of TCA cycle and OXPHOS in regulating tumor initiation and progression, shifting the focus towards mitochondrial metabolism. This progress has deepened our understanding of mitochondrial dynamics and quality control in the metabolic adaptability of melanoma. Studies have also explored the mitochondrial alterations responsible for redox imbalance and the evasion of apoptosis, revealing new pharmacological targets for treating melanoma. In fact, it has become clear that targeting mitochondrial function could be a highly effective approach for melanoma therapy. Several compounds directed against mitochondrial proteins have shown promise in preclinical studies, although translating these findings into clinical applications remains challenging; currently, only a few of these agents are in early-stage clinical trials. The use of next-generation technologies, such as metabolic profiling and single-cell sequencing, will likely provide further insights into the mechanisms controlling mitochondrial metabolism in melanoma. These technologies could enable more personalized and less toxic treatment options, while combining mitochondrial inhibitors with standard targeted and immunotherapeutic therapies could offer a novel strategy for melanoma management.</p></sec></body><back><fn-group><fn><p><bold>Publisher&#8217;s note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ack><p>We thank Federica Camarda, Federico Palvarini, and Alessio Tonioni for their support in the laboratory.</p></ack><notes notes-type="author-contribution"><title>Author contributions</title><p>Conceptualization: F.F.; Writing&#8211; original draft G.G., A.J.J.P., S.R., R.G., F.F.; Writing&#8211; review and editing G.G., A.J.J.P., S.R., R.G., F.F. Visualization: G.G., A.J.J.P., F.F; Funding acquisition: F.F.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>This research was funded by MIUR Progetto di Eccellenza (Department of Pharmacological and Biomolecular Sciences &#8220;Rodolfo Paoletti&#8221;, Universit&#224; degli Studi di Milano) and PSR 2023 (F.F.).</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>No datasets were generated or analysed during the current study.</p></notes><notes><title>Declarations</title><notes id="FPar1" notes-type="COI-statement"><title>Competing interests</title><p id="Par32">The authors declare no competing interests.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Siegel</surname><given-names>RL</given-names></name><name name-style="western"><surname>Kratzer</surname><given-names>TB</given-names></name><name name-style="western"><surname>Giaquinto</surname><given-names>AN</given-names></name><etal/></person-group><article-title>Cancer statistics, 2025</article-title><source>CA Cancer J Clin</source><year>2025</year><volume>75</volume><fpage>10</fpage><lpage>45</lpage><pub-id pub-id-type="doi">10.3322/caac.21871</pub-id><pub-id pub-id-type="pmid">39817679</pub-id><pub-id pub-id-type="pmcid">PMC11745215</pub-id></element-citation><mixed-citation id="mc-CR1" publication-type="journal">Siegel RL, Kratzer TB, Giaquinto AN et al (2025) Cancer statistics, 2025. CA Cancer J Clin 75:10&#8211;45. 10.3322/caac.21871<pub-id pub-id-type="pmid">39817679</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3322/caac.21871</pub-id><pub-id pub-id-type="pmcid">PMC11745215</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Boutros</surname><given-names>A</given-names></name><name name-style="western"><surname>Croce</surname><given-names>E</given-names></name><name name-style="western"><surname>Ferrari</surname><given-names>M</given-names></name><etal/></person-group><article-title>The treatment of advanced melanoma: current approaches and new challenges</article-title><source>Crit Rev Oncol Hematol</source><year>2024</year><volume>196</volume><fpage>104276</fpage><pub-id pub-id-type="doi">10.1016/j.critrevonc.2024.104276</pub-id><pub-id pub-id-type="pmid">38295889</pub-id></element-citation><mixed-citation id="mc-CR2" publication-type="journal">Boutros A, Croce E, Ferrari M et al (2024) The treatment of advanced melanoma: current approaches and new challenges. Crit Rev Oncol Hematol 196:104276. 10.1016/j.critrevonc.2024.104276<pub-id pub-id-type="pmid">38295889</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.critrevonc.2024.104276</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>C</given-names></name><name name-style="western"><surname>Radi</surname><given-names>RH</given-names></name><name name-style="western"><surname>Arbiser</surname><given-names>JL</given-names></name></person-group><article-title>Mitochondrial metabolism in melanoma</article-title><source>Cells</source><year>2021</year><volume>10</volume><issue>11</issue><fpage>3197</fpage><pub-id pub-id-type="doi">10.3390/cells10113197</pub-id><pub-id pub-id-type="pmid">34831420</pub-id><pub-id pub-id-type="pmcid">PMC8618235</pub-id></element-citation><mixed-citation id="mc-CR3" publication-type="journal">Huang C, Radi RH, Arbiser JL (2021) Mitochondrial metabolism in melanoma. Cells 10(11):3197. 10.3390/cells10113197<pub-id pub-id-type="pmid">34831420</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/cells10113197</pub-id><pub-id pub-id-type="pmcid">PMC8618235</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kumar</surname><given-names>PR</given-names></name><name name-style="western"><surname>Moore</surname><given-names>JA</given-names></name><name name-style="western"><surname>Bowles</surname><given-names>KM</given-names></name><etal/></person-group><article-title>Mitochondrial oxidative phosphorylation in cutaneous melanoma</article-title><source>Br J Cancer</source><year>2021</year><volume>124</volume><fpage>115</fpage><lpage>123</lpage><pub-id pub-id-type="doi">10.1038/s41416-020-01159-y</pub-id><pub-id pub-id-type="pmid">33204029</pub-id><pub-id pub-id-type="pmcid">PMC7782830</pub-id></element-citation><mixed-citation id="mc-CR4" publication-type="journal">Kumar PR, Moore JA, Bowles KM et al (2021) Mitochondrial oxidative phosphorylation in cutaneous melanoma. Br J Cancer 124:115&#8211;123. 10.1038/s41416-020-01159-y<pub-id pub-id-type="pmid">33204029</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41416-020-01159-y</pub-id><pub-id pub-id-type="pmcid">PMC7782830</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>N</given-names></name><name name-style="western"><surname>Tian</surname><given-names>Y</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Metabolic rewiring directs melanoma immunology</article-title><source>Front Immunol</source><year>2022</year><pub-id pub-id-type="doi">10.3389/fimmu.2022.909580</pub-id><pub-id pub-id-type="pmid">36003368</pub-id><pub-id pub-id-type="pmcid">PMC9393691</pub-id></element-citation><mixed-citation id="mc-CR5" publication-type="journal">Sun N, Tian Y, Chen Y et al (2022) Metabolic rewiring directs melanoma immunology. Front Immunol. 10.3389/fimmu.2022.909580<pub-id pub-id-type="pmid">36003368</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2022.909580</pub-id><pub-id pub-id-type="pmcid">PMC9393691</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tan</surname><given-names>IJ</given-names></name><name name-style="western"><surname>Parikh</surname><given-names>AK</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>BA</given-names></name></person-group><article-title>Melanoma metabolism: molecular mechanisms and therapeutic implications in cutaneous oncology</article-title><source>Cancer Med</source><year>2024</year><pub-id pub-id-type="doi">10.1002/cam4.70386</pub-id><pub-id pub-id-type="pmid">39494561</pub-id><pub-id pub-id-type="pmcid">PMC11532834</pub-id></element-citation><mixed-citation id="mc-CR6" publication-type="journal">Tan IJ, Parikh AK, Cohen BA (2024) Melanoma metabolism: molecular mechanisms and therapeutic implications in cutaneous oncology. Cancer Med. 10.1002/cam4.70386<pub-id pub-id-type="pmid">39494561</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cam4.70386</pub-id><pub-id pub-id-type="pmcid">PMC11532834</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Arnold</surname><given-names>PK</given-names></name><name name-style="western"><surname>Finley</surname><given-names>LWS</given-names></name></person-group><article-title>Regulation and function of the mammalian tricarboxylic acid cycle</article-title><source>J Biol Chem</source><year>2023</year><volume>299</volume><fpage>102838</fpage><pub-id pub-id-type="doi">10.1016/j.jbc.2022.102838</pub-id><pub-id pub-id-type="pmid">36581208</pub-id><pub-id pub-id-type="pmcid">PMC9871338</pub-id></element-citation><mixed-citation id="mc-CR7" publication-type="journal">Arnold PK, Finley LWS (2023) Regulation and function of the mammalian tricarboxylic acid cycle. J Biol Chem 299:102838. 10.1016/j.jbc.2022.102838<pub-id pub-id-type="pmid">36581208</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jbc.2022.102838</pub-id><pub-id pub-id-type="pmcid">PMC9871338</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lopez</surname><given-names>GY</given-names></name><name name-style="western"><surname>Reitman</surname><given-names>ZJ</given-names></name><name name-style="western"><surname>Solomon</surname><given-names>D</given-names></name><etal/></person-group><article-title><italic toggle="yes">IDH1</italic> mutation identified in one human melanoma metastasis, but not correlated with metastases to the brain</article-title><source>Biochem Biophys Res Commun</source><year>2010</year><volume>398</volume><fpage>585</fpage><lpage>587</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2010.06.125</pub-id><pub-id pub-id-type="pmid">20603105</pub-id><pub-id pub-id-type="pmcid">PMC2987603</pub-id></element-citation><mixed-citation id="mc-CR8" publication-type="journal">Lopez GY, Reitman ZJ, Solomon D et al (2010) <italic toggle="yes">IDH1</italic> mutation identified in one human melanoma metastasis, but not correlated with metastases to the brain. Biochem Biophys Res Commun 398:585&#8211;587. 10.1016/j.bbrc.2010.06.125<pub-id pub-id-type="pmid">20603105</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bbrc.2010.06.125</pub-id><pub-id pub-id-type="pmcid">PMC2987603</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shibata</surname><given-names>T</given-names></name><name name-style="western"><surname>Kokubu</surname><given-names>A</given-names></name><name name-style="western"><surname>Miyamoto</surname><given-names>M</given-names></name><etal/></person-group><article-title>Mutant IDH1 confers an in vivo growth in a melanoma cell line with BRAF mutation</article-title><source>Am J Pathol</source><year>2011</year><volume>178</volume><fpage>1395</fpage><lpage>1402</lpage><pub-id pub-id-type="doi">10.1016/j.ajpath.2010.12.011</pub-id><pub-id pub-id-type="pmid">21356389</pub-id><pub-id pub-id-type="pmcid">PMC3069821</pub-id></element-citation><mixed-citation id="mc-CR9" publication-type="journal">Shibata T, Kokubu A, Miyamoto M et al (2011) Mutant IDH1 confers an in vivo growth in a melanoma cell line with BRAF mutation. Am J Pathol 178:1395&#8211;1402. 10.1016/j.ajpath.2010.12.011<pub-id pub-id-type="pmid">21356389</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ajpath.2010.12.011</pub-id><pub-id pub-id-type="pmcid">PMC3069821</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Linos</surname><given-names>K</given-names></name><name name-style="western"><surname>Tafe</surname><given-names>LJ</given-names></name></person-group><article-title>Isocitrate dehydrogenase 1 mutations in melanoma frequently co-occur with NRAS mutations</article-title><source>Histopathology</source><year>2018</year><volume>73</volume><fpage>963</fpage><lpage>968</lpage><pub-id pub-id-type="doi">10.1111/his.13707</pub-id><pub-id pub-id-type="pmid">30003571</pub-id></element-citation><mixed-citation id="mc-CR10" publication-type="journal">Linos K, Tafe LJ (2018) Isocitrate dehydrogenase 1 mutations in melanoma frequently co-occur with NRAS mutations. Histopathology 73:963&#8211;968. 10.1111/his.13707<pub-id pub-id-type="pmid">30003571</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/his.13707</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Scott</surname><given-names>DA</given-names></name><name name-style="western"><surname>Richardson</surname><given-names>AD</given-names></name><name name-style="western"><surname>Filipp</surname><given-names>FV</given-names></name><etal/></person-group><article-title>Comparative metabolic flux profiling of melanoma cell lines</article-title><source>J Biol Chem</source><year>2011</year><volume>286</volume><fpage>42626</fpage><lpage>42634</lpage><pub-id pub-id-type="doi">10.1074/jbc.M111.282046</pub-id><pub-id pub-id-type="pmid">21998308</pub-id><pub-id pub-id-type="pmcid">PMC3234981</pub-id></element-citation><mixed-citation id="mc-CR11" publication-type="journal">Scott DA, Richardson AD, Filipp FV et al (2011) Comparative metabolic flux profiling of melanoma cell lines. J Biol Chem 286:42626&#8211;42634. 10.1074/jbc.M111.282046<pub-id pub-id-type="pmid">21998308</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1074/jbc.M111.282046</pub-id><pub-id pub-id-type="pmcid">PMC3234981</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Filipp</surname><given-names>FV</given-names></name><name name-style="western"><surname>Scott</surname><given-names>DA</given-names></name><name name-style="western"><surname>Ronai</surname><given-names>ZA</given-names></name><etal/></person-group><article-title>Reverse TCA cycle flux through isocitrate dehydrogenases 1 and 2 is required for lipogenesis in hypoxic melanoma cells</article-title><source>Pigment Cell Melanoma Res</source><year>2012</year><volume>25</volume><fpage>375</fpage><lpage>383</lpage><pub-id pub-id-type="doi">10.1111/j.1755-148X.2012.00989.x</pub-id><pub-id pub-id-type="pmid">22360810</pub-id><pub-id pub-id-type="pmcid">PMC3329592</pub-id></element-citation><mixed-citation id="mc-CR12" publication-type="journal">Filipp FV, Scott DA, Ronai ZA et al (2012) Reverse TCA cycle flux through isocitrate dehydrogenases 1 and 2 is required for lipogenesis in hypoxic melanoma cells. Pigment Cell Melanoma Res 25:375&#8211;383. 10.1111/j.1755-148X.2012.00989.x<pub-id pub-id-type="pmid">22360810</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1755-148X.2012.00989.x</pub-id><pub-id pub-id-type="pmcid">PMC3329592</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Filipp</surname><given-names>FV</given-names></name><name name-style="western"><surname>Ratnikov</surname><given-names>B</given-names></name><name name-style="western"><surname>De Ingeniis</surname><given-names>J</given-names></name><etal/></person-group><article-title>Glutamine-fueled mitochondrial metabolism is decoupled from glycolysis in melanoma</article-title><source>Pigment Cell Melanoma Res</source><year>2012</year><volume>25</volume><fpage>732</fpage><lpage>739</lpage><pub-id pub-id-type="doi">10.1111/pcmr.12000</pub-id><pub-id pub-id-type="pmid">22846158</pub-id><pub-id pub-id-type="pmcid">PMC3639292</pub-id></element-citation><mixed-citation id="mc-CR13" publication-type="journal">Filipp FV, Ratnikov B, De Ingeniis J et al (2012) Glutamine-fueled mitochondrial metabolism is decoupled from glycolysis in melanoma. Pigment Cell Melanoma Res 25:732&#8211;739. 10.1111/pcmr.12000<pub-id pub-id-type="pmid">22846158</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/pcmr.12000</pub-id><pub-id pub-id-type="pmcid">PMC3639292</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>N</given-names></name><name name-style="western"><surname>Yan</surname><given-names>M</given-names></name><name name-style="western"><surname>Tao</surname><given-names>Q</given-names></name><etal/></person-group><article-title>Inhibition of TCA cycle improves the anti-PD-1 immunotherapy efficacy in melanoma cells via ATF3-mediated PD-L1 expression and glycolysis</article-title><source>J Immunother Cancer</source><year>2023</year><volume>11</volume><fpage>e007146</fpage><pub-id pub-id-type="doi">10.1136/jitc-2023-007146</pub-id><pub-id pub-id-type="pmid">37678921</pub-id><pub-id pub-id-type="pmcid">PMC10496672</pub-id></element-citation><mixed-citation id="mc-CR14" publication-type="journal">Liu N, Yan M, Tao Q et al (2023) Inhibition of TCA cycle improves the anti-PD-1 immunotherapy efficacy in melanoma cells via ATF3-mediated PD-L1 expression and glycolysis. J Immunother Cancer 11:e007146. 10.1136/jitc-2023-007146<pub-id pub-id-type="pmid">37678921</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/jitc-2023-007146</pub-id><pub-id pub-id-type="pmcid">PMC10496672</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Icard</surname><given-names>P</given-names></name><name name-style="western"><surname>Coquerel</surname><given-names>A</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Understanding the central role of citrate in the metabolism of cancer cells and tumors: an update</article-title><source>Int J Mol Sci</source><year>2021</year><volume>22</volume><fpage>6587</fpage><pub-id pub-id-type="doi">10.3390/ijms22126587</pub-id><pub-id pub-id-type="pmid">34205414</pub-id><pub-id pub-id-type="pmcid">PMC8235534</pub-id></element-citation><mixed-citation id="mc-CR15" publication-type="journal">Icard P, Coquerel A, Wu Z et al (2021) Understanding the central role of citrate in the metabolism of cancer cells and tumors: an update. Int J Mol Sci 22:6587. 10.3390/ijms22126587<pub-id pub-id-type="pmid">34205414</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms22126587</pub-id><pub-id pub-id-type="pmcid">PMC8235534</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jeong</surname><given-names>Y-M</given-names></name><name name-style="western"><surname>Lee</surname><given-names>JE</given-names></name><name name-style="western"><surname>Kim</surname><given-names>SY</given-names></name><etal/></person-group><article-title>Enhanced effects of citrate on UVB-induced apoptosis of B16 melanoma cells</article-title><source>Pharmazie</source><year>2009</year><volume>64</volume><fpage>829</fpage><lpage>833</lpage><pub-id pub-id-type="doi">10.1691/ph.2009.9622</pub-id><pub-id pub-id-type="pmid">20095142</pub-id></element-citation><mixed-citation id="mc-CR16" publication-type="journal">Jeong Y-M, Lee JE, Kim SY et al (2009) Enhanced effects of citrate on UVB-induced apoptosis of B16 melanoma cells. Pharmazie 64:829&#8211;833. 10.1691/ph.2009.9622<pub-id pub-id-type="pmid">20095142</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>S</given-names></name><name name-style="western"><surname>Sakamoto</surname><given-names>K</given-names></name></person-group><article-title>Citric acid promoted melanin synthesis in B16F10 mouse melanoma cells, but inhibited it in human epidermal melanocytes and HMV-II melanoma cells via the GSK3&#946;/&#946;-catenin signaling pathway</article-title><source>PLoS ONE</source><year>2020</year><volume>15</volume><fpage>e0243565</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0243565</pub-id><pub-id pub-id-type="pmid">33332393</pub-id><pub-id pub-id-type="pmcid">PMC7746170</pub-id></element-citation><mixed-citation id="mc-CR17" publication-type="journal">Zhou S, Sakamoto K (2020) Citric acid promoted melanin synthesis in B16F10 mouse melanoma cells, but inhibited it in human epidermal melanocytes and HMV-II melanoma cells via the GSK3&#946;/&#946;-catenin signaling pathway. PLoS ONE 15:e0243565. 10.1371/journal.pone.0243565<pub-id pub-id-type="pmid">33332393</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0243565</pub-id><pub-id pub-id-type="pmcid">PMC7746170</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fontana</surname><given-names>F</given-names></name><name name-style="western"><surname>Limonta</surname><given-names>P</given-names></name></person-group><article-title>The multifaceted roles of mitochondria at the crossroads of cell life and death in cancer</article-title><source>Free Radic Biol Med</source><year>2021</year><volume>176</volume><fpage>203</fpage><lpage>221</lpage><pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2021.09.024</pub-id><pub-id pub-id-type="pmid">34597798</pub-id></element-citation><mixed-citation id="mc-CR18" publication-type="journal">Fontana F, Limonta P (2021) The multifaceted roles of mitochondria at the crossroads of cell life and death in cancer. Free Radic Biol Med 176:203&#8211;221. 10.1016/j.freeradbiomed.2021.09.024<pub-id pub-id-type="pmid">34597798</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.freeradbiomed.2021.09.024</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hall</surname><given-names>A</given-names></name><name name-style="western"><surname>Meyle</surname><given-names>KD</given-names></name><name name-style="western"><surname>Lange</surname><given-names>MK</given-names></name><etal/></person-group><article-title>Dysfunctional oxidative phosphorylation makes malignant melanoma cells addicted to glycolysis driven by the V600EBRAF oncogene</article-title><source>Oncotarget</source><year>2013</year><volume>4</volume><fpage>584</fpage><lpage>599</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.965</pub-id><pub-id pub-id-type="pmid">23603840</pub-id><pub-id pub-id-type="pmcid">PMC3720606</pub-id></element-citation><mixed-citation id="mc-CR19" publication-type="journal">Hall A, Meyle KD, Lange MK et al (2013) Dysfunctional oxidative phosphorylation makes malignant melanoma cells addicted to glycolysis driven by the V600EBRAF oncogene. Oncotarget 4:584&#8211;599. 10.18632/oncotarget.965<pub-id pub-id-type="pmid">23603840</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.18632/oncotarget.965</pub-id><pub-id pub-id-type="pmcid">PMC3720606</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Slominski</surname><given-names>A</given-names></name><name name-style="western"><surname>Kim</surname><given-names>T-K</given-names></name><name name-style="western"><surname>Bro&#380;yna</surname><given-names>AA</given-names></name><etal/></person-group><article-title>The role of melanogenesis in regulation of melanoma behavior: melanogenesis leads to stimulation of HIF-1&#945; expression and HIF-dependent attendant pathways</article-title><source>Arch Biochem Biophys</source><year>2014</year><volume>563</volume><fpage>79</fpage><lpage>93</lpage><pub-id pub-id-type="doi">10.1016/j.abb.2014.06.030</pub-id><pub-id pub-id-type="pmid">24997364</pub-id><pub-id pub-id-type="pmcid">PMC4221528</pub-id></element-citation><mixed-citation id="mc-CR20" publication-type="journal">Slominski A, Kim T-K, Bro&#380;yna AA et al (2014) The role of melanogenesis in regulation of melanoma behavior: melanogenesis leads to stimulation of HIF-1&#945; expression and HIF-dependent attendant pathways. Arch Biochem Biophys 563:79&#8211;93. 10.1016/j.abb.2014.06.030<pub-id pub-id-type="pmid">24997364</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.abb.2014.06.030</pub-id><pub-id pub-id-type="pmcid">PMC4221528</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>D&#367;ra</surname><given-names>M</given-names></name><name name-style="western"><surname>N&#283;mejcov&#225;</surname><given-names>K</given-names></name><name name-style="western"><surname>Jak&#353;a</surname><given-names>R</given-names></name><etal/></person-group><article-title>Expression of Glut-1 in malignant melanoma and melanocytic nevi: an immunohistochemical study of 400 cases</article-title><source>Pathol Oncol Res</source><year>2019</year><volume>25</volume><fpage>361</fpage><lpage>368</lpage><pub-id pub-id-type="doi">10.1007/s12253-017-0363-7</pub-id><pub-id pub-id-type="pmid">29128957</pub-id></element-citation><mixed-citation id="mc-CR21" publication-type="journal">D&#367;ra M, N&#283;mejcov&#225; K, Jak&#353;a R et al (2019) Expression of Glut-1 in malignant melanoma and melanocytic nevi: an immunohistochemical study of 400 cases. Pathol Oncol Res 25:361&#8211;368. 10.1007/s12253-017-0363-7<pub-id pub-id-type="pmid">29128957</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12253-017-0363-7</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zbytek</surname><given-names>B</given-names></name><name name-style="western"><surname>Peacock</surname><given-names>DL</given-names></name><name name-style="western"><surname>Seagroves</surname><given-names>TN</given-names></name><name name-style="western"><surname>Slominski</surname><given-names>A</given-names></name></person-group><article-title>Putative role of HIF transcriptional activity in melanocytes and melanoma biology</article-title><source>Dermatoendocrinol</source><year>2013</year><volume>5</volume><fpage>239</fpage><lpage>251</lpage><pub-id pub-id-type="doi">10.4161/derm.22678</pub-id><pub-id pub-id-type="pmid">24194964</pub-id><pub-id pub-id-type="pmcid">PMC3772912</pub-id></element-citation><mixed-citation id="mc-CR22" publication-type="journal">Zbytek B, Peacock DL, Seagroves TN, Slominski A (2013) Putative role of HIF transcriptional activity in melanocytes and melanoma biology. Dermatoendocrinol 5:239&#8211;251. 10.4161/derm.22678<pub-id pub-id-type="pmid">24194964</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4161/derm.22678</pub-id><pub-id pub-id-type="pmcid">PMC3772912</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Haq</surname><given-names>R</given-names></name><name name-style="western"><surname>Shoag</surname><given-names>J</given-names></name><name name-style="western"><surname>Andreu-Perez</surname><given-names>P</given-names></name><etal/></person-group><article-title>Oncogenic BRAF regulates oxidative metabolism via PGC1&#945; and MITF</article-title><source>Cancer Cell</source><year>2013</year><volume>23</volume><fpage>302</fpage><lpage>315</lpage><pub-id pub-id-type="doi">10.1016/j.ccr.2013.02.003</pub-id><pub-id pub-id-type="pmid">23477830</pub-id><pub-id pub-id-type="pmcid">PMC3635826</pub-id></element-citation><mixed-citation id="mc-CR23" publication-type="journal">Haq R, Shoag J, Andreu-Perez P et al (2013) Oncogenic BRAF regulates oxidative metabolism via PGC1&#945; and MITF. Cancer Cell 23:302&#8211;315. 10.1016/j.ccr.2013.02.003<pub-id pub-id-type="pmid">23477830</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ccr.2013.02.003</pub-id><pub-id pub-id-type="pmcid">PMC3635826</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dai</surname><given-names>W</given-names></name><name name-style="western"><surname>Xu</surname><given-names>X</given-names></name><name name-style="western"><surname>Li</surname><given-names>S</given-names></name><etal/></person-group><article-title>SOX4 promotes proliferative signals by regulating glycolysis through AKT activation in melanoma cells</article-title><source>J Invest Dermatol</source><year>2017</year><volume>137</volume><fpage>2407</fpage><lpage>2416</lpage><pub-id pub-id-type="doi">10.1016/j.jid.2017.06.026</pub-id><pub-id pub-id-type="pmid">28760661</pub-id></element-citation><mixed-citation id="mc-CR24" publication-type="journal">Dai W, Xu X, Li S et al (2017) SOX4 promotes proliferative signals by regulating glycolysis through AKT activation in melanoma cells. J Invest Dermatol 137:2407&#8211;2416. 10.1016/j.jid.2017.06.026<pub-id pub-id-type="pmid">28760661</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jid.2017.06.026</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>K</given-names></name><name name-style="western"><surname>Mao</surname><given-names>X</given-names></name><name name-style="western"><surname>Mehta</surname><given-names>M</given-names></name><etal/></person-group><article-title>A comparative study of gene-expression data of basal cell carcinoma and melanoma reveals new insights about the two cancers</article-title><source>PLoS ONE</source><year>2012</year><volume>7</volume><fpage>e30750</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0030750</pub-id><pub-id pub-id-type="pmid">22295108</pub-id><pub-id pub-id-type="pmcid">PMC3266277</pub-id></element-citation><mixed-citation id="mc-CR25" publication-type="journal">Xu K, Mao X, Mehta M et al (2012) A comparative study of gene-expression data of basal cell carcinoma and melanoma reveals new insights about the two cancers. PLoS ONE 7:e30750. 10.1371/journal.pone.0030750<pub-id pub-id-type="pmid">22295108</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0030750</pub-id><pub-id pub-id-type="pmcid">PMC3266277</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ho</surname><given-names>J</given-names></name><name name-style="western"><surname>de Moura</surname><given-names>MB</given-names></name><name name-style="western"><surname>Lin</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Importance of glycolysis and oxidative phosphorylation in advanced melanoma</article-title><source>Mol Cancer</source><year>2012</year><volume>11</volume><fpage>76</fpage><pub-id pub-id-type="doi">10.1186/1476-4598-11-76</pub-id><pub-id pub-id-type="pmid">23043612</pub-id><pub-id pub-id-type="pmcid">PMC3537610</pub-id></element-citation><mixed-citation id="mc-CR26" publication-type="journal">Ho J, de Moura MB, Lin Y et al (2012) Importance of glycolysis and oxidative phosphorylation in advanced melanoma. Mol Cancer 11:76. 10.1186/1476-4598-11-76<pub-id pub-id-type="pmid">23043612</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/1476-4598-11-76</pub-id><pub-id pub-id-type="pmcid">PMC3537610</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>D</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Shi</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Metabolic reprogramming of cancer-associated fibroblasts by IDH3&#945; downregulation</article-title><source>Cell Rep</source><year>2015</year><volume>10</volume><fpage>1335</fpage><lpage>1348</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2015.02.006</pub-id><pub-id pub-id-type="pmid">25732824</pub-id></element-citation><mixed-citation id="mc-CR27" publication-type="journal">Zhang D, Wang Y, Shi Z et al (2015) Metabolic reprogramming of cancer-associated fibroblasts by IDH3&#945; downregulation. Cell Rep 10:1335&#8211;1348. 10.1016/j.celrep.2015.02.006<pub-id pub-id-type="pmid">25732824</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.celrep.2015.02.006</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>La</surname><given-names>ShuS</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Allen</surname><given-names>CL</given-names></name><etal/></person-group><article-title>Metabolic reprogramming of stromal fibroblasts by melanoma exosome microRNA favours a pre-metastatic microenvironment</article-title><source>Sci Rep</source><year>2018</year><volume>8</volume><fpage>12905</fpage><pub-id pub-id-type="doi">10.1038/s41598-018-31323-7</pub-id><pub-id pub-id-type="pmid">30150674</pub-id><pub-id pub-id-type="pmcid">PMC6110845</pub-id></element-citation><mixed-citation id="mc-CR28" publication-type="journal">La ShuS, Yang Y, Allen CL et al (2018) Metabolic reprogramming of stromal fibroblasts by melanoma exosome microRNA favours a pre-metastatic microenvironment. Sci Rep 8:12905. 10.1038/s41598-018-31323-7<pub-id pub-id-type="pmid">30150674</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-018-31323-7</pub-id><pub-id pub-id-type="pmcid">PMC6110845</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mazurkiewicz</surname><given-names>J</given-names></name><name name-style="western"><surname>Simiczyjew</surname><given-names>A</given-names></name><name name-style="western"><surname>Dratkiewicz</surname><given-names>E</given-names></name><etal/></person-group><article-title>Melanoma cells with diverse invasive potential differentially induce the activation of normal human fibroblasts</article-title><source>Cell Commun Signal</source><year>2022</year><volume>20</volume><fpage>63</fpage><pub-id pub-id-type="doi">10.1186/s12964-022-00871-x</pub-id><pub-id pub-id-type="pmid">35538545</pub-id><pub-id pub-id-type="pmcid">PMC9092709</pub-id></element-citation><mixed-citation id="mc-CR29" publication-type="journal">Mazurkiewicz J, Simiczyjew A, Dratkiewicz E et al (2022) Melanoma cells with diverse invasive potential differentially induce the activation of normal human fibroblasts. Cell Commun Signal 20:63. 10.1186/s12964-022-00871-x<pub-id pub-id-type="pmid">35538545</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12964-022-00871-x</pub-id><pub-id pub-id-type="pmcid">PMC9092709</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ratnikov</surname><given-names>B</given-names></name><name name-style="western"><surname>Aza-Blanc</surname><given-names>P</given-names></name><name name-style="western"><surname>Ronai</surname><given-names>ZA</given-names></name><etal/></person-group><article-title>Glutamate and asparagine cataplerosis underlie glutamine addiction in melanoma</article-title><source>Oncotarget</source><year>2015</year><volume>6</volume><fpage>7379</fpage><lpage>7389</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.3132</pub-id><pub-id pub-id-type="pmid">25749035</pub-id><pub-id pub-id-type="pmcid">PMC4480687</pub-id></element-citation><mixed-citation id="mc-CR30" publication-type="journal">Ratnikov B, Aza-Blanc P, Ronai ZA et al (2015) Glutamate and asparagine cataplerosis underlie glutamine addiction in melanoma. Oncotarget 6:7379&#8211;7389. 10.18632/oncotarget.3132<pub-id pub-id-type="pmid">25749035</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.18632/oncotarget.3132</pub-id><pub-id pub-id-type="pmcid">PMC4480687</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baenke</surname><given-names>F</given-names></name><name name-style="western"><surname>Chaneton</surname><given-names>B</given-names></name><name name-style="western"><surname>Smith</surname><given-names>M</given-names></name><etal/></person-group><article-title>Resistance to BRAF inhibitors induces glutamine dependency in melanoma cells</article-title><source>Mol Oncol</source><year>2016</year><volume>10</volume><fpage>73</fpage><lpage>84</lpage><pub-id pub-id-type="doi">10.1016/j.molonc.2015.08.003</pub-id><pub-id pub-id-type="pmid">26365896</pub-id><pub-id pub-id-type="pmcid">PMC4717845</pub-id></element-citation><mixed-citation id="mc-CR31" publication-type="journal">Baenke F, Chaneton B, Smith M et al (2016) Resistance to BRAF inhibitors induces glutamine dependency in melanoma cells. Mol Oncol 10:73&#8211;84. 10.1016/j.molonc.2015.08.003<pub-id pub-id-type="pmid">26365896</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.molonc.2015.08.003</pub-id><pub-id pub-id-type="pmcid">PMC4717845</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>X</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Nuclear receptor Nur77 facilitates melanoma cell survival under metabolic stress by protecting fatty acid oxidation</article-title><source>Mol Cell</source><year>2018</year><volume>69</volume><fpage>480</fpage><lpage>492.e7</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2018.01.001</pub-id><pub-id pub-id-type="pmid">29395065</pub-id></element-citation><mixed-citation id="mc-CR32" publication-type="journal">Li X, Wang Z, Zheng Y et al (2018) Nuclear receptor Nur77 facilitates melanoma cell survival under metabolic stress by protecting fatty acid oxidation. Mol Cell 69:480-492.e7. 10.1016/j.molcel.2018.01.001<pub-id pub-id-type="pmid">29395065</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.molcel.2018.01.001</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shin</surname><given-names>S</given-names></name><name name-style="western"><surname>Yang</surname><given-names>S</given-names></name><name name-style="western"><surname>Kim</surname><given-names>M</given-names></name><etal/></person-group><article-title>Fatty acid oxidation supports melanoma cell migration through autophagy regulation</article-title><source>Biochem Biophys Res Commun</source><year>2023</year><volume>674</volume><fpage>124</fpage><lpage>132</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2023.06.090</pub-id><pub-id pub-id-type="pmid">37419033</pub-id></element-citation><mixed-citation id="mc-CR33" publication-type="journal">Shin S, Yang S, Kim M et al (2023) Fatty acid oxidation supports melanoma cell migration through autophagy regulation. Biochem Biophys Res Commun 674:124&#8211;132. 10.1016/j.bbrc.2023.06.090<pub-id pub-id-type="pmid">37419033</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bbrc.2023.06.090</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Peppicelli</surname><given-names>S</given-names></name><name name-style="western"><surname>Kersikla</surname><given-names>T</given-names></name><name name-style="western"><surname>Menegazzi</surname><given-names>G</given-names></name><etal/></person-group><article-title>The critical role of glutamine and fatty acids in the metabolic reprogramming of anoikis-resistant melanoma cells</article-title><source>Front Pharmacol</source><year>2024</year><pub-id pub-id-type="doi">10.3389/fphar.2024.1422281</pub-id><pub-id pub-id-type="pmid">39175551</pub-id><pub-id pub-id-type="pmcid">PMC11338773</pub-id></element-citation><mixed-citation id="mc-CR34" publication-type="journal">Peppicelli S, Kersikla T, Menegazzi G et al (2024) The critical role of glutamine and fatty acids in the metabolic reprogramming of anoikis-resistant melanoma cells. Front Pharmacol. 10.3389/fphar.2024.1422281<pub-id pub-id-type="pmid">39175551</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fphar.2024.1422281</pub-id><pub-id pub-id-type="pmcid">PMC11338773</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aloia</surname><given-names>A</given-names></name><name name-style="western"><surname>M&#252;llhaupt</surname><given-names>D</given-names></name><name name-style="western"><surname>Chabbert</surname><given-names>CD</given-names></name><etal/></person-group><article-title>A fatty acid oxidation-dependent metabolic shift regulates the adaptation of BRAF -mutated melanoma to MAPK inhibitors</article-title><source>Clin Cancer Res</source><year>2019</year><volume>25</volume><fpage>6852</fpage><lpage>6867</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-19-0253</pub-id><pub-id pub-id-type="pmid">31375515</pub-id><pub-id pub-id-type="pmcid">PMC6906212</pub-id></element-citation><mixed-citation id="mc-CR35" publication-type="journal">Aloia A, M&#252;llhaupt D, Chabbert CD et al (2019) A fatty acid oxidation-dependent metabolic shift regulates the adaptation of BRAF -mutated melanoma to MAPK inhibitors. Clin Cancer Res 25:6852&#8211;6867. 10.1158/1078-0432.CCR-19-0253<pub-id pub-id-type="pmid">31375515</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/1078-0432.CCR-19-0253</pub-id><pub-id pub-id-type="pmcid">PMC6906212</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ho</surname><given-names>P-C</given-names></name><name name-style="western"><surname>Bihuniak</surname><given-names>JD</given-names></name><name name-style="western"><surname>Macintyre</surname><given-names>AN</given-names></name><etal/></person-group><article-title>Phosphoenolpyruvate is a metabolic checkpoint of anti-tumor T cell responses</article-title><source>Cell</source><year>2015</year><volume>162</volume><fpage>1217</fpage><lpage>1228</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2015.08.012</pub-id><pub-id pub-id-type="pmid">26321681</pub-id><pub-id pub-id-type="pmcid">PMC4567953</pub-id></element-citation><mixed-citation id="mc-CR36" publication-type="journal">Ho P-C, Bihuniak JD, Macintyre AN et al (2015) Phosphoenolpyruvate is a metabolic checkpoint of anti-tumor T cell responses. Cell 162:1217&#8211;1228. 10.1016/j.cell.2015.08.012<pub-id pub-id-type="pmid">26321681</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2015.08.012</pub-id><pub-id pub-id-type="pmcid">PMC4567953</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Kurupati</surname><given-names>R</given-names></name><name name-style="western"><surname>Liu</surname><given-names>L</given-names></name><etal/></person-group><article-title>Enhancing CD8+ T cell fatty acid catabolism within a metabolically challenging tumor microenvironment increases the efficacy of melanoma immunotherapy</article-title><source>Cancer Cell</source><year>2017</year><volume>32</volume><fpage>377</fpage><lpage>391.e9</lpage><pub-id pub-id-type="doi">10.1016/j.ccell.2017.08.004</pub-id><pub-id pub-id-type="pmid">28898698</pub-id><pub-id pub-id-type="pmcid">PMC5751418</pub-id></element-citation><mixed-citation id="mc-CR37" publication-type="journal">Zhang Y, Kurupati R, Liu L et al (2017) Enhancing CD8+ T cell fatty acid catabolism within a metabolically challenging tumor microenvironment increases the efficacy of melanoma immunotherapy. Cancer Cell 32:377-391.e9. 10.1016/j.ccell.2017.08.004<pub-id pub-id-type="pmid">28898698</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ccell.2017.08.004</pub-id><pub-id pub-id-type="pmcid">PMC5751418</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR38"><label>38.</label><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brand</surname><given-names>A</given-names></name><name name-style="western"><surname>Singer</surname><given-names>K</given-names></name><name name-style="western"><surname>Koehl</surname><given-names>GE</given-names></name><etal/></person-group><article-title>LDHA-associated lactic acid production blunts tumor immunosurveillance by T and NK cells</article-title><source>Cell Metab</source><year>2016</year><volume>24</volume><fpage>657</fpage><lpage>671</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2016.08.011</pub-id><pub-id pub-id-type="pmid">27641098</pub-id></element-citation><mixed-citation id="mc-CR38" publication-type="journal">Brand A, Singer K, Koehl GE et al (2016) LDHA-associated lactic acid production blunts tumor immunosurveillance by T and NK cells. Cell Metab 24:657&#8211;671. 10.1016/j.cmet.2016.08.011<pub-id pub-id-type="pmid">27641098</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cmet.2016.08.011</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR39"><label>39.</label><citation-alternatives><element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Colegio</surname><given-names>OR</given-names></name><name name-style="western"><surname>Chu</surname><given-names>N-Q</given-names></name><name name-style="western"><surname>Szabo</surname><given-names>AL</given-names></name><etal/></person-group><article-title>Functional polarization of tumour-associated macrophages by tumour-derived lactic acid</article-title><source>Nature</source><year>2014</year><volume>513</volume><fpage>559</fpage><lpage>563</lpage><pub-id pub-id-type="doi">10.1038/nature13490</pub-id><pub-id pub-id-type="pmid">25043024</pub-id><pub-id pub-id-type="pmcid">PMC4301845</pub-id></element-citation><mixed-citation id="mc-CR39" publication-type="journal">Colegio OR, Chu N-Q, Szabo AL et al (2014) Functional polarization of tumour-associated macrophages by tumour-derived lactic acid. Nature 513:559&#8211;563. 10.1038/nature13490<pub-id pub-id-type="pmid">25043024</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nature13490</pub-id><pub-id pub-id-type="pmcid">PMC4301845</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR40"><label>40.</label><citation-alternatives><element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Najjar</surname><given-names>YG</given-names></name><name name-style="western"><surname>Menk</surname><given-names>AV</given-names></name><name name-style="western"><surname>Sander</surname><given-names>C</given-names></name><etal/></person-group><article-title>Tumor cell oxidative metabolism as a barrier to PD-1 blockade immunotherapy in melanoma</article-title><source>JCI Insight</source><year>2019</year><pub-id pub-id-type="doi">10.1172/jci.insight.124989</pub-id><pub-id pub-id-type="pmid">30721155</pub-id><pub-id pub-id-type="pmcid">PMC6483505</pub-id></element-citation><mixed-citation id="mc-CR40" publication-type="journal">Najjar YG, Menk AV, Sander C et al (2019) Tumor cell oxidative metabolism as a barrier to PD-1 blockade immunotherapy in melanoma. JCI Insight. 10.1172/jci.insight.124989<pub-id pub-id-type="pmid">30721155</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1172/jci.insight.124989</pub-id><pub-id pub-id-type="pmcid">PMC6483505</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR41"><label>41.</label><citation-alternatives><element-citation id="ec-CR41" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>B-H</given-names></name><name name-style="western"><surname>Xu</surname><given-names>C-Z</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Mitochondrial quality control in human health and disease</article-title><source>Mil Med Res</source><year>2024</year><volume>11</volume><fpage>32</fpage><pub-id pub-id-type="doi">10.1186/s40779-024-00536-5</pub-id><pub-id pub-id-type="pmid">38812059</pub-id><pub-id pub-id-type="pmcid">PMC11134732</pub-id></element-citation><mixed-citation id="mc-CR41" publication-type="journal">Liu B-H, Xu C-Z, Liu Y et al (2024) Mitochondrial quality control in human health and disease. Mil Med Res 11:32. 10.1186/s40779-024-00536-5<pub-id pub-id-type="pmid">38812059</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s40779-024-00536-5</pub-id><pub-id pub-id-type="pmcid">PMC11134732</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR42"><label>42.</label><citation-alternatives><element-citation id="ec-CR42" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Qian</surname><given-names>L</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Deng</surname><given-names>C</given-names></name><etal/></person-group><article-title>Peroxisome proliferator-activated receptor gamma coactivator-1 (PGC-1) family in physiological and pathophysiological process and diseases</article-title><source>Signal Transduct Target Ther</source><year>2024</year><volume>9</volume><fpage>50</fpage><pub-id pub-id-type="doi">10.1038/s41392-024-01756-w</pub-id><pub-id pub-id-type="pmid">38424050</pub-id><pub-id pub-id-type="pmcid">PMC10904817</pub-id></element-citation><mixed-citation id="mc-CR42" publication-type="journal">Qian L, Zhu Y, Deng C et al (2024) Peroxisome proliferator-activated receptor gamma coactivator-1 (PGC-1) family in physiological and pathophysiological process and diseases. Signal Transduct Target Ther 9:50. 10.1038/s41392-024-01756-w<pub-id pub-id-type="pmid">38424050</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41392-024-01756-w</pub-id><pub-id pub-id-type="pmcid">PMC10904817</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR43"><label>43.</label><citation-alternatives><element-citation id="ec-CR43" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vazquez</surname><given-names>F</given-names></name><name name-style="western"><surname>Lim</surname><given-names>J-H</given-names></name><name name-style="western"><surname>Chim</surname><given-names>H</given-names></name><etal/></person-group><article-title>PGC1&#945; expression defines a subset of human melanoma tumors with increased mitochondrial capacity and resistance to oxidative stress</article-title><source>Cancer Cell</source><year>2013</year><volume>23</volume><fpage>287</fpage><lpage>301</lpage><pub-id pub-id-type="doi">10.1016/j.ccr.2012.11.020</pub-id><pub-id pub-id-type="pmid">23416000</pub-id><pub-id pub-id-type="pmcid">PMC3708305</pub-id></element-citation><mixed-citation id="mc-CR43" publication-type="journal">Vazquez F, Lim J-H, Chim H et al (2013) PGC1&#945; expression defines a subset of human melanoma tumors with increased mitochondrial capacity and resistance to oxidative stress. Cancer Cell 23:287&#8211;301. 10.1016/j.ccr.2012.11.020<pub-id pub-id-type="pmid">23416000</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ccr.2012.11.020</pub-id><pub-id pub-id-type="pmcid">PMC3708305</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR44"><label>44.</label><citation-alternatives><element-citation id="ec-CR44" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Luo</surname><given-names>C</given-names></name><name name-style="western"><surname>Lim</surname><given-names>J-H</given-names></name><name name-style="western"><surname>Lee</surname><given-names>Y</given-names></name><etal/></person-group><article-title>A PGC1&#945;-mediated transcriptional axis suppresses melanoma metastasis</article-title><source>Nature</source><year>2016</year><volume>537</volume><fpage>422</fpage><lpage>426</lpage><pub-id pub-id-type="doi">10.1038/nature19347</pub-id><pub-id pub-id-type="pmid">27580028</pub-id><pub-id pub-id-type="pmcid">PMC5161587</pub-id></element-citation><mixed-citation id="mc-CR44" publication-type="journal">Luo C, Lim J-H, Lee Y et al (2016) A PGC1&#945;-mediated transcriptional axis suppresses melanoma metastasis. Nature 537:422&#8211;426. 10.1038/nature19347<pub-id pub-id-type="pmid">27580028</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nature19347</pub-id><pub-id pub-id-type="pmcid">PMC5161587</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR45"><label>45.</label><citation-alternatives><element-citation id="ec-CR45" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gelato</surname><given-names>KA</given-names></name><name name-style="western"><surname>Sch&#246;ckel</surname><given-names>L</given-names></name><name name-style="western"><surname>Klingbeil</surname><given-names>O</given-names></name><etal/></person-group><article-title>Super-enhancers define a proliferative PGC-1&#945;-expressing melanoma subgroup sensitive to BET inhibition</article-title><source>Oncogene</source><year>2018</year><volume>37</volume><fpage>512</fpage><lpage>521</lpage><pub-id pub-id-type="doi">10.1038/onc.2017.325</pub-id><pub-id pub-id-type="pmid">28991225</pub-id><pub-id pub-id-type="pmcid">PMC5799712</pub-id></element-citation><mixed-citation id="mc-CR45" publication-type="journal">Gelato KA, Sch&#246;ckel L, Klingbeil O et al (2018) Super-enhancers define a proliferative PGC-1&#945;-expressing melanoma subgroup sensitive to BET inhibition. Oncogene 37:512&#8211;521. 10.1038/onc.2017.325<pub-id pub-id-type="pmid">28991225</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/onc.2017.325</pub-id><pub-id pub-id-type="pmcid">PMC5799712</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR46"><label>46.</label><citation-alternatives><element-citation id="ec-CR46" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Luo</surname><given-names>C</given-names></name><name name-style="western"><surname>Balsa</surname><given-names>E</given-names></name><name name-style="western"><surname>Perry</surname><given-names>EA</given-names></name><etal/></person-group><article-title>H3K27me3-mediated PGC1&#945; gene silencing promotes melanoma invasion through WNT5A and YAP</article-title><source>J Clin Invest</source><year>2020</year><volume>130</volume><fpage>853</fpage><lpage>862</lpage><pub-id pub-id-type="doi">10.1172/JCI130038</pub-id><pub-id pub-id-type="pmid">31929186</pub-id><pub-id pub-id-type="pmcid">PMC6994149</pub-id></element-citation><mixed-citation id="mc-CR46" publication-type="journal">Luo C, Balsa E, Perry EA et al (2020) H3K27me3-mediated PGC1&#945; gene silencing promotes melanoma invasion through WNT5A and YAP. J Clin Invest 130:853&#8211;862. 10.1172/JCI130038<pub-id pub-id-type="pmid">31929186</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1172/JCI130038</pub-id><pub-id pub-id-type="pmcid">PMC6994149</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR47"><label>47.</label><citation-alternatives><element-citation id="ec-CR47" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fontana</surname><given-names>F</given-names></name><name name-style="western"><surname>Macchi</surname><given-names>C</given-names></name><name name-style="western"><surname>Anselmi</surname><given-names>M</given-names></name><etal/></person-group><article-title>PGC1-&#945;-driven mitochondrial biogenesis contributes to a cancer stem cell phenotype in melanoma</article-title><source>Biochim Biophys Acta Mol Basis Dis</source><year>2024</year><volume>1870</volume><fpage>166897</fpage><pub-id pub-id-type="doi">10.1016/j.bbadis.2023.166897</pub-id><pub-id pub-id-type="pmid">37758066</pub-id></element-citation><mixed-citation id="mc-CR47" publication-type="journal">Fontana F, Macchi C, Anselmi M et al (2024) PGC1-&#945;-driven mitochondrial biogenesis contributes to a cancer stem cell phenotype in melanoma. Biochim Biophys Acta Mol Basis Dis 1870:166897. 10.1016/j.bbadis.2023.166897<pub-id pub-id-type="pmid">37758066</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bbadis.2023.166897</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR48"><label>48.</label><citation-alternatives><element-citation id="ec-CR48" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gopal</surname><given-names>YNV</given-names></name><name name-style="western"><surname>Rizos</surname><given-names>H</given-names></name><name name-style="western"><surname>Chen</surname><given-names>G</given-names></name><etal/></person-group><article-title>Inhibition of mTORC1/2 overcomes resistance to MAPK pathway inhibitors mediated by PGC1&#945; and oxidative phosphorylation in melanoma</article-title><source>Cancer Res</source><year>2014</year><volume>74</volume><fpage>7037</fpage><lpage>7047</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-14-1392</pub-id><pub-id pub-id-type="pmid">25297634</pub-id><pub-id pub-id-type="pmcid">PMC4347853</pub-id></element-citation><mixed-citation id="mc-CR48" publication-type="journal">Gopal YNV, Rizos H, Chen G et al (2014) Inhibition of mTORC1/2 overcomes resistance to MAPK pathway inhibitors mediated by PGC1&#945; and oxidative phosphorylation in melanoma. Cancer Res 74:7037&#8211;7047. 10.1158/0008-5472.CAN-14-1392<pub-id pub-id-type="pmid">25297634</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/0008-5472.CAN-14-1392</pub-id><pub-id pub-id-type="pmcid">PMC4347853</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR49"><label>49.</label><citation-alternatives><element-citation id="ec-CR49" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Corazao-Rozas</surname><given-names>P</given-names></name><name name-style="western"><surname>Guerreschi</surname><given-names>P</given-names></name><name name-style="western"><surname>Andr&#233;</surname><given-names>F</given-names></name><etal/></person-group><article-title>Mitochondrial oxidative phosphorylation controls cancer cell&#8217;s life and death decisions upon exposure to MAPK inhibitors</article-title><source>Oncotarget</source><year>2016</year><volume>7</volume><fpage>39473</fpage><lpage>39485</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.7790</pub-id><pub-id pub-id-type="pmid">27250023</pub-id><pub-id pub-id-type="pmcid">PMC5129946</pub-id></element-citation><mixed-citation id="mc-CR49" publication-type="journal">Corazao-Rozas P, Guerreschi P, Andr&#233; F et al (2016) Mitochondrial oxidative phosphorylation controls cancer cell&#8217;s life and death decisions upon exposure to MAPK inhibitors. Oncotarget 7:39473&#8211;39485. 10.18632/oncotarget.7790<pub-id pub-id-type="pmid">27250023</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.18632/oncotarget.7790</pub-id><pub-id pub-id-type="pmcid">PMC5129946</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR50"><label>50.</label><citation-alternatives><element-citation id="ec-CR50" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Trotta</surname><given-names>AP</given-names></name><name name-style="western"><surname>Gelles</surname><given-names>JD</given-names></name><name name-style="western"><surname>Serasinghe</surname><given-names>MN</given-names></name><etal/></person-group><article-title>Disruption of mitochondrial electron transport chain function potentiates the pro-apoptotic effects of MAPK inhibition</article-title><source>J Biol Chem</source><year>2017</year><pub-id pub-id-type="doi">10.1074/jbc.M117.786442</pub-id><pub-id pub-id-type="pmid">28546431</pub-id><pub-id pub-id-type="pmcid">PMC5512068</pub-id></element-citation><mixed-citation id="mc-CR50" publication-type="journal">Trotta AP, Gelles JD, Serasinghe MN et al (2017) Disruption of mitochondrial electron transport chain function potentiates the pro-apoptotic effects of MAPK inhibition. J Biol Chem. 10.1074/jbc.M117.786442<pub-id pub-id-type="pmid">28546431</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1074/jbc.M117.786442</pub-id><pub-id pub-id-type="pmcid">PMC5512068</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR51"><label>51.</label><citation-alternatives><element-citation id="ec-CR51" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Adebayo</surname><given-names>M</given-names></name><name name-style="western"><surname>Singh</surname><given-names>S</given-names></name><name name-style="western"><surname>Singh</surname><given-names>AP</given-names></name><name name-style="western"><surname>Dasgupta</surname><given-names>S</given-names></name></person-group><article-title>Mitochondrial fusion and fission: The fine-tune balance for cellular homeostasis</article-title><source>FASEB J</source><year>2021</year><pub-id pub-id-type="doi">10.1096/fj.202100067R</pub-id><pub-id pub-id-type="pmid">34048084</pub-id><pub-id pub-id-type="pmcid">PMC8415099</pub-id></element-citation><mixed-citation id="mc-CR51" publication-type="journal">Adebayo M, Singh S, Singh AP, Dasgupta S (2021) Mitochondrial fusion and fission: The fine-tune balance for cellular homeostasis. FASEB J. 10.1096/fj.202100067R<pub-id pub-id-type="pmid">34048084</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1096/fj.202100067R</pub-id><pub-id pub-id-type="pmcid">PMC8415099</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR52"><label>52.</label><citation-alternatives><element-citation id="ec-CR52" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>ES</given-names></name><name name-style="western"><surname>Park</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Goh</surname><given-names>M</given-names></name><etal/></person-group><article-title>Mitochondrial dynamics regulate melanogenesis through proteasomal degradation of MITF via ROS-ERK activation</article-title><source>Pigment Cell Melanoma Res</source><year>2014</year><volume>27</volume><fpage>1051</fpage><lpage>1062</lpage><pub-id pub-id-type="doi">10.1111/pcmr.12298</pub-id><pub-id pub-id-type="pmid">25065405</pub-id></element-citation><mixed-citation id="mc-CR52" publication-type="journal">Kim ES, Park SJ, Goh M et al (2014) Mitochondrial dynamics regulate melanogenesis through proteasomal degradation of MITF via ROS-ERK activation. Pigment Cell Melanoma Res 27:1051&#8211;1062. 10.1111/pcmr.12298<pub-id pub-id-type="pmid">25065405</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/pcmr.12298</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR53"><label>53.</label><citation-alternatives><element-citation id="ec-CR53" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tanwar</surname><given-names>J</given-names></name><name name-style="western"><surname>Saurav</surname><given-names>S</given-names></name><name name-style="western"><surname>Basu</surname><given-names>R</given-names></name><etal/></person-group><article-title>Mitofusin-2 negatively regulates melanogenesis by modulating mitochondrial ROS generation</article-title><source>Cells</source><year>2022</year><volume>11</volume><fpage>701</fpage><pub-id pub-id-type="doi">10.3390/cells11040701</pub-id><pub-id pub-id-type="pmid">35203350</pub-id><pub-id pub-id-type="pmcid">PMC8869806</pub-id></element-citation><mixed-citation id="mc-CR53" publication-type="journal">Tanwar J, Saurav S, Basu R et al (2022) Mitofusin-2 negatively regulates melanogenesis by modulating mitochondrial ROS generation. Cells 11:701. 10.3390/cells11040701<pub-id pub-id-type="pmid">35203350</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/cells11040701</pub-id><pub-id pub-id-type="pmcid">PMC8869806</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR54"><label>54.</label><citation-alternatives><element-citation id="ec-CR54" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Serasinghe</surname><given-names>MN</given-names></name><name name-style="western"><surname>Wieder</surname><given-names>SY</given-names></name><name name-style="western"><surname>Renault</surname><given-names>TT</given-names></name><etal/></person-group><article-title>Mitochondrial division is requisite to RAS-induced transformation and targeted by oncogenic MAPK pathway inhibitors</article-title><source>Mol Cell</source><year>2015</year><volume>57</volume><fpage>521</fpage><lpage>536</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2015.01.003</pub-id><pub-id pub-id-type="pmid">25658204</pub-id><pub-id pub-id-type="pmcid">PMC4320323</pub-id></element-citation><mixed-citation id="mc-CR54" publication-type="journal">Serasinghe MN, Wieder SY, Renault TT et al (2015) Mitochondrial division is requisite to RAS-induced transformation and targeted by oncogenic MAPK pathway inhibitors. Mol Cell 57:521&#8211;536. 10.1016/j.molcel.2015.01.003<pub-id pub-id-type="pmid">25658204</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.molcel.2015.01.003</pub-id><pub-id pub-id-type="pmcid">PMC4320323</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR55"><label>55.</label><citation-alternatives><element-citation id="ec-CR55" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dal Yontem</surname><given-names>F</given-names></name><name name-style="western"><surname>Kim</surname><given-names>S</given-names></name><name name-style="western"><surname>Ding</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Mitochondrial dynamic alterations regulate melanoma cell progression</article-title><source>J Cell Biochem</source><year>2019</year><volume>120</volume><issue>2</issue><fpage>2098</fpage><lpage>2108</lpage><pub-id pub-id-type="doi">10.1002/jcb.27518</pub-id><pub-id pub-id-type="pmid">30256441</pub-id></element-citation><mixed-citation id="mc-CR55" publication-type="journal">Dal Yontem F, Kim S, Ding Z et al (2019) Mitochondrial dynamic alterations regulate melanoma cell progression. J Cell Biochem 120(2):2098&#8211;2108. 10.1002/jcb.27518<pub-id pub-id-type="pmid">30256441</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jcb.27518</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR56"><label>56.</label><citation-alternatives><element-citation id="ec-CR56" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ferraz</surname><given-names>LS</given-names></name><name name-style="western"><surname>da Costa</surname><given-names>RT</given-names></name><name name-style="western"><surname>da Costa</surname><given-names>CA</given-names></name><etal/></person-group><article-title>Targeting mitochondria in melanoma: interplay between MAPK signaling pathway and mitochondrial dynamics</article-title><source>Biochem Pharmacol</source><year>2020</year><volume>178</volume><fpage>114104</fpage><pub-id pub-id-type="doi">10.1016/j.bcp.2020.114104</pub-id><pub-id pub-id-type="pmid">32562785</pub-id></element-citation><mixed-citation id="mc-CR56" publication-type="journal">Ferraz LS, da Costa RT, da Costa CA et al (2020) Targeting mitochondria in melanoma: interplay between MAPK signaling pathway and mitochondrial dynamics. Biochem Pharmacol 178:114104. 10.1016/j.bcp.2020.114104<pub-id pub-id-type="pmid">32562785</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bcp.2020.114104</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR57"><label>57.</label><citation-alternatives><element-citation id="ec-CR57" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tarallo</surname><given-names>D</given-names></name><name name-style="western"><surname>Mart&#237;nez</surname><given-names>J</given-names></name><name name-style="western"><surname>Leyva</surname><given-names>A</given-names></name><etal/></person-group><article-title>Mitofusin 1 silencing decreases the senescent associated secretory phenotype, promotes immune cell recruitment and delays melanoma tumor growth after chemotherapy</article-title><source>Sci Rep</source><year>2024</year><volume>14</volume><fpage>909</fpage><pub-id pub-id-type="doi">10.1038/s41598-024-51427-7</pub-id><pub-id pub-id-type="pmid">38195762</pub-id><pub-id pub-id-type="pmcid">PMC10776601</pub-id></element-citation><mixed-citation id="mc-CR57" publication-type="journal">Tarallo D, Mart&#237;nez J, Leyva A et al (2024) Mitofusin 1 silencing decreases the senescent associated secretory phenotype, promotes immune cell recruitment and delays melanoma tumor growth after chemotherapy. Sci Rep 14:909. 10.1038/s41598-024-51427-7<pub-id pub-id-type="pmid">38195762</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-024-51427-7</pub-id><pub-id pub-id-type="pmcid">PMC10776601</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR58"><label>58.</label><citation-alternatives><element-citation id="ec-CR58" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Picca</surname><given-names>A</given-names></name><name name-style="western"><surname>Faitg</surname><given-names>J</given-names></name><name name-style="western"><surname>Auwerx</surname><given-names>J</given-names></name><etal/></person-group><article-title>Mitophagy in human health, ageing and disease</article-title><source>Nat Metab</source><year>2023</year><volume>5</volume><fpage>2047</fpage><lpage>2061</lpage><pub-id pub-id-type="doi">10.1038/s42255-023-00930-8</pub-id><pub-id pub-id-type="pmid">38036770</pub-id><pub-id pub-id-type="pmcid">PMC12159423</pub-id></element-citation><mixed-citation id="mc-CR58" publication-type="journal">Picca A, Faitg J, Auwerx J et al (2023) Mitophagy in human health, ageing and disease. Nat Metab 5:2047&#8211;2061. 10.1038/s42255-023-00930-8<pub-id pub-id-type="pmid">38036770</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s42255-023-00930-8</pub-id><pub-id pub-id-type="pmcid">PMC12159423</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR59"><label>59.</label><citation-alternatives><element-citation id="ec-CR59" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hu</surname><given-names>H-H</given-names></name><name name-style="western"><surname>Kannengiesser</surname><given-names>C</given-names></name><name name-style="western"><surname>Lesage</surname><given-names>S</given-names></name><etal/></person-group><article-title>PARKIN inactivation links Parkinson&#8217;s disease to melanoma</article-title><source>J Natl Cancer Inst</source><year>2016</year><volume>108</volume><fpage>djv340</fpage><pub-id pub-id-type="doi">10.1093/jnci/djv340</pub-id><pub-id pub-id-type="pmid">26683220</pub-id></element-citation><mixed-citation id="mc-CR59" publication-type="journal">Hu H-H, Kannengiesser C, Lesage S et al (2016) PARKIN inactivation links Parkinson&#8217;s disease to melanoma. J Natl Cancer Inst 108:djv340. 10.1093/jnci/djv340<pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/jnci/djv340</pub-id><pub-id pub-id-type="pmid">26683220</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR60"><label>60.</label><citation-alternatives><element-citation id="ec-CR60" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vara-P&#233;rez</surname><given-names>M</given-names></name><name name-style="western"><surname>Rossi</surname><given-names>M</given-names></name><name name-style="western"><surname>Van den Haute</surname><given-names>C</given-names></name><etal/></person-group><article-title>BNIP3 promotes HIF-1&#945;-driven melanoma growth by curbing intracellular iron homeostasis</article-title><source>EMBO J</source><year>2021</year><pub-id pub-id-type="doi">10.15252/embj.2020106214</pub-id><pub-id pub-id-type="pmid">33932034</pub-id><pub-id pub-id-type="pmcid">PMC8126921</pub-id></element-citation><mixed-citation id="mc-CR60" publication-type="journal">Vara-P&#233;rez M, Rossi M, Van den Haute C et al (2021) BNIP3 promotes HIF-1&#945;-driven melanoma growth by curbing intracellular iron homeostasis. EMBO J. 10.15252/embj.2020106214<pub-id pub-id-type="pmid">33932034</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.15252/embj.2020106214</pub-id><pub-id pub-id-type="pmcid">PMC8126921</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR61"><label>61.</label><citation-alternatives><element-citation id="ec-CR61" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>J</given-names></name><name name-style="western"><surname>Ding</surname><given-names>J</given-names></name><name name-style="western"><surname>Yue</surname><given-names>H</given-names></name><etal/></person-group><article-title>Hypoxia-induced BNIP3 facilitates the progression and metastasis of uveal melanoma by driving metabolic reprogramming</article-title><source>Autophagy</source><year>2025</year><volume>21</volume><fpage>191</fpage><lpage>209</lpage><pub-id pub-id-type="doi">10.1080/15548627.2024.2395142</pub-id><pub-id pub-id-type="pmid">39265983</pub-id><pub-id pub-id-type="pmcid">PMC11702930</pub-id></element-citation><mixed-citation id="mc-CR61" publication-type="journal">Sun J, Ding J, Yue H et al (2025) Hypoxia-induced BNIP3 facilitates the progression and metastasis of uveal melanoma by driving metabolic reprogramming. Autophagy 21:191&#8211;209. 10.1080/15548627.2024.2395142<pub-id pub-id-type="pmid">39265983</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/15548627.2024.2395142</pub-id><pub-id pub-id-type="pmcid">PMC11702930</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR62"><label>62.</label><citation-alternatives><element-citation id="ec-CR62" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>H</given-names></name><name name-style="western"><surname>Yi</surname><given-names>X</given-names></name><name name-style="western"><surname>Guo</surname><given-names>S</given-names></name><etal/></person-group><article-title>The XBP1-MARCH5-MFN2 axis confers endoplasmic reticulum stress resistance by coordinating mitochondrial fission and mitophagy in melanoma</article-title><source>J Invest Dermatol</source><year>2021</year><volume>141</volume><fpage>2932</fpage><lpage>2943.e12</lpage><pub-id pub-id-type="doi">10.1016/j.jid.2021.03.031</pub-id><pub-id pub-id-type="pmid">34048729</pub-id></element-citation><mixed-citation id="mc-CR62" publication-type="journal">Wang H, Yi X, Guo S et al (2021) The XBP1-MARCH5-MFN2 axis confers endoplasmic reticulum stress resistance by coordinating mitochondrial fission and mitophagy in melanoma. J Invest Dermatol 141:2932-2943.e12. 10.1016/j.jid.2021.03.031<pub-id pub-id-type="pmid">34048729</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jid.2021.03.031</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR63"><label>63.</label><citation-alternatives><element-citation id="ec-CR63" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Desler</surname><given-names>C</given-names></name><name name-style="western"><surname>Marcker</surname><given-names>ML</given-names></name><name name-style="western"><surname>Singh</surname><given-names>KK</given-names></name><name name-style="western"><surname>Rasmussen</surname><given-names>LJ</given-names></name></person-group><article-title>The importance of mitochondrial DNA in aging and cancer</article-title><source>J Aging Res</source><year>2011</year><volume>2011</volume><fpage>1</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.4061/2011/407536</pub-id><pub-id pub-id-type="pmcid">PMC3092560</pub-id><pub-id pub-id-type="pmid">21584235</pub-id></element-citation><mixed-citation id="mc-CR63" publication-type="journal">Desler C, Marcker ML, Singh KK, Rasmussen LJ (2011) The importance of mitochondrial DNA in aging and cancer. J Aging Res 2011:1&#8211;9. 10.4061/2011/407536<pub-id pub-id-type="doi" assigning-authority="pmc">10.4061/2011/407536</pub-id><pub-id pub-id-type="pmcid">PMC3092560</pub-id><pub-id pub-id-type="pmid">21584235</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR64"><label>64.</label><citation-alternatives><element-citation id="ec-CR64" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Friedman</surname><given-names>JR</given-names></name><name name-style="western"><surname>Nunnari</surname><given-names>J</given-names></name></person-group><article-title>Mitochondrial form and function</article-title><source>Nature</source><year>2014</year><volume>505</volume><fpage>335</fpage><lpage>343</lpage><pub-id pub-id-type="doi">10.1038/nature12985</pub-id><pub-id pub-id-type="pmid">24429632</pub-id><pub-id pub-id-type="pmcid">PMC4075653</pub-id></element-citation><mixed-citation id="mc-CR64" publication-type="journal">Friedman JR, Nunnari J (2014) Mitochondrial form and function. Nature 505:335&#8211;343. 10.1038/nature12985<pub-id pub-id-type="pmid">24429632</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nature12985</pub-id><pub-id pub-id-type="pmcid">PMC4075653</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR65"><label>65.</label><citation-alternatives><element-citation id="ec-CR65" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kuo</surname><given-names>F-C</given-names></name><name name-style="western"><surname>Tsai</surname><given-names>H-Y</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>B-L</given-names></name><etal/></person-group><article-title>Endothelial mitochondria transfer to melanoma induces M2-type macrophage polarization and promotes tumor growth by the Nrf2/HO-1-mediated pathway</article-title><source>Int J Mol Sci</source><year>2024</year><volume>25</volume><fpage>1857</fpage><pub-id pub-id-type="doi">10.3390/ijms25031857</pub-id><pub-id pub-id-type="pmid">38339136</pub-id><pub-id pub-id-type="pmcid">PMC10855867</pub-id></element-citation><mixed-citation id="mc-CR65" publication-type="journal">Kuo F-C, Tsai H-Y, Cheng B-L et al (2024) Endothelial mitochondria transfer to melanoma induces M2-type macrophage polarization and promotes tumor growth by the Nrf2/HO-1-mediated pathway. Int J Mol Sci 25:1857. 10.3390/ijms25031857<pub-id pub-id-type="pmid">38339136</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms25031857</pub-id><pub-id pub-id-type="pmcid">PMC10855867</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR66"><label>66.</label><citation-alternatives><element-citation id="ec-CR66" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kumar</surname><given-names>PR</given-names></name><name name-style="western"><surname>Saad</surname><given-names>M</given-names></name><name name-style="western"><surname>Hellmich</surname><given-names>C</given-names></name><etal/></person-group><article-title>PGC-1&#945; induced mitochondrial biogenesis in stromal cells underpins mitochondrial transfer to melanoma</article-title><source>Br J Cancer</source><year>2022</year><volume>127</volume><fpage>69</fpage><lpage>78</lpage><pub-id pub-id-type="doi">10.1038/s41416-022-01783-w</pub-id><pub-id pub-id-type="pmid">35347324</pub-id><pub-id pub-id-type="pmcid">PMC9276678</pub-id></element-citation><mixed-citation id="mc-CR66" publication-type="journal">Kumar PR, Saad M, Hellmich C et al (2022) PGC-1&#945; induced mitochondrial biogenesis in stromal cells underpins mitochondrial transfer to melanoma. Br J Cancer 127:69&#8211;78. 10.1038/s41416-022-01783-w<pub-id pub-id-type="pmid">35347324</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41416-022-01783-w</pub-id><pub-id pub-id-type="pmcid">PMC9276678</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR67"><label>67.</label><citation-alternatives><element-citation id="ec-CR67" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dong</surname><given-names>L-F</given-names></name><name name-style="western"><surname>Kovarova</surname><given-names>J</given-names></name><name name-style="western"><surname>Bajzikova</surname><given-names>M</given-names></name><etal/></person-group><article-title>Horizontal transfer of whole mitochondria restores tumorigenic potential in mitochondrial DNA-deficient cancer cells</article-title><source>Elife</source><year>2017</year><pub-id pub-id-type="doi">10.7554/eLife.22187</pub-id><pub-id pub-id-type="pmid">28195532</pub-id><pub-id pub-id-type="pmcid">PMC5367896</pub-id></element-citation><mixed-citation id="mc-CR67" publication-type="journal">Dong L-F, Kovarova J, Bajzikova M et al (2017) Horizontal transfer of whole mitochondria restores tumorigenic potential in mitochondrial DNA-deficient cancer cells. Elife. 10.7554/eLife.22187<pub-id pub-id-type="pmid">28195532</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7554/eLife.22187</pub-id><pub-id pub-id-type="pmcid">PMC5367896</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR68"><label>68.</label><citation-alternatives><element-citation id="ec-CR68" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jang</surname><given-names>SC</given-names></name><name name-style="western"><surname>Crescitelli</surname><given-names>R</given-names></name><name name-style="western"><surname>Cvjetkovic</surname><given-names>A</given-names></name><etal/></person-group><article-title>Mitochondrial protein enriched extracellular vesicles discovered in human melanoma tissues can be detected in patient plasma</article-title><source>J Extracell Vesicles</source><year>2019</year><pub-id pub-id-type="doi">10.1080/20013078.2019.1635420</pub-id><pub-id pub-id-type="pmid">31497264</pub-id><pub-id pub-id-type="pmcid">PMC6719261</pub-id></element-citation><mixed-citation id="mc-CR68" publication-type="journal">Jang SC, Crescitelli R, Cvjetkovic A et al (2019) Mitochondrial protein enriched extracellular vesicles discovered in human melanoma tissues can be detected in patient plasma. J Extracell Vesicles. 10.1080/20013078.2019.1635420<pub-id pub-id-type="pmid">31497264</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/20013078.2019.1635420</pub-id><pub-id pub-id-type="pmcid">PMC6719261</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR69"><label>69.</label><citation-alternatives><element-citation id="ec-CR69" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Karbanov&#225;</surname><given-names>J</given-names></name><name name-style="western"><surname>Deniz</surname><given-names>IA</given-names></name><name name-style="western"><surname>Wilsch-Br&#228;uninger</surname><given-names>M</given-names></name><etal/></person-group><article-title>Extracellular lipidosomes containing lipid droplets and mitochondria are released during melanoma cell division</article-title><source>Cell Commun Signal</source><year>2024</year><volume>22</volume><fpage>57</fpage><pub-id pub-id-type="doi">10.1186/s12964-024-01471-7</pub-id><pub-id pub-id-type="pmid">38243233</pub-id><pub-id pub-id-type="pmcid">PMC10799373</pub-id></element-citation><mixed-citation id="mc-CR69" publication-type="journal">Karbanov&#225; J, Deniz IA, Wilsch-Br&#228;uninger M et al (2024) Extracellular lipidosomes containing lipid droplets and mitochondria are released during melanoma cell division. Cell Commun Signal 22:57. 10.1186/s12964-024-01471-7<pub-id pub-id-type="pmid">38243233</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12964-024-01471-7</pub-id><pub-id pub-id-type="pmcid">PMC10799373</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR70"><label>70.</label><citation-alternatives><element-citation id="ec-CR70" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lazar</surname><given-names>I</given-names></name><name name-style="western"><surname>Clement</surname><given-names>E</given-names></name><name name-style="western"><surname>Dauvillier</surname><given-names>S</given-names></name><etal/></person-group><article-title>Adipocyte exosomes promote melanoma aggressiveness through fatty acid oxidation: a novel mechanism linking obesity and cancer</article-title><source>Cancer Res</source><year>2016</year><volume>76</volume><fpage>4051</fpage><lpage>4057</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-16-0651</pub-id><pub-id pub-id-type="pmid">27216185</pub-id></element-citation><mixed-citation id="mc-CR70" publication-type="journal">Lazar I, Clement E, Dauvillier S et al (2016) Adipocyte exosomes promote melanoma aggressiveness through fatty acid oxidation: a novel mechanism linking obesity and cancer. Cancer Res 76:4051&#8211;4057. 10.1158/0008-5472.CAN-16-0651<pub-id pub-id-type="pmid">27216185</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/0008-5472.CAN-16-0651</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR71"><label>71.</label><citation-alternatives><element-citation id="ec-CR71" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>M</given-names></name><name name-style="western"><surname>Mahmood</surname><given-names>M</given-names></name><name name-style="western"><surname>Reznik</surname><given-names>E</given-names></name><name name-style="western"><surname>Gammage</surname><given-names>PA</given-names></name></person-group><article-title>Mitochondrial DNA is a major source of driver mutations in cancer</article-title><source>Trends Cancer</source><year>2022</year><volume>8</volume><fpage>1046</fpage><lpage>1059</lpage><pub-id pub-id-type="doi">10.1016/j.trecan.2022.08.001</pub-id><pub-id pub-id-type="pmid">36041967</pub-id><pub-id pub-id-type="pmcid">PMC9671861</pub-id></element-citation><mixed-citation id="mc-CR71" publication-type="journal">Kim M, Mahmood M, Reznik E, Gammage PA (2022) Mitochondrial DNA is a major source of driver mutations in cancer. Trends Cancer 8:1046&#8211;1059. 10.1016/j.trecan.2022.08.001<pub-id pub-id-type="pmid">36041967</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.trecan.2022.08.001</pub-id><pub-id pub-id-type="pmcid">PMC9671861</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR72"><label>72.</label><citation-alternatives><element-citation id="ec-CR72" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shelton</surname><given-names>SD</given-names></name><name name-style="western"><surname>House</surname><given-names>S</given-names></name><name name-style="western"><surname>Martins Nascentes Melo</surname><given-names>L</given-names></name><etal/></person-group><article-title>Pathogenic mitochondrial DNA mutations inhibit melanoma metastasis</article-title><source>Sci Adv</source><year>2024</year><volume>10</volume><fpage>eadk8801</fpage><pub-id pub-id-type="doi">10.1126/sciadv.adk8801</pub-id><pub-id pub-id-type="pmid">39485847</pub-id><pub-id pub-id-type="pmcid">PMC11529715</pub-id></element-citation><mixed-citation id="mc-CR72" publication-type="journal">Shelton SD, House S, Martins Nascentes Melo L et al (2024) Pathogenic mitochondrial DNA mutations inhibit melanoma metastasis. Sci Adv 10:eadk8801. 10.1126/sciadv.adk8801<pub-id pub-id-type="pmid">39485847</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/sciadv.adk8801</pub-id><pub-id pub-id-type="pmcid">PMC11529715</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR73"><label>73.</label><citation-alternatives><element-citation id="ec-CR73" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mahmood</surname><given-names>M</given-names></name><name name-style="western"><surname>Liu</surname><given-names>EM</given-names></name><name name-style="western"><surname>Shergold</surname><given-names>AL</given-names></name><etal/></person-group><article-title>Mitochondrial DNA mutations drive aerobic glycolysis to enhance checkpoint blockade response in melanoma</article-title><source>Nat Cancer</source><year>2024</year><volume>5</volume><fpage>659</fpage><lpage>672</lpage><pub-id pub-id-type="doi">10.1038/s43018-023-00721-w</pub-id><pub-id pub-id-type="pmid">38286828</pub-id><pub-id pub-id-type="pmcid">PMC11056318</pub-id></element-citation><mixed-citation id="mc-CR73" publication-type="journal">Mahmood M, Liu EM, Shergold AL et al (2024) Mitochondrial DNA mutations drive aerobic glycolysis to enhance checkpoint blockade response in melanoma. Nat Cancer 5:659&#8211;672. 10.1038/s43018-023-00721-w<pub-id pub-id-type="pmid">38286828</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s43018-023-00721-w</pub-id><pub-id pub-id-type="pmcid">PMC11056318</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR74"><label>74.</label><citation-alternatives><element-citation id="ec-CR74" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Parakatselaki</surname><given-names>M-E</given-names></name><name name-style="western"><surname>Ladoukakis</surname><given-names>ED</given-names></name></person-group><article-title>mtDNA heteroplasmy: origin, detection, significance, and evolutionary consequences</article-title><source>Life</source><year>2021</year><volume>11</volume><fpage>633</fpage><pub-id pub-id-type="doi">10.3390/life11070633</pub-id><pub-id pub-id-type="pmid">34209862</pub-id><pub-id pub-id-type="pmcid">PMC8307225</pub-id></element-citation><mixed-citation id="mc-CR74" publication-type="journal">Parakatselaki M-E, Ladoukakis ED (2021) mtDNA heteroplasmy: origin, detection, significance, and evolutionary consequences. Life 11:633. 10.3390/life11070633<pub-id pub-id-type="pmid">34209862</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/life11070633</pub-id><pub-id pub-id-type="pmcid">PMC8307225</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR75"><label>75.</label><citation-alternatives><element-citation id="ec-CR75" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sch&#228;fer</surname><given-names>JA</given-names></name><name name-style="western"><surname>Sutandy</surname><given-names>FXR</given-names></name><name name-style="western"><surname>M&#252;nch</surname><given-names>C</given-names></name></person-group><article-title>Omics-based approaches for the systematic profiling of mitochondrial biology</article-title><source>Mol Cell</source><year>2023</year><volume>83</volume><fpage>911</fpage><lpage>926</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2023.02.015</pub-id><pub-id pub-id-type="pmid">36931258</pub-id></element-citation><mixed-citation id="mc-CR75" publication-type="journal">Sch&#228;fer JA, Sutandy FXR, M&#252;nch C (2023) Omics-based approaches for the systematic profiling of mitochondrial biology. Mol Cell 83:911&#8211;926. 10.1016/j.molcel.2023.02.015<pub-id pub-id-type="pmid">36931258</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.molcel.2023.02.015</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR76"><label>76.</label><citation-alternatives><element-citation id="ec-CR76" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hong</surname><given-names>W-L</given-names></name><name name-style="western"><surname>Huang</surname><given-names>H</given-names></name><name name-style="western"><surname>Zeng</surname><given-names>X</given-names></name><name name-style="western"><surname>Duan</surname><given-names>C-Y</given-names></name></person-group><article-title>Targeting mitochondrial quality control: new therapeutic strategies for major diseases</article-title><source>Mil Med Res</source><year>2024</year><volume>11</volume><fpage>59</fpage><pub-id pub-id-type="doi">10.1186/s40779-024-00556-1</pub-id><pub-id pub-id-type="pmid">39164792</pub-id><pub-id pub-id-type="pmcid">PMC11337860</pub-id></element-citation><mixed-citation id="mc-CR76" publication-type="journal">Hong W-L, Huang H, Zeng X, Duan C-Y (2024) Targeting mitochondrial quality control: new therapeutic strategies for major diseases. Mil Med Res 11:59. 10.1186/s40779-024-00556-1<pub-id pub-id-type="pmid">39164792</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s40779-024-00556-1</pub-id><pub-id pub-id-type="pmcid">PMC11337860</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR77"><label>77.</label><citation-alternatives><element-citation id="ec-CR77" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Deshwal</surname><given-names>S</given-names></name><name name-style="western"><surname>Fiedler</surname><given-names>KU</given-names></name><name name-style="western"><surname>Langer</surname><given-names>T</given-names></name></person-group><article-title>Mitochondrial proteases: multifaceted regulators of mitochondrial plasticity</article-title><source>Annu Rev Biochem</source><year>2020</year><volume>89</volume><fpage>501</fpage><lpage>528</lpage><pub-id pub-id-type="doi">10.1146/annurev-biochem-062917-012739</pub-id><pub-id pub-id-type="pmid">32075415</pub-id></element-citation><mixed-citation id="mc-CR77" publication-type="journal">Deshwal S, Fiedler KU, Langer T (2020) Mitochondrial proteases: multifaceted regulators of mitochondrial plasticity. Annu Rev Biochem 89:501&#8211;528. 10.1146/annurev-biochem-062917-012739<pub-id pub-id-type="pmid">32075415</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1146/annurev-biochem-062917-012739</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR78"><label>78.</label><citation-alternatives><element-citation id="ec-CR78" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Quir&#243;s</surname><given-names>PM</given-names></name><name name-style="western"><surname>Espa&#241;ol</surname><given-names>Y</given-names></name><name name-style="western"><surname>Ac&#237;n-P&#233;rez</surname><given-names>R</given-names></name><etal/></person-group><article-title>ATP-dependent lon protease controls tumor bioenergetics by reprogramming mitochondrial activity</article-title><source>Cell Rep</source><year>2014</year><volume>8</volume><fpage>542</fpage><lpage>556</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2014.06.018</pub-id><pub-id pub-id-type="pmid">25017063</pub-id></element-citation><mixed-citation id="mc-CR78" publication-type="journal">Quir&#243;s PM, Espa&#241;ol Y, Ac&#237;n-P&#233;rez R et al (2014) ATP-dependent lon protease controls tumor bioenergetics by reprogramming mitochondrial activity. Cell Rep 8:542&#8211;556. 10.1016/j.celrep.2014.06.018<pub-id pub-id-type="pmid">25017063</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.celrep.2014.06.018</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR79"><label>79.</label><citation-alternatives><element-citation id="ec-CR79" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Seo</surname><given-names>JH</given-names></name><name name-style="western"><surname>Rivadeneira</surname><given-names>DB</given-names></name><name name-style="western"><surname>Caino</surname><given-names>MC</given-names></name><etal/></person-group><article-title>The mitochondrial unfoldase-peptidase complex ClpXP controls bioenergetics stress and metastasis</article-title><source>PLoS Biol</source><year>2016</year><volume>14</volume><fpage>e1002507</fpage><pub-id pub-id-type="doi">10.1371/journal.pbio.1002507</pub-id><pub-id pub-id-type="pmid">27389535</pub-id><pub-id pub-id-type="pmcid">PMC4936714</pub-id></element-citation><mixed-citation id="mc-CR79" publication-type="journal">Seo JH, Rivadeneira DB, Caino MC et al (2016) The mitochondrial unfoldase-peptidase complex ClpXP controls bioenergetics stress and metastasis. PLoS Biol 14:e1002507. 10.1371/journal.pbio.1002507<pub-id pub-id-type="pmid">27389535</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pbio.1002507</pub-id><pub-id pub-id-type="pmcid">PMC4936714</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR80"><label>80.</label><citation-alternatives><element-citation id="ec-CR80" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Venza</surname><given-names>I</given-names></name><name name-style="western"><surname>Venza</surname><given-names>M</given-names></name><name name-style="western"><surname>Visalli</surname><given-names>M</given-names></name><etal/></person-group><article-title>ROS as regulators of cellular processes in melanoma</article-title><source>Oxid Med Cell Longev</source><year>2021</year><pub-id pub-id-type="doi">10.1155/2021/1208690</pub-id><pub-id pub-id-type="pmid">34725562</pub-id><pub-id pub-id-type="pmcid">PMC8557056</pub-id></element-citation><mixed-citation id="mc-CR80" publication-type="journal">Venza I, Venza M, Visalli M et al (2021) ROS as regulators of cellular processes in melanoma. Oxid Med Cell Longev. 10.1155/2021/1208690<pub-id pub-id-type="pmid">34725562</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1155/2021/1208690</pub-id><pub-id pub-id-type="pmcid">PMC8557056</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR81"><label>81.</label><citation-alternatives><element-citation id="ec-CR81" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Emanuelli</surname><given-names>M</given-names></name><name name-style="western"><surname>Sartini</surname><given-names>D</given-names></name><name name-style="western"><surname>Molinelli</surname><given-names>E</given-names></name><etal/></person-group><article-title>The double-edged sword of oxidative stress in skin damage and melanoma: from physiopathology to therapeutical approaches</article-title><source>Antioxidants</source><year>2022</year><volume>11</volume><fpage>612</fpage><pub-id pub-id-type="doi">10.3390/antiox11040612</pub-id><pub-id pub-id-type="pmid">35453297</pub-id><pub-id pub-id-type="pmcid">PMC9027913</pub-id></element-citation><mixed-citation id="mc-CR81" publication-type="journal">Emanuelli M, Sartini D, Molinelli E et al (2022) The double-edged sword of oxidative stress in skin damage and melanoma: from physiopathology to therapeutical approaches. Antioxidants 11:612. 10.3390/antiox11040612<pub-id pub-id-type="pmid">35453297</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/antiox11040612</pub-id><pub-id pub-id-type="pmcid">PMC9027913</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR82"><label>82.</label><citation-alternatives><element-citation id="ec-CR82" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Y-N</given-names></name><name name-style="western"><surname>Xi</surname><given-names>M-M</given-names></name><name name-style="western"><surname>Guo</surname><given-names>Y</given-names></name><etal/></person-group><article-title>NADPH oxidase-mitochondria axis-derived ROS mediate arsenite-induced HIF-1&#945; stabilization by inhibiting prolyl hydroxylases activity</article-title><source>Toxicol Lett</source><year>2014</year><volume>224</volume><fpage>165</fpage><lpage>174</lpage><pub-id pub-id-type="doi">10.1016/j.toxlet.2013.10.029</pub-id><pub-id pub-id-type="pmid">24188932</pub-id></element-citation><mixed-citation id="mc-CR82" publication-type="journal">Li Y-N, Xi M-M, Guo Y et al (2014) NADPH oxidase-mitochondria axis-derived ROS mediate arsenite-induced HIF-1&#945; stabilization by inhibiting prolyl hydroxylases activity. Toxicol Lett 224:165&#8211;174. 10.1016/j.toxlet.2013.10.029<pub-id pub-id-type="pmid">24188932</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.toxlet.2013.10.029</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR83"><label>83.</label><citation-alternatives><element-citation id="ec-CR83" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gao</surname><given-names>P</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H</given-names></name><name name-style="western"><surname>Dinavahi</surname><given-names>R</given-names></name><etal/></person-group><article-title>HIF-dependent antitumorigenic effect of antioxidants in vivo</article-title><source>Cancer Cell</source><year>2007</year><volume>12</volume><fpage>230</fpage><lpage>238</lpage><pub-id pub-id-type="doi">10.1016/j.ccr.2007.08.004</pub-id><pub-id pub-id-type="pmid">17785204</pub-id><pub-id pub-id-type="pmcid">PMC2084208</pub-id></element-citation><mixed-citation id="mc-CR83" publication-type="journal">Gao P, Zhang H, Dinavahi R et al (2007) HIF-dependent antitumorigenic effect of antioxidants in vivo. Cancer Cell 12:230&#8211;238. 10.1016/j.ccr.2007.08.004<pub-id pub-id-type="pmid">17785204</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ccr.2007.08.004</pub-id><pub-id pub-id-type="pmcid">PMC2084208</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR84"><label>84.</label><citation-alternatives><element-citation id="ec-CR84" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Comito</surname><given-names>G</given-names></name><name name-style="western"><surname>Calvani</surname><given-names>M</given-names></name><name name-style="western"><surname>Giannoni</surname><given-names>E</given-names></name><etal/></person-group><article-title>HIF-1&#945; stabilization by mitochondrial ROS promotes Met-dependent invasive growth and vasculogenic mimicry in melanoma cells</article-title><source>Free Radic Biol Med</source><year>2011</year><volume>51</volume><fpage>893</fpage><lpage>904</lpage><pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2011.05.042</pub-id><pub-id pub-id-type="pmid">21703345</pub-id></element-citation><mixed-citation id="mc-CR84" publication-type="journal">Comito G, Calvani M, Giannoni E et al (2011) HIF-1&#945; stabilization by mitochondrial ROS promotes Met-dependent invasive growth and vasculogenic mimicry in melanoma cells. Free Radic Biol Med 51:893&#8211;904. 10.1016/j.freeradbiomed.2011.05.042<pub-id pub-id-type="pmid">21703345</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.freeradbiomed.2011.05.042</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR85"><label>85.</label><citation-alternatives><element-citation id="ec-CR85" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Malekan</surname><given-names>M</given-names></name><name name-style="western"><surname>Ebrahimzadeh</surname><given-names>MA</given-names></name><name name-style="western"><surname>Sheida</surname><given-names>F</given-names></name></person-group><article-title>The role of Hypoxia-inducible factor-1alpha and its signaling in melanoma</article-title><source>Biomed Pharmacother</source><year>2021</year><volume>141</volume><fpage>111873</fpage><pub-id pub-id-type="doi">10.1016/j.biopha.2021.111873</pub-id><pub-id pub-id-type="pmid">34225012</pub-id></element-citation><mixed-citation id="mc-CR85" publication-type="journal">Malekan M, Ebrahimzadeh MA, Sheida F (2021) The role of Hypoxia-inducible factor-1alpha and its signaling in melanoma. Biomed Pharmacother 141:111873. 10.1016/j.biopha.2021.111873<pub-id pub-id-type="pmid">34225012</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biopha.2021.111873</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR86"><label>86.</label><citation-alternatives><element-citation id="ec-CR86" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kuo</surname><given-names>C-L</given-names></name><name name-style="western"><surname>Chou</surname><given-names>H-Y</given-names></name><name name-style="western"><surname>Chiu</surname><given-names>Y-C</given-names></name><etal/></person-group><article-title>Mitochondrial oxidative stress by Lon-PYCR1 maintains an immunosuppressive tumor microenvironment that promotes cancer progression and metastasis</article-title><source>Cancer Lett</source><year>2020</year><volume>474</volume><fpage>138</fpage><lpage>150</lpage><pub-id pub-id-type="doi">10.1016/j.canlet.2020.01.019</pub-id><pub-id pub-id-type="pmid">31987921</pub-id></element-citation><mixed-citation id="mc-CR86" publication-type="journal">Kuo C-L, Chou H-Y, Chiu Y-C et al (2020) Mitochondrial oxidative stress by Lon-PYCR1 maintains an immunosuppressive tumor microenvironment that promotes cancer progression and metastasis. Cancer Lett 474:138&#8211;150. 10.1016/j.canlet.2020.01.019<pub-id pub-id-type="pmid">31987921</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.canlet.2020.01.019</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR87"><label>87.</label><citation-alternatives><element-citation id="ec-CR87" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Perillo</surname><given-names>B</given-names></name><name name-style="western"><surname>Di Donato</surname><given-names>M</given-names></name><name name-style="western"><surname>Pezone</surname><given-names>A</given-names></name><etal/></person-group><article-title>ROS in cancer therapy: the bright side of the moon</article-title><source>Exp Mol Med</source><year>2020</year><volume>52</volume><fpage>192</fpage><lpage>203</lpage><pub-id pub-id-type="doi">10.1038/s12276-020-0384-2</pub-id><pub-id pub-id-type="pmid">32060354</pub-id><pub-id pub-id-type="pmcid">PMC7062874</pub-id></element-citation><mixed-citation id="mc-CR87" publication-type="journal">Perillo B, Di Donato M, Pezone A et al (2020) ROS in cancer therapy: the bright side of the moon. Exp Mol Med 52:192&#8211;203. 10.1038/s12276-020-0384-2<pub-id pub-id-type="pmid">32060354</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s12276-020-0384-2</pub-id><pub-id pub-id-type="pmcid">PMC7062874</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR88"><label>88.</label><citation-alternatives><element-citation id="ec-CR88" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hasan</surname><given-names>A</given-names></name><name name-style="western"><surname>Rizvi</surname><given-names>SF</given-names></name><name name-style="western"><surname>Parveen</surname><given-names>S</given-names></name><etal/></person-group><article-title>Crosstalk between ROS and autophagy in tumorigenesis: understanding the multifaceted paradox</article-title><source>Front Oncol</source><year>2022</year><pub-id pub-id-type="doi">10.3389/fonc.2022.852424</pub-id><pub-id pub-id-type="pmid">35359388</pub-id><pub-id pub-id-type="pmcid">PMC8960719</pub-id></element-citation><mixed-citation id="mc-CR88" publication-type="journal">Hasan A, Rizvi SF, Parveen S et al (2022) Crosstalk between ROS and autophagy in tumorigenesis: understanding the multifaceted paradox. Front Oncol. 10.3389/fonc.2022.852424<pub-id pub-id-type="pmid">35359388</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fonc.2022.852424</pub-id><pub-id pub-id-type="pmcid">PMC8960719</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR89"><label>89.</label><citation-alternatives><element-citation id="ec-CR89" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>X</given-names></name><name name-style="western"><surname>Li</surname><given-names>H</given-names></name><name name-style="western"><surname>Liu</surname><given-names>C</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>X</given-names></name></person-group><article-title>Role of ROS-mediated autophagy in melanoma (Review)</article-title><source>Mol Med Rep</source><year>2022</year><volume>26</volume><fpage>303</fpage><pub-id pub-id-type="doi">10.3892/mmr.2022.12819</pub-id><pub-id pub-id-type="pmid">35946460</pub-id><pub-id pub-id-type="pmcid">PMC9434998</pub-id></element-citation><mixed-citation id="mc-CR89" publication-type="journal">Zhang X, Li H, Liu C, Yuan X (2022) Role of ROS-mediated autophagy in melanoma (Review). Mol Med Rep 26:303. 10.3892/mmr.2022.12819<pub-id pub-id-type="pmid">35946460</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3892/mmr.2022.12819</pub-id><pub-id pub-id-type="pmcid">PMC9434998</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR90"><label>90.</label><citation-alternatives><element-citation id="ec-CR90" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pangilinan</surname><given-names>C</given-names></name><name name-style="western"><surname>Xu</surname><given-names>X</given-names></name><name name-style="western"><surname>Herlyn</surname><given-names>M</given-names></name><name name-style="western"><surname>Liang</surname><given-names>C</given-names></name></person-group><article-title>Autophagy paradox: strategizing treatment modality in melanoma</article-title><source>Curr Treat Options Oncol</source><year>2023</year><volume>24</volume><fpage>130</fpage><lpage>145</lpage><pub-id pub-id-type="doi">10.1007/s11864-023-01053-8</pub-id><pub-id pub-id-type="pmid">36670319</pub-id><pub-id pub-id-type="pmcid">PMC9883356</pub-id></element-citation><mixed-citation id="mc-CR90" publication-type="journal">Pangilinan C, Xu X, Herlyn M, Liang C (2023) Autophagy paradox: strategizing treatment modality in melanoma. Curr Treat Options Oncol 24:130&#8211;145. 10.1007/s11864-023-01053-8<pub-id pub-id-type="pmid">36670319</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11864-023-01053-8</pub-id><pub-id pub-id-type="pmcid">PMC9883356</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR91"><label>91.</label><citation-alternatives><element-citation id="ec-CR91" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mustafa</surname><given-names>M</given-names></name><name name-style="western"><surname>Ahmad</surname><given-names>R</given-names></name><name name-style="western"><surname>Tantry</surname><given-names>IQ</given-names></name><etal/></person-group><article-title>Apoptosis: a comprehensive overview of signaling pathways, morphological changes, and physiological significance and therapeutic implications</article-title><source>Cells</source><year>2024</year><volume>13</volume><fpage>1838</fpage><pub-id pub-id-type="doi">10.3390/cells13221838</pub-id><pub-id pub-id-type="pmid">39594587</pub-id><pub-id pub-id-type="pmcid">PMC11592877</pub-id></element-citation><mixed-citation id="mc-CR91" publication-type="journal">Mustafa M, Ahmad R, Tantry IQ et al (2024) Apoptosis: a comprehensive overview of signaling pathways, morphological changes, and physiological significance and therapeutic implications. Cells 13:1838. 10.3390/cells13221838<pub-id pub-id-type="pmid">39594587</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/cells13221838</pub-id><pub-id pub-id-type="pmcid">PMC11592877</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR92"><label>92.</label><citation-alternatives><element-citation id="ec-CR92" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tian</surname><given-names>X</given-names></name><name name-style="western"><surname>Srinivasan</surname><given-names>PR</given-names></name><name name-style="western"><surname>Tajiknia</surname><given-names>V</given-names></name><etal/></person-group><article-title>Targeting apoptotic pathways for cancer therapy</article-title><source>J Clin Invest</source><year>2024</year><pub-id pub-id-type="doi">10.1172/JCI179570</pub-id><pub-id pub-id-type="pmid">39007268</pub-id><pub-id pub-id-type="pmcid">PMC11245162</pub-id></element-citation><mixed-citation id="mc-CR92" publication-type="journal">Tian X, Srinivasan PR, Tajiknia V et al (2024) Targeting apoptotic pathways for cancer therapy. J Clin Invest. 10.1172/JCI179570<pub-id pub-id-type="pmid">39007268</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1172/JCI179570</pub-id><pub-id pub-id-type="pmcid">PMC11245162</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR93"><label>93.</label><citation-alternatives><element-citation id="ec-CR93" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kale</surname><given-names>J</given-names></name><name name-style="western"><surname>Osterlund</surname><given-names>EJ</given-names></name><name name-style="western"><surname>Andrews</surname><given-names>DW</given-names></name></person-group><article-title>BCL-2 family proteins: changing partners in the dance towards death</article-title><source>Cell Death Differ</source><year>2018</year><volume>25</volume><fpage>65</fpage><lpage>80</lpage><pub-id pub-id-type="doi">10.1038/cdd.2017.186</pub-id><pub-id pub-id-type="pmid">29149100</pub-id><pub-id pub-id-type="pmcid">PMC5729540</pub-id></element-citation><mixed-citation id="mc-CR93" publication-type="journal">Kale J, Osterlund EJ, Andrews DW (2018) BCL-2 family proteins: changing partners in the dance towards death. Cell Death Differ 25:65&#8211;80. 10.1038/cdd.2017.186<pub-id pub-id-type="pmid">29149100</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/cdd.2017.186</pub-id><pub-id pub-id-type="pmcid">PMC5729540</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR94"><label>94.</label><citation-alternatives><element-citation id="ec-CR94" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nessling</surname><given-names>M</given-names></name><name name-style="western"><surname>Kern</surname><given-names>MA</given-names></name><name name-style="western"><surname>Schadendorf</surname><given-names>D</given-names></name><name name-style="western"><surname>Lichter</surname><given-names>P</given-names></name></person-group><article-title>Association of genomic imbalances with resistance to therapeutic drugs in human melanoma cell lines</article-title><source>Cytogenet Genome Res</source><year>1999</year><volume>87</volume><fpage>286</fpage><lpage>290</lpage><pub-id pub-id-type="doi">10.1159/000015451</pub-id><pub-id pub-id-type="pmid">10702697</pub-id></element-citation><mixed-citation id="mc-CR94" publication-type="journal">Nessling M, Kern MA, Schadendorf D, Lichter P (1999) Association of genomic imbalances with resistance to therapeutic drugs in human melanoma cell lines. Cytogenet Genome Res 87:286&#8211;290. 10.1159/000015451<pub-id pub-id-type="doi" assigning-authority="pmc">10.1159/000015451</pub-id><pub-id pub-id-type="pmid">10702697</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR95"><label>95.</label><citation-alternatives><element-citation id="ec-CR95" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McGill</surname><given-names>GG</given-names></name><name name-style="western"><surname>Horstmann</surname><given-names>M</given-names></name><name name-style="western"><surname>Widlund</surname><given-names>HR</given-names></name><etal/></person-group><article-title>Bcl2 regulation by the melanocyte master regulator Mitf modulates lineage survival and melanoma cell viability</article-title><source>Cell</source><year>2002</year><volume>109</volume><fpage>707</fpage><lpage>718</lpage><pub-id pub-id-type="doi">10.1016/S0092-8674(02)00762-6</pub-id><pub-id pub-id-type="pmid">12086670</pub-id></element-citation><mixed-citation id="mc-CR95" publication-type="journal">McGill GG, Horstmann M, Widlund HR et al (2002) Bcl2 regulation by the melanocyte master regulator Mitf modulates lineage survival and melanoma cell viability. Cell 109:707&#8211;718. 10.1016/S0092-8674(02)00762-6<pub-id pub-id-type="pmid">12086670</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0092-8674(02)00762-6</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR96"><label>96.</label><citation-alternatives><element-citation id="ec-CR96" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Haq</surname><given-names>R</given-names></name><name name-style="western"><surname>Yokoyama</surname><given-names>S</given-names></name><name name-style="western"><surname>Hawryluk</surname><given-names>EB</given-names></name><etal/></person-group><article-title>BCL2A1 is a lineage-specific antiapoptotic melanoma oncogene that confers resistance to BRAF inhibition</article-title><source>Proc Natl Acad Sci</source><year>2013</year><volume>110</volume><fpage>4321</fpage><lpage>4326</lpage><pub-id pub-id-type="doi">10.1073/pnas.1205575110</pub-id><pub-id pub-id-type="pmid">23447565</pub-id><pub-id pub-id-type="pmcid">PMC3600451</pub-id></element-citation><mixed-citation id="mc-CR96" publication-type="journal">Haq R, Yokoyama S, Hawryluk EB et al (2013) BCL2A1 is a lineage-specific antiapoptotic melanoma oncogene that confers resistance to BRAF inhibition. Proc Natl Acad Sci 110:4321&#8211;4326. 10.1073/pnas.1205575110<pub-id pub-id-type="pmid">23447565</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.1205575110</pub-id><pub-id pub-id-type="pmcid">PMC3600451</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR97"><label>97.</label><citation-alternatives><element-citation id="ec-CR97" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leiter</surname><given-names>U</given-names></name><name name-style="western"><surname>Schmid</surname><given-names>RM</given-names></name><name name-style="western"><surname>Kaskel</surname><given-names>P</given-names></name><etal/></person-group><article-title>Antiapoptotic bcl-2 and bcl-xL in advanced malignant melanoma</article-title><source>Arch Dermatol Res</source><year>2000</year><volume>292</volume><fpage>225</fpage><lpage>232</lpage><pub-id pub-id-type="doi">10.1007/s004030050479</pub-id><pub-id pub-id-type="pmid">10867810</pub-id></element-citation><mixed-citation id="mc-CR97" publication-type="journal">Leiter U, Schmid RM, Kaskel P et al (2000) Antiapoptotic bcl-2 and bcl-xL in advanced malignant melanoma. Arch Dermatol Res 292:225&#8211;232. 10.1007/s004030050479<pub-id pub-id-type="pmid">10867810</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s004030050479</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR98"><label>98.</label><citation-alternatives><element-citation id="ec-CR98" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Heere-Ress</surname><given-names>E</given-names></name><name name-style="western"><surname>Thallinger</surname><given-names>C</given-names></name><name name-style="western"><surname>Lucas</surname><given-names>T</given-names></name><etal/></person-group><article-title>Bcl-X L is a chemoresistance factor in human melanoma cells that can be inhibited by antisense therapy</article-title><source>Int J Cancer</source><year>2002</year><volume>99</volume><fpage>29</fpage><lpage>34</lpage><pub-id pub-id-type="doi">10.1002/ijc.10248</pub-id><pub-id pub-id-type="pmid">11948488</pub-id></element-citation><mixed-citation id="mc-CR98" publication-type="journal">Heere-Ress E, Thallinger C, Lucas T et al (2002) Bcl-X L is a chemoresistance factor in human melanoma cells that can be inhibited by antisense therapy. Int J Cancer 99:29&#8211;34. 10.1002/ijc.10248<pub-id pub-id-type="pmid">11948488</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ijc.10248</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR99"><label>99.</label><citation-alternatives><element-citation id="ec-CR99" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>H</given-names></name><name name-style="western"><surname>Rosdahl</surname><given-names>I</given-names></name></person-group><article-title>Bcl-xL and bcl-2 proteins in melanoma progression and UVB-induced apoptosis</article-title><source>Int J Oncol</source><year>2006</year><pub-id pub-id-type="doi">10.3892/ijo.28.3.661</pub-id><pub-id pub-id-type="pmid">16465371</pub-id></element-citation><mixed-citation id="mc-CR99" publication-type="journal">Zhang H, Rosdahl I (2006) Bcl-xL and bcl-2 proteins in melanoma progression and UVB-induced apoptosis. Int J Oncol. 10.3892/ijo.28.3.661<pub-id pub-id-type="pmid">16465371</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR100"><label>100.</label><citation-alternatives><element-citation id="ec-CR100" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hilmi</surname><given-names>C</given-names></name><name name-style="western"><surname>Larribere</surname><given-names>L</given-names></name><name name-style="western"><surname>Giuliano</surname><given-names>S</given-names></name><etal/></person-group><article-title>IGF1 promotes resistance to apoptosis in melanoma cells through an increased expression of BCL2, BCL-X(L), and survivin</article-title><source>J Invest Dermatol</source><year>2008</year><volume>128</volume><fpage>1499</fpage><lpage>1505</lpage><pub-id pub-id-type="doi">10.1038/sj.jid.5701185</pub-id><pub-id pub-id-type="pmid">18079751</pub-id></element-citation><mixed-citation id="mc-CR100" publication-type="journal">Hilmi C, Larribere L, Giuliano S et al (2008) IGF1 promotes resistance to apoptosis in melanoma cells through an increased expression of BCL2, BCL-X(L), and survivin. J Invest Dermatol 128:1499&#8211;1505. 10.1038/sj.jid.5701185<pub-id pub-id-type="pmid">18079751</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/sj.jid.5701185</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR101"><label>101.</label><citation-alternatives><element-citation id="ec-CR101" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Trisciuoglio</surname><given-names>D</given-names></name><name name-style="western"><surname>Tupone</surname><given-names>MG</given-names></name><name name-style="western"><surname>Desideri</surname><given-names>M</given-names></name><etal/></person-group><article-title>Bcl-xl overexpression promotes tumor progression-associated properties</article-title><source>Cell Death Dis</source><year>2017</year><volume>8</volume><fpage>3216</fpage><pub-id pub-id-type="doi">10.1038/s41419-017-0055-y</pub-id><pub-id pub-id-type="pmid">29238043</pub-id><pub-id pub-id-type="pmcid">PMC5870591</pub-id></element-citation><mixed-citation id="mc-CR101" publication-type="journal">Trisciuoglio D, Tupone MG, Desideri M et al (2017) Bcl-xl overexpression promotes tumor progression-associated properties. Cell Death Dis 8:3216. 10.1038/s41419-017-0055-y<pub-id pub-id-type="pmid">29238043</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41419-017-0055-y</pub-id><pub-id pub-id-type="pmcid">PMC5870591</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR102"><label>102.</label><citation-alternatives><element-citation id="ec-CR102" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gabellini</surname><given-names>C</given-names></name><name name-style="western"><surname>G&#243;mez-Abenza</surname><given-names>E</given-names></name><name name-style="western"><surname>Ib&#225;&#241;ez-Molero</surname><given-names>S</given-names></name><etal/></person-group><article-title>Interleukin 8 mediates bcl-xL-induced enhancement of human melanoma cell dissemination and angiogenesis in a zebrafish xenograft model</article-title><source>Int J Cancer</source><year>2018</year><volume>142</volume><fpage>584</fpage><lpage>596</lpage><pub-id pub-id-type="doi">10.1002/ijc.31075</pub-id><pub-id pub-id-type="pmid">28949016</pub-id></element-citation><mixed-citation id="mc-CR102" publication-type="journal">Gabellini C, G&#243;mez-Abenza E, Ib&#225;&#241;ez-Molero S et al (2018) Interleukin 8 mediates bcl-xL-induced enhancement of human melanoma cell dissemination and angiogenesis in a zebrafish xenograft model. Int J Cancer 142:584&#8211;596. 10.1002/ijc.31075<pub-id pub-id-type="pmid">28949016</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ijc.31075</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR103"><label>103.</label><citation-alternatives><element-citation id="ec-CR103" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lucian&#242;</surname><given-names>AM</given-names></name><name name-style="western"><surname>Di Martile</surname><given-names>M</given-names></name><name name-style="western"><surname>P&#233;rez-Oliva</surname><given-names>AB</given-names></name><etal/></person-group><article-title>Exploring association of melanoma-specific Bcl-xL with tumor immune microenvironment</article-title><source>J Exp Clin Cancer Res</source><year>2023</year><volume>42</volume><fpage>178</fpage><pub-id pub-id-type="doi">10.1186/s13046-023-02735-9</pub-id><pub-id pub-id-type="pmid">37488586</pub-id><pub-id pub-id-type="pmcid">PMC10364435</pub-id></element-citation><mixed-citation id="mc-CR103" publication-type="journal">Lucian&#242; AM, Di Martile M, P&#233;rez-Oliva AB et al (2023) Exploring association of melanoma-specific Bcl-xL with tumor immune microenvironment. J Exp Clin Cancer Res 42:178. 10.1186/s13046-023-02735-9<pub-id pub-id-type="pmid">37488586</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13046-023-02735-9</pub-id><pub-id pub-id-type="pmcid">PMC10364435</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR104"><label>104.</label><citation-alternatives><element-citation id="ec-CR104" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Domina</surname><given-names>AM</given-names></name><name name-style="western"><surname>Vrana</surname><given-names>JA</given-names></name><name name-style="western"><surname>Gregory</surname><given-names>MA</given-names></name><etal/></person-group><article-title>MCL1 is phosphorylated in the PEST region and stabilized upon ERK activation in viable cells, and at additional sites with cytotoxic okadaic acid or taxol</article-title><source>Oncogene</source><year>2004</year><volume>23</volume><fpage>5301</fpage><lpage>5315</lpage><pub-id pub-id-type="doi">10.1038/sj.onc.1207692</pub-id><pub-id pub-id-type="pmid">15241487</pub-id></element-citation><mixed-citation id="mc-CR104" publication-type="journal">Domina AM, Vrana JA, Gregory MA et al (2004) MCL1 is phosphorylated in the PEST region and stabilized upon ERK activation in viable cells, and at additional sites with cytotoxic okadaic acid or taxol. Oncogene 23:5301&#8211;5315. 10.1038/sj.onc.1207692<pub-id pub-id-type="pmid">15241487</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/sj.onc.1207692</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR105"><label>105.</label><citation-alternatives><element-citation id="ec-CR105" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McKee</surname><given-names>CS</given-names></name><name name-style="western"><surname>Hill</surname><given-names>DS</given-names></name><name name-style="western"><surname>Redfern</surname><given-names>CPF</given-names></name><etal/></person-group><article-title>Oncogenic BRAF signalling increases Mcl-1 expression in cutaneous metastatic melanoma</article-title><source>Exp Dermatol</source><year>2013</year><volume>22</volume><fpage>767</fpage><lpage>769</lpage><pub-id pub-id-type="doi">10.1111/exd.12254</pub-id><pub-id pub-id-type="pmid">24118207</pub-id></element-citation><mixed-citation id="mc-CR105" publication-type="journal">McKee CS, Hill DS, Redfern CPF et al (2013) Oncogenic BRAF signalling increases Mcl-1 expression in cutaneous metastatic melanoma. Exp Dermatol 22:767&#8211;769. 10.1111/exd.12254<pub-id pub-id-type="pmid">24118207</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/exd.12254</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR106"><label>106.</label><citation-alternatives><element-citation id="ec-CR106" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cook</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Stuart</surname><given-names>K</given-names></name><name name-style="western"><surname>Gilley</surname><given-names>R</given-names></name><name name-style="western"><surname>Sale</surname><given-names>MJ</given-names></name></person-group><article-title>Control of cell death and mitochondrial fission by ERK 1/2 MAP kinase signalling</article-title><source>FEBS J</source><year>2017</year><volume>284</volume><fpage>4177</fpage><lpage>4195</lpage><pub-id pub-id-type="doi">10.1111/febs.14122</pub-id><pub-id pub-id-type="pmid">28548464</pub-id><pub-id pub-id-type="pmcid">PMC6193418</pub-id></element-citation><mixed-citation id="mc-CR106" publication-type="journal">Cook SJ, Stuart K, Gilley R, Sale MJ (2017) Control of cell death and mitochondrial fission by ERK 1/2 MAP kinase signalling. FEBS J 284:4177&#8211;4195. 10.1111/febs.14122<pub-id pub-id-type="pmid">28548464</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/febs.14122</pub-id><pub-id pub-id-type="pmcid">PMC6193418</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR107"><label>107.</label><citation-alternatives><element-citation id="ec-CR107" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sale</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Minihane</surname><given-names>E</given-names></name><name name-style="western"><surname>Monks</surname><given-names>NR</given-names></name><etal/></person-group><article-title>Targeting melanoma&#8217;s MCL1 bias unleashes the apoptotic potential of BRAF and ERK1/2 pathway inhibitors</article-title><source>Nat Commun</source><year>2019</year><volume>10</volume><fpage>5167</fpage><pub-id pub-id-type="doi">10.1038/s41467-019-12409-w</pub-id><pub-id pub-id-type="pmid">31727888</pub-id><pub-id pub-id-type="pmcid">PMC6856071</pub-id></element-citation><mixed-citation id="mc-CR107" publication-type="journal">Sale MJ, Minihane E, Monks NR et al (2019) Targeting melanoma&#8217;s MCL1 bias unleashes the apoptotic potential of BRAF and ERK1/2 pathway inhibitors. Nat Commun 10:5167. 10.1038/s41467-019-12409-w<pub-id pub-id-type="pmid">31727888</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-019-12409-w</pub-id><pub-id pub-id-type="pmcid">PMC6856071</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR108"><label>108.</label><citation-alternatives><element-citation id="ec-CR108" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bolomsky</surname><given-names>A</given-names></name><name name-style="western"><surname>Vogler</surname><given-names>M</given-names></name><name name-style="western"><surname>K&#246;se</surname><given-names>MC</given-names></name><etal/></person-group><article-title>MCL-1 inhibitors, fast-lane development of a new class of anti-cancer agents</article-title><source>J Hematol Oncol</source><year>2020</year><volume>13</volume><fpage>173</fpage><pub-id pub-id-type="doi">10.1186/s13045-020-01007-9</pub-id><pub-id pub-id-type="pmid">33308268</pub-id><pub-id pub-id-type="pmcid">PMC7731749</pub-id></element-citation><mixed-citation id="mc-CR108" publication-type="journal">Bolomsky A, Vogler M, K&#246;se MC et al (2020) MCL-1 inhibitors, fast-lane development of a new class of anti-cancer agents. J Hematol Oncol 13:173. 10.1186/s13045-020-01007-9<pub-id pub-id-type="pmid">33308268</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13045-020-01007-9</pub-id><pub-id pub-id-type="pmcid">PMC7731749</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR109"><label>109.</label><citation-alternatives><element-citation id="ec-CR109" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sch&#246;ckel</surname><given-names>L</given-names></name><name name-style="western"><surname>Glasauer</surname><given-names>A</given-names></name><name name-style="western"><surname>Basit</surname><given-names>F</given-names></name><etal/></person-group><article-title>Targeting mitochondrial complex I using BAY 87&#8211;2243 reduces melanoma tumor growth</article-title><source>Cancer Metab</source><year>2015</year><volume>3</volume><fpage>11</fpage><pub-id pub-id-type="doi">10.1186/s40170-015-0138-0</pub-id><pub-id pub-id-type="pmid">26500770</pub-id><pub-id pub-id-type="pmcid">PMC4615872</pub-id></element-citation><mixed-citation id="mc-CR109" publication-type="journal">Sch&#246;ckel L, Glasauer A, Basit F et al (2015) Targeting mitochondrial complex I using BAY 87&#8211;2243 reduces melanoma tumor growth. Cancer Metab 3:11. 10.1186/s40170-015-0138-0<pub-id pub-id-type="pmid">26500770</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s40170-015-0138-0</pub-id><pub-id pub-id-type="pmcid">PMC4615872</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR110"><label>110.</label><citation-alternatives><element-citation id="ec-CR110" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vashisht Gopal</surname><given-names>YN</given-names></name><name name-style="western"><surname>Gammon</surname><given-names>S</given-names></name><name name-style="western"><surname>Prasad</surname><given-names>R</given-names></name><etal/></person-group><article-title>A novel mitochondrial inhibitor blocks MAPK pathway and overcomes MAPK inhibitor resistance in melanoma</article-title><source>Clin Cancer Res</source><year>2019</year><volume>25</volume><fpage>6429</fpage><lpage>6442</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-19-0836</pub-id><pub-id pub-id-type="pmid">31439581</pub-id><pub-id pub-id-type="pmcid">PMC6825560</pub-id></element-citation><mixed-citation id="mc-CR110" publication-type="journal">Vashisht Gopal YN, Gammon S, Prasad R et al (2019) A novel mitochondrial inhibitor blocks MAPK pathway and overcomes MAPK inhibitor resistance in melanoma. Clin Cancer Res 25:6429&#8211;6442. 10.1158/1078-0432.CCR-19-0836<pub-id pub-id-type="pmid">31439581</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/1078-0432.CCR-19-0836</pub-id><pub-id pub-id-type="pmcid">PMC6825560</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR111"><label>111.</label><citation-alternatives><element-citation id="ec-CR111" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Krakowski</surname><given-names>I</given-names></name><name name-style="western"><surname>H&#228;bel</surname><given-names>H</given-names></name><name name-style="western"><surname>Nielsen</surname><given-names>K</given-names></name><etal/></person-group><article-title>Association of metformin use and survival in patients with cutaneous melanoma and diabetes</article-title><source>Br J Dermatol</source><year>2023</year><volume>188</volume><fpage>32</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.1093/bjd/ljac003</pub-id><pub-id pub-id-type="pmid">36689497</pub-id></element-citation><mixed-citation id="mc-CR111" publication-type="journal">Krakowski I, H&#228;bel H, Nielsen K et al (2023) Association of metformin use and survival in patients with cutaneous melanoma and diabetes. Br J Dermatol 188:32&#8211;40. 10.1093/bjd/ljac003<pub-id pub-id-type="pmid">36689497</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/bjd/ljac003</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR112"><label>112.</label><citation-alternatives><element-citation id="ec-CR112" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Augustin</surname><given-names>RC</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Ding</surname><given-names>F</given-names></name><etal/></person-group><article-title>Metformin is associated with improved clinical outcomes in patients with melanoma: a retrospective, multi-institutional study</article-title><source>Front Oncol</source><year>2023</year><pub-id pub-id-type="doi">10.3389/fonc.2023.1075823</pub-id><pub-id pub-id-type="pmid">37397389</pub-id><pub-id pub-id-type="pmcid">PMC10312386</pub-id></element-citation><mixed-citation id="mc-CR112" publication-type="journal">Augustin RC, Huang Z, Ding F et al (2023) Metformin is associated with improved clinical outcomes in patients with melanoma: a retrospective, multi-institutional study. Front Oncol. 10.3389/fonc.2023.1075823<pub-id pub-id-type="pmid">37397389</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fonc.2023.1075823</pub-id><pub-id pub-id-type="pmcid">PMC10312386</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR113"><label>113.</label><citation-alternatives><element-citation id="ec-CR113" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Feng</surname><given-names>H</given-names></name><name name-style="western"><surname>Shang</surname><given-names>S</given-names></name><name name-style="western"><surname>Chen</surname><given-names>K</given-names></name><etal/></person-group><article-title>Impact of metformin on melanoma: a meta-analysis and systematic review</article-title><source>Front Oncol</source><year>2024</year><pub-id pub-id-type="doi">10.3389/fonc.2024.1399693</pub-id><pub-id pub-id-type="pmid">38846983</pub-id><pub-id pub-id-type="pmcid">PMC11153730</pub-id></element-citation><mixed-citation id="mc-CR113" publication-type="journal">Feng H, Shang S, Chen K et al (2024) Impact of metformin on melanoma: a meta-analysis and systematic review. Front Oncol. 10.3389/fonc.2024.1399693<pub-id pub-id-type="pmid">38846983</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fonc.2024.1399693</pub-id><pub-id pub-id-type="pmcid">PMC11153730</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR114"><label>114.</label><citation-alternatives><element-citation id="ec-CR114" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ryabaya</surname><given-names>O</given-names></name><name name-style="western"><surname>Prokofieva</surname><given-names>A</given-names></name><name name-style="western"><surname>Akasov</surname><given-names>R</given-names></name><etal/></person-group><article-title>Metformin increases antitumor activity of MEK inhibitor binimetinib in 2D and 3D models of human metastatic melanoma cells</article-title><source>Biomed Pharmacother</source><year>2019</year><volume>109</volume><fpage>2548</fpage><lpage>2560</lpage><pub-id pub-id-type="doi">10.1016/j.biopha.2018.11.109</pub-id><pub-id pub-id-type="pmid">30551515</pub-id></element-citation><mixed-citation id="mc-CR114" publication-type="journal">Ryabaya O, Prokofieva A, Akasov R et al (2019) Metformin increases antitumor activity of MEK inhibitor binimetinib in 2D and 3D models of human metastatic melanoma cells. Biomed Pharmacother 109:2548&#8211;2560. 10.1016/j.biopha.2018.11.109<pub-id pub-id-type="pmid">30551515</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biopha.2018.11.109</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR115"><label>115.</label><citation-alternatives><element-citation id="ec-CR115" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>Y</given-names></name><name name-style="western"><surname>Park</surname><given-names>D</given-names></name></person-group><article-title>Effect of metformin in combination with trametinib and paclitaxel on cell survival and metastasis in melanoma cells</article-title><source>Anticancer Res</source><year>2021</year><volume>41</volume><issue>3</issue><fpage>1387</fpage><lpage>1399</lpage><pub-id pub-id-type="doi">10.21873/anticanres.14896</pub-id><pub-id pub-id-type="pmid">33788730</pub-id></element-citation><mixed-citation id="mc-CR115" publication-type="journal">Lee Y, Park D (2021) Effect of metformin in combination with trametinib and paclitaxel on cell survival and metastasis in melanoma cells. Anticancer Res 41(3):1387&#8211;1399. 10.21873/anticanres.14896<pub-id pub-id-type="pmid">33788730</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.21873/anticanres.14896</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR116"><label>116.</label><citation-alternatives><element-citation id="ec-CR116" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yuan</surname><given-names>P</given-names></name><name name-style="western"><surname>Ito</surname><given-names>K</given-names></name><name name-style="western"><surname>Perez-Lorenzo</surname><given-names>R</given-names></name><etal/></person-group><article-title>Phenformin enhances the therapeutic benefit of BRAF V600E inhibition in melanoma</article-title><source>Proc Natl Acad Sci</source><year>2013</year><volume>110</volume><fpage>18226</fpage><lpage>18231</lpage><pub-id pub-id-type="doi">10.1073/pnas.1317577110</pub-id><pub-id pub-id-type="pmid">24145418</pub-id><pub-id pub-id-type="pmcid">PMC3831456</pub-id></element-citation><mixed-citation id="mc-CR116" publication-type="journal">Yuan P, Ito K, Perez-Lorenzo R et al (2013) Phenformin enhances the therapeutic benefit of BRAF V600E inhibition in melanoma. Proc Natl Acad Sci 110:18226&#8211;18231. 10.1073/pnas.1317577110<pub-id pub-id-type="pmid">24145418</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.1317577110</pub-id><pub-id pub-id-type="pmcid">PMC3831456</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR117"><label>117.</label><citation-alternatives><element-citation id="ec-CR117" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fischer</surname><given-names>GM</given-names></name><name name-style="western"><surname>Jalali</surname><given-names>A</given-names></name><name name-style="western"><surname>Kircher</surname><given-names>DA</given-names></name><etal/></person-group><article-title>Molecular profiling reveals unique immune and metabolic features of melanoma brain metastases</article-title><source>Cancer Discov</source><year>2019</year><volume>9</volume><fpage>628</fpage><lpage>645</lpage><pub-id pub-id-type="doi">10.1158/2159-8290.CD-18-1489</pub-id><pub-id pub-id-type="pmid">30787016</pub-id><pub-id pub-id-type="pmcid">PMC6497554</pub-id></element-citation><mixed-citation id="mc-CR117" publication-type="journal">Fischer GM, Jalali A, Kircher DA et al (2019) Molecular profiling reveals unique immune and metabolic features of melanoma brain metastases. Cancer Discov 9:628&#8211;645. 10.1158/2159-8290.CD-18-1489<pub-id pub-id-type="pmid">30787016</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/2159-8290.CD-18-1489</pub-id><pub-id pub-id-type="pmcid">PMC6497554</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR118"><label>118.</label><citation-alternatives><element-citation id="ec-CR118" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Eikawa</surname><given-names>S</given-names></name><name name-style="western"><surname>Nishida</surname><given-names>M</given-names></name><name name-style="western"><surname>Mizukami</surname><given-names>S</given-names></name><etal/></person-group><article-title>Immune-mediated antitumor effect by type 2 diabetes drug, metformin</article-title><source>Proc Natl Acad Sci</source><year>2015</year><volume>112</volume><fpage>1809</fpage><lpage>1814</lpage><pub-id pub-id-type="doi">10.1073/pnas.1417636112</pub-id><pub-id pub-id-type="pmid">25624476</pub-id><pub-id pub-id-type="pmcid">PMC4330733</pub-id></element-citation><mixed-citation id="mc-CR118" publication-type="journal">Eikawa S, Nishida M, Mizukami S et al (2015) Immune-mediated antitumor effect by type 2 diabetes drug, metformin. Proc Natl Acad Sci 112:1809&#8211;1814. 10.1073/pnas.1417636112<pub-id pub-id-type="pmid">25624476</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.1417636112</pub-id><pub-id pub-id-type="pmcid">PMC4330733</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR119"><label>119.</label><citation-alternatives><element-citation id="ec-CR119" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Scharping</surname><given-names>NE</given-names></name><name name-style="western"><surname>Menk</surname><given-names>AV</given-names></name><name name-style="western"><surname>Whetstone</surname><given-names>RD</given-names></name><etal/></person-group><article-title>Efficacy of PD-1 blockade is potentiated by metformin-induced reduction of tumor hypoxia</article-title><source>Cancer Immunol Res</source><year>2017</year><volume>5</volume><fpage>9</fpage><lpage>16</lpage><pub-id pub-id-type="doi">10.1158/2326-6066.CIR-16-0103</pub-id><pub-id pub-id-type="pmid">27941003</pub-id><pub-id pub-id-type="pmcid">PMC5340074</pub-id></element-citation><mixed-citation id="mc-CR119" publication-type="journal">Scharping NE, Menk AV, Whetstone RD et al (2017) Efficacy of PD-1 blockade is potentiated by metformin-induced reduction of tumor hypoxia. Cancer Immunol Res 5:9&#8211;16. 10.1158/2326-6066.CIR-16-0103<pub-id pub-id-type="pmid">27941003</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/2326-6066.CIR-16-0103</pub-id><pub-id pub-id-type="pmcid">PMC5340074</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR120"><label>120.</label><citation-alternatives><element-citation id="ec-CR120" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Afzal</surname><given-names>MZ</given-names></name><name name-style="western"><surname>Mercado</surname><given-names>RR</given-names></name><name name-style="western"><surname>Shirai</surname><given-names>K</given-names></name></person-group><article-title>Efficacy of metformin in combination with immune checkpoint inhibitors (anti-PD-1/anti-CTLA-4) in metastatic malignant melanoma</article-title><source>J Immunother Cancer</source><year>2018</year><volume>6</volume><fpage>64</fpage><pub-id pub-id-type="doi">10.1186/s40425-018-0375-1</pub-id><pub-id pub-id-type="pmid">29966520</pub-id><pub-id pub-id-type="pmcid">PMC6027578</pub-id></element-citation><mixed-citation id="mc-CR120" publication-type="journal">Afzal MZ, Mercado RR, Shirai K (2018) Efficacy of metformin in combination with immune checkpoint inhibitors (anti-PD-1/anti-CTLA-4) in metastatic malignant melanoma. J Immunother Cancer 6:64. 10.1186/s40425-018-0375-1<pub-id pub-id-type="pmid">29966520</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s40425-018-0375-1</pub-id><pub-id pub-id-type="pmcid">PMC6027578</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR121"><label>121.</label><citation-alternatives><element-citation id="ec-CR121" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cadassou</surname><given-names>O</given-names></name><name name-style="western"><surname>Jordheim</surname><given-names>LP</given-names></name></person-group><article-title>OXPHOS inhibitors, metabolism and targeted therapies in cancer</article-title><source>Biochem Pharmacol</source><year>2023</year><volume>211</volume><fpage>115531</fpage><pub-id pub-id-type="doi">10.1016/j.bcp.2023.115531</pub-id><pub-id pub-id-type="pmid">37019188</pub-id></element-citation><mixed-citation id="mc-CR121" publication-type="journal">Cadassou O, Jordheim LP (2023) OXPHOS inhibitors, metabolism and targeted therapies in cancer. Biochem Pharmacol 211:115531. 10.1016/j.bcp.2023.115531<pub-id pub-id-type="pmid">37019188</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bcp.2023.115531</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR122"><label>122.</label><citation-alternatives><element-citation id="ec-CR122" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Plitzko</surname><given-names>B</given-names></name><name name-style="western"><surname>Kaweesa</surname><given-names>EN</given-names></name><name name-style="western"><surname>Loesgen</surname><given-names>S</given-names></name></person-group><article-title>The natural product mensacarcin induces mitochondrial toxicity and apoptosis in melanoma cells</article-title><source>J Biol Chem</source><year>2017</year><volume>292</volume><fpage>21102</fpage><lpage>21116</lpage><pub-id pub-id-type="doi">10.1074/jbc.M116.774836</pub-id><pub-id pub-id-type="pmid">29074620</pub-id><pub-id pub-id-type="pmcid">PMC5743083</pub-id></element-citation><mixed-citation id="mc-CR122" publication-type="journal">Plitzko B, Kaweesa EN, Loesgen S (2017) The natural product mensacarcin induces mitochondrial toxicity and apoptosis in melanoma cells. J Biol Chem 292:21102&#8211;21116. 10.1074/jbc.M116.774836<pub-id pub-id-type="pmid">29074620</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1074/jbc.M116.774836</pub-id><pub-id pub-id-type="pmcid">PMC5743083</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR123"><label>123.</label><citation-alternatives><element-citation id="ec-CR123" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pal</surname><given-names>HC</given-names></name><name name-style="western"><surname>Prasad</surname><given-names>R</given-names></name><name name-style="western"><surname>Katiyar</surname><given-names>SK</given-names></name></person-group><article-title>Cryptolepine inhibits melanoma cell growth through coordinated changes in mitochondrial biogenesis, dynamics and metabolic tumor suppressor AMPK&#945;1/2-LKB1</article-title><source>Sci Rep</source><year>2017</year><volume>7</volume><fpage>1498</fpage><pub-id pub-id-type="doi">10.1038/s41598-017-01659-7</pub-id><pub-id pub-id-type="pmid">28473727</pub-id><pub-id pub-id-type="pmcid">PMC5431443</pub-id></element-citation><mixed-citation id="mc-CR123" publication-type="journal">Pal HC, Prasad R, Katiyar SK (2017) Cryptolepine inhibits melanoma cell growth through coordinated changes in mitochondrial biogenesis, dynamics and metabolic tumor suppressor AMPK&#945;1/2-LKB1. Sci Rep 7:1498. 10.1038/s41598-017-01659-7<pub-id pub-id-type="pmid">28473727</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-017-01659-7</pub-id><pub-id pub-id-type="pmcid">PMC5431443</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR124"><label>124.</label><citation-alternatives><element-citation id="ec-CR124" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Carpenter</surname><given-names>EL</given-names></name><name name-style="western"><surname>Chagani</surname><given-names>S</given-names></name><name name-style="western"><surname>Nelson</surname><given-names>D</given-names></name><etal/></person-group><article-title>Mitochondrial complex I inhibitor deguelin induces metabolic reprogramming and sensitizes vemurafenib-resistant BRAF V600E mutation bearing metastatic melanoma cells</article-title><source>Mol Carcinog</source><year>2019</year><volume>58</volume><fpage>1680</fpage><lpage>1690</lpage><pub-id pub-id-type="doi">10.1002/mc.23068</pub-id><pub-id pub-id-type="pmid">31211467</pub-id><pub-id pub-id-type="pmcid">PMC6692247</pub-id></element-citation><mixed-citation id="mc-CR124" publication-type="journal">Carpenter EL, Chagani S, Nelson D et al (2019) Mitochondrial complex I inhibitor deguelin induces metabolic reprogramming and sensitizes vemurafenib-resistant BRAF V600E mutation bearing metastatic melanoma cells. Mol Carcinog 58:1680&#8211;1690. 10.1002/mc.23068<pub-id pub-id-type="pmid">31211467</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/mc.23068</pub-id><pub-id pub-id-type="pmcid">PMC6692247</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR125"><label>125.</label><citation-alternatives><element-citation id="ec-CR125" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Raimondi</surname><given-names>M</given-names></name><name name-style="western"><surname>Fontana</surname><given-names>F</given-names></name><name name-style="western"><surname>Marzagalli</surname><given-names>M</given-names></name><etal/></person-group><article-title>Ca2+ overload- and ROS-associated mitochondrial dysfunction contributes to &#948;-tocotrienol-mediated paraptosis in melanoma cells</article-title><source>Apoptosis</source><year>2021</year><pub-id pub-id-type="doi">10.1007/s10495-021-01668-y</pub-id><pub-id pub-id-type="pmid">33811561</pub-id><pub-id pub-id-type="pmcid">PMC8197726</pub-id></element-citation><mixed-citation id="mc-CR125" publication-type="journal">Raimondi M, Fontana F, Marzagalli M et al (2021) Ca2+ overload- and ROS-associated mitochondrial dysfunction contributes to &#948;-tocotrienol-mediated paraptosis in melanoma cells. Apoptosis. 10.1007/s10495-021-01668-y<pub-id pub-id-type="pmid">33811561</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10495-021-01668-y</pub-id><pub-id pub-id-type="pmcid">PMC8197726</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR126"><label>126.</label><citation-alternatives><element-citation id="ec-CR126" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cho</surname><given-names>H</given-names></name><name name-style="western"><surname>Shen</surname><given-names>Q</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>LH</given-names></name><etal/></person-group><article-title>CYP27A1-dependent anti-melanoma activity of limonoid natural products targets mitochondrial metabolism</article-title><source>Cell Chem Biol</source><year>2021</year><volume>28</volume><fpage>1407</fpage><lpage>1419.e6</lpage><pub-id pub-id-type="doi">10.1016/j.chembiol.2021.03.004</pub-id><pub-id pub-id-type="pmid">33794192</pub-id><pub-id pub-id-type="pmcid">PMC8481390</pub-id></element-citation><mixed-citation id="mc-CR126" publication-type="journal">Cho H, Shen Q, Zhang LH et al (2021) CYP27A1-dependent anti-melanoma activity of limonoid natural products targets mitochondrial metabolism. Cell Chem Biol 28:1407-1419.e6. 10.1016/j.chembiol.2021.03.004<pub-id pub-id-type="pmid">33794192</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.chembiol.2021.03.004</pub-id><pub-id pub-id-type="pmcid">PMC8481390</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR127"><label>127.</label><citation-alternatives><element-citation id="ec-CR127" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Akita</surname><given-names>M</given-names></name><name name-style="western"><surname>Suzuki-Karasaki</surname><given-names>M</given-names></name><name name-style="western"><surname>Fujiwara</surname><given-names>K</given-names></name><etal/></person-group><article-title>Mitochondrial division inhibitor-1 induces mitochondrial hyperfusion and sensitizes human cancer cells to TRAIL-induced apoptosis</article-title><source>Int J Oncol</source><year>2014</year><volume>45</volume><fpage>1901</fpage><lpage>1912</lpage><pub-id pub-id-type="doi">10.3892/ijo.2014.2608</pub-id><pub-id pub-id-type="pmid">25174275</pub-id></element-citation><mixed-citation id="mc-CR127" publication-type="journal">Akita M, Suzuki-Karasaki M, Fujiwara K et al (2014) Mitochondrial division inhibitor-1 induces mitochondrial hyperfusion and sensitizes human cancer cells to TRAIL-induced apoptosis. Int J Oncol 45:1901&#8211;1912. 10.3892/ijo.2014.2608<pub-id pub-id-type="pmid">25174275</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3892/ijo.2014.2608</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR128"><label>128.</label><citation-alternatives><element-citation id="ec-CR128" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Torres</surname><given-names>AK</given-names></name><name name-style="western"><surname>Fleischhart</surname><given-names>V</given-names></name><name name-style="western"><surname>Inestrosa</surname><given-names>NC</given-names></name></person-group><article-title>Mitochondrial unfolded protein response (UPRmt): what we know thus far</article-title><source>Front Cell Dev Biol</source><year>2024</year><pub-id pub-id-type="doi">10.3389/fcell.2024.1405393</pub-id><pub-id pub-id-type="pmid">38882057</pub-id><pub-id pub-id-type="pmcid">PMC11176431</pub-id></element-citation><mixed-citation id="mc-CR128" publication-type="journal">Torres AK, Fleischhart V, Inestrosa NC (2024) Mitochondrial unfolded protein response (UPRmt): what we know thus far. Front Cell Dev Biol. 10.3389/fcell.2024.1405393<pub-id pub-id-type="pmid">38882057</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fcell.2024.1405393</pub-id><pub-id pub-id-type="pmcid">PMC11176431</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR129"><label>129.</label><citation-alternatives><element-citation id="ec-CR129" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bonner</surname><given-names>ER</given-names></name><name name-style="western"><surname>Waszak</surname><given-names>SM</given-names></name><name name-style="western"><surname>Grotzer</surname><given-names>MA</given-names></name><etal/></person-group><article-title>Mechanisms of imipridones in targeting mitochondrial metabolism in cancer cells</article-title><source>Neuro Oncol</source><year>2021</year><volume>23</volume><fpage>542</fpage><lpage>556</lpage><pub-id pub-id-type="doi">10.1093/neuonc/noaa283</pub-id><pub-id pub-id-type="pmid">33336683</pub-id><pub-id pub-id-type="pmcid">PMC8041338</pub-id></element-citation><mixed-citation id="mc-CR129" publication-type="journal">Bonner ER, Waszak SM, Grotzer MA et al (2021) Mechanisms of imipridones in targeting mitochondrial metabolism in cancer cells. Neuro Oncol 23:542&#8211;556. 10.1093/neuonc/noaa283<pub-id pub-id-type="pmid">33336683</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/neuonc/noaa283</pub-id><pub-id pub-id-type="pmcid">PMC8041338</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR130"><label>130.</label><citation-alternatives><element-citation id="ec-CR130" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wagner</surname><given-names>J</given-names></name><name name-style="western"><surname>Kline</surname><given-names>CL</given-names></name><name name-style="western"><surname>Ralff</surname><given-names>MD</given-names></name><etal/></person-group><article-title>Preclinical evaluation of the imipridone family, analogs of clinical stage anti-cancer small molecule ONC201, reveals potent anti-cancer effects of ONC212</article-title><source>Cell Cycle</source><year>2017</year><volume>16</volume><fpage>1790</fpage><lpage>1799</lpage><pub-id pub-id-type="doi">10.1080/15384101.2017.1325046</pub-id><pub-id pub-id-type="pmid">28489985</pub-id><pub-id pub-id-type="pmcid">PMC5628644</pub-id></element-citation><mixed-citation id="mc-CR130" publication-type="journal">Wagner J, Kline CL, Ralff MD et al (2017) Preclinical evaluation of the imipridone family, analogs of clinical stage anti-cancer small molecule ONC201, reveals potent anti-cancer effects of ONC212. Cell Cycle 16:1790&#8211;1799. 10.1080/15384101.2017.1325046<pub-id pub-id-type="pmid">28489985</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/15384101.2017.1325046</pub-id><pub-id pub-id-type="pmcid">PMC5628644</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR131"><label>131.</label><citation-alternatives><element-citation id="ec-CR131" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aminzadeh-Gohari</surname><given-names>S</given-names></name><name name-style="western"><surname>Weber</surname><given-names>DD</given-names></name><name name-style="western"><surname>Catalano</surname><given-names>L</given-names></name><etal/></person-group><article-title>Targeting mitochondria in melanoma</article-title><source>Biomolecules</source><year>2020</year><volume>10</volume><fpage>1395</fpage><pub-id pub-id-type="doi">10.3390/biom10101395</pub-id><pub-id pub-id-type="pmid">33007949</pub-id><pub-id pub-id-type="pmcid">PMC7599575</pub-id></element-citation><mixed-citation id="mc-CR131" publication-type="journal">Aminzadeh-Gohari S, Weber DD, Catalano L et al (2020) Targeting mitochondria in melanoma. Biomolecules 10:1395. 10.3390/biom10101395<pub-id pub-id-type="pmid">33007949</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/biom10101395</pub-id><pub-id pub-id-type="pmcid">PMC7599575</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR132"><label>132.</label><citation-alternatives><element-citation id="ec-CR132" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chattopadhyay</surname><given-names>C</given-names></name><name name-style="western"><surname>Roszik</surname><given-names>J</given-names></name><name name-style="western"><surname>Bhattacharya</surname><given-names>R</given-names></name><etal/></person-group><article-title>Imipridones inhibit tumor growth and improve survival in an orthotopic liver metastasis mouse model of human uveal melanoma</article-title><source>Br J Cancer</source><year>2024</year><volume>131</volume><fpage>1846</fpage><lpage>1857</lpage><pub-id pub-id-type="doi">10.1038/s41416-024-02866-6</pub-id><pub-id pub-id-type="pmid">39394450</pub-id><pub-id pub-id-type="pmcid">PMC11589887</pub-id></element-citation><mixed-citation id="mc-CR132" publication-type="journal">Chattopadhyay C, Roszik J, Bhattacharya R et al (2024) Imipridones inhibit tumor growth and improve survival in an orthotopic liver metastasis mouse model of human uveal melanoma. Br J Cancer 131:1846&#8211;1857. 10.1038/s41416-024-02866-6<pub-id pub-id-type="pmid">39394450</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41416-024-02866-6</pub-id><pub-id pub-id-type="pmcid">PMC11589887</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR133"><label>133.</label><citation-alternatives><element-citation id="ec-CR133" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>T</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>N</given-names></name><name name-style="western"><surname>Ni</surname><given-names>C</given-names></name><etal/></person-group><article-title>Doxycycline inhibits the adhesion and migration of melanoma cells by inhibiting the expression and phosphorylation of focal adhesion kinase (FAK)</article-title><source>Cancer Lett</source><year>2009</year><volume>285</volume><fpage>141</fpage><lpage>150</lpage><pub-id pub-id-type="doi">10.1016/j.canlet.2009.05.004</pub-id><pub-id pub-id-type="pmid">19482420</pub-id></element-citation><mixed-citation id="mc-CR133" publication-type="journal">Sun T, Zhao N, Ni C et al (2009) Doxycycline inhibits the adhesion and migration of melanoma cells by inhibiting the expression and phosphorylation of focal adhesion kinase (FAK). Cancer Lett 285:141&#8211;150. 10.1016/j.canlet.2009.05.004<pub-id pub-id-type="pmid">19482420</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.canlet.2009.05.004</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR134"><label>134.</label><citation-alternatives><element-citation id="ec-CR134" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hu</surname><given-names>H</given-names></name><name name-style="western"><surname>Dong</surname><given-names>Z</given-names></name><name name-style="western"><surname>Tan</surname><given-names>P</given-names></name><etal/></person-group><article-title>Antibiotic drug tigecycline inhibits melanoma progression and metastasis in a p21CIP1/Waf1-dependent manner</article-title><source>Oncotarget</source><year>2016</year><volume>7</volume><fpage>3171</fpage><lpage>3185</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.6419</pub-id><pub-id pub-id-type="pmid">26621850</pub-id><pub-id pub-id-type="pmcid">PMC4823098</pub-id></element-citation><mixed-citation id="mc-CR134" publication-type="journal">Hu H, Dong Z, Tan P et al (2016) Antibiotic drug tigecycline inhibits melanoma progression and metastasis in a p21CIP1/Waf1-dependent manner. Oncotarget 7:3171&#8211;3185. 10.18632/oncotarget.6419<pub-id pub-id-type="pmid">26621850</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.18632/oncotarget.6419</pub-id><pub-id pub-id-type="pmcid">PMC4823098</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR135"><label>135.</label><citation-alternatives><element-citation id="ec-CR135" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rok</surname><given-names>J</given-names></name><name name-style="western"><surname>Karkoszka</surname><given-names>M</given-names></name><name name-style="western"><surname>Rzepka</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Cytotoxic and proapoptotic effect of doxycycline&#8211; an in vitro study on the human skin melanoma cells</article-title><source>Toxicol In Vitro</source><year>2020</year><volume>65</volume><fpage>104790</fpage><pub-id pub-id-type="doi">10.1016/j.tiv.2020.104790</pub-id><pub-id pub-id-type="pmid">32044399</pub-id></element-citation><mixed-citation id="mc-CR135" publication-type="journal">Rok J, Karkoszka M, Rzepka Z et al (2020) Cytotoxic and proapoptotic effect of doxycycline&#8211; an in vitro study on the human skin melanoma cells. Toxicol In Vitro 65:104790. 10.1016/j.tiv.2020.104790<pub-id pub-id-type="pmid">32044399</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.tiv.2020.104790</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR136"><label>136.</label><citation-alternatives><element-citation id="ec-CR136" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rok</surname><given-names>J</given-names></name><name name-style="western"><surname>Rzepka</surname><given-names>Z</given-names></name><name name-style="western"><surname>Kowalska</surname><given-names>J</given-names></name><etal/></person-group><article-title>The anticancer potential of doxycycline and minocycline&#8212;a comparative study on amelanotic melanoma cell lines</article-title><source>Int J Mol Sci</source><year>2022</year><volume>23</volume><fpage>831</fpage><pub-id pub-id-type="doi">10.3390/ijms23020831</pub-id><pub-id pub-id-type="pmid">35055021</pub-id><pub-id pub-id-type="pmcid">PMC8775630</pub-id></element-citation><mixed-citation id="mc-CR136" publication-type="journal">Rok J, Rzepka Z, Kowalska J et al (2022) The anticancer potential of doxycycline and minocycline&#8212;a comparative study on amelanotic melanoma cell lines. Int J Mol Sci 23:831. 10.3390/ijms23020831<pub-id pub-id-type="pmid">35055021</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms23020831</pub-id><pub-id pub-id-type="pmcid">PMC8775630</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR137"><label>137.</label><citation-alternatives><element-citation id="ec-CR137" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rok</surname><given-names>J</given-names></name><name name-style="western"><surname>Kowalska</surname><given-names>J</given-names></name><name name-style="western"><surname>Rzepka</surname><given-names>Z</given-names></name><etal/></person-group><article-title>The assessment of anti-melanoma potential of Tigecycline&#8212;cellular and molecular studies of cell proliferation, apoptosis and autophagy on amelanotic and melanotic melanoma cells</article-title><source>Cells</source><year>2023</year><volume>12</volume><fpage>1564</fpage><pub-id pub-id-type="doi">10.3390/cells12121564</pub-id><pub-id pub-id-type="pmid">37371034</pub-id><pub-id pub-id-type="pmcid">PMC10296940</pub-id></element-citation><mixed-citation id="mc-CR137" publication-type="journal">Rok J, Kowalska J, Rzepka Z et al (2023) The assessment of anti-melanoma potential of Tigecycline&#8212;cellular and molecular studies of cell proliferation, apoptosis and autophagy on amelanotic and melanotic melanoma cells. Cells 12:1564. 10.3390/cells12121564<pub-id pub-id-type="pmid">37371034</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/cells12121564</pub-id><pub-id pub-id-type="pmcid">PMC10296940</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR138"><label>138.</label><citation-alternatives><element-citation id="ec-CR138" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lamb</surname><given-names>R</given-names></name><name name-style="western"><surname>Ozsvari</surname><given-names>B</given-names></name><name name-style="western"><surname>Lisanti</surname><given-names>CL</given-names></name><etal/></person-group><article-title>Antibiotics that target mitochondria effectively eradicate cancer stem cells, across multiple tumor types: treating cancer like an infectious disease</article-title><source>Oncotarget</source><year>2015</year><volume>6</volume><fpage>4569</fpage><lpage>4584</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.3174</pub-id><pub-id pub-id-type="pmid">25625193</pub-id><pub-id pub-id-type="pmcid">PMC4467100</pub-id></element-citation><mixed-citation id="mc-CR138" publication-type="journal">Lamb R, Ozsvari B, Lisanti CL et al (2015) Antibiotics that target mitochondria effectively eradicate cancer stem cells, across multiple tumor types: treating cancer like an infectious disease. Oncotarget 6:4569&#8211;4584. 10.18632/oncotarget.3174<pub-id pub-id-type="pmid">25625193</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.18632/oncotarget.3174</pub-id><pub-id pub-id-type="pmcid">PMC4467100</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR139"><label>139.</label><citation-alternatives><element-citation id="ec-CR139" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Petrelli</surname><given-names>F</given-names></name><name name-style="western"><surname>Ghidini</surname><given-names>M</given-names></name><name name-style="western"><surname>Ghidini</surname><given-names>A</given-names></name><etal/></person-group><article-title>Use of antibiotics and risk of cancer: a systematic review and meta-analysis of observational studies</article-title><source>Cancers (Basel)</source><year>2019</year><volume>11</volume><fpage>1174</fpage><pub-id pub-id-type="doi">10.3390/cancers11081174</pub-id><pub-id pub-id-type="pmid">31416208</pub-id><pub-id pub-id-type="pmcid">PMC6721461</pub-id></element-citation><mixed-citation id="mc-CR139" publication-type="journal">Petrelli F, Ghidini M, Ghidini A et al (2019) Use of antibiotics and risk of cancer: a systematic review and meta-analysis of observational studies. Cancers (Basel) 11:1174. 10.3390/cancers11081174<pub-id pub-id-type="pmid">31416208</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/cancers11081174</pub-id><pub-id pub-id-type="pmcid">PMC6721461</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR140"><label>140.</label><citation-alternatives><element-citation id="ec-CR140" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Amadei</surname><given-names>SS</given-names></name><name name-style="western"><surname>Notario</surname><given-names>V</given-names></name></person-group><article-title>A significant question in cancer risk and therapy: are antibiotics positive or negative effectors? Current answers and possible alternatives</article-title><source>Antibiotics</source><year>2020</year><volume>9</volume><fpage>580</fpage><pub-id pub-id-type="doi">10.3390/antibiotics9090580</pub-id><pub-id pub-id-type="pmid">32899961</pub-id><pub-id pub-id-type="pmcid">PMC7558931</pub-id></element-citation><mixed-citation id="mc-CR140" publication-type="journal">Amadei SS, Notario V (2020) A significant question in cancer risk and therapy: are antibiotics positive or negative effectors? Current answers and possible alternatives. Antibiotics 9:580. 10.3390/antibiotics9090580<pub-id pub-id-type="pmid">32899961</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/antibiotics9090580</pub-id><pub-id pub-id-type="pmcid">PMC7558931</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR141"><label>141.</label><citation-alternatives><element-citation id="ec-CR141" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barbi de Moura</surname><given-names>M</given-names></name><name name-style="western"><surname>Vincent</surname><given-names>G</given-names></name><name name-style="western"><surname>Fayewicz</surname><given-names>SL</given-names></name><etal/></person-group><article-title>Mitochondrial respiration&#8212;an important therapeutic target in melanoma</article-title><source>PLoS ONE</source><year>2012</year><volume>7</volume><fpage>e40690</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0040690</pub-id><pub-id pub-id-type="pmid">22912665</pub-id><pub-id pub-id-type="pmcid">PMC3422349</pub-id></element-citation><mixed-citation id="mc-CR141" publication-type="journal">Barbi de Moura M, Vincent G, Fayewicz SL et al (2012) Mitochondrial respiration&#8212;an important therapeutic target in melanoma. PLoS ONE 7:e40690. 10.1371/journal.pone.0040690<pub-id pub-id-type="pmid">22912665</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0040690</pub-id><pub-id pub-id-type="pmcid">PMC3422349</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR142"><label>142.</label><citation-alternatives><element-citation id="ec-CR142" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>de Guterres</surname><given-names>FALB</given-names></name><name name-style="western"><surname>Martinez</surname><given-names>GR</given-names></name><name name-style="western"><surname>Rocha</surname><given-names>MEM</given-names></name><name name-style="western"><surname>Winnischofer</surname><given-names>SMB</given-names></name></person-group><article-title>Simvastatin rises reactive oxygen species levels and induces senescence in human melanoma cells by activation of p53/p21 pathway</article-title><source>Exp Cell Res</source><year>2013</year><volume>319</volume><fpage>2977</fpage><lpage>2988</lpage><pub-id pub-id-type="doi">10.1016/j.yexcr.2013.07.026</pub-id><pub-id pub-id-type="pmid">23933099</pub-id></element-citation><mixed-citation id="mc-CR142" publication-type="journal">de Guterres FALB, Martinez GR, Rocha MEM, Winnischofer SMB (2013) Simvastatin rises reactive oxygen species levels and induces senescence in human melanoma cells by activation of p53/p21 pathway. Exp Cell Res 319:2977&#8211;2988. 10.1016/j.yexcr.2013.07.026<pub-id pub-id-type="pmid">23933099</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.yexcr.2013.07.026</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR143"><label>143.</label><citation-alternatives><element-citation id="ec-CR143" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Heo</surname><given-names>J-R</given-names></name><name name-style="western"><surname>Kim</surname><given-names>S-M</given-names></name><name name-style="western"><surname>Hwang</surname><given-names>K-A</given-names></name><etal/></person-group><article-title>Resveratrol induced reactive oxygen species and endoplasmic reticulum stress-mediated apoptosis, and cell cycle arrest in the A375SM malignant melanoma cell line</article-title><source>Int J Mol Med</source><year>2018</year><volume>42</volume><fpage>1427</fpage><lpage>1435</lpage><pub-id pub-id-type="doi">10.3892/ijmm.2018.3732</pub-id><pub-id pub-id-type="pmid">29916532</pub-id><pub-id pub-id-type="pmcid">PMC6089775</pub-id></element-citation><mixed-citation id="mc-CR143" publication-type="journal">Heo J-R, Kim S-M, Hwang K-A et al (2018) Resveratrol induced reactive oxygen species and endoplasmic reticulum stress-mediated apoptosis, and cell cycle arrest in the A375SM malignant melanoma cell line. Int J Mol Med 42:1427&#8211;1435. 10.3892/ijmm.2018.3732<pub-id pub-id-type="pmid">29916532</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3892/ijmm.2018.3732</pub-id><pub-id pub-id-type="pmcid">PMC6089775</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR144"><label>144.</label><citation-alternatives><element-citation id="ec-CR144" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>K</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>S</given-names></name><name name-style="western"><surname>Long</surname><given-names>J</given-names></name><etal/></person-group><article-title>A novel chalcone derivative has antitumor activity in melanoma by inducing DNA damage through the upregulation of ROS products</article-title><source>Cancer Cell Int</source><year>2020</year><volume>20</volume><fpage>36</fpage><pub-id pub-id-type="doi">10.1186/s12935-020-1114-5</pub-id><pub-id pub-id-type="pmid">32021565</pub-id><pub-id pub-id-type="pmcid">PMC6993520</pub-id></element-citation><mixed-citation id="mc-CR144" publication-type="journal">Li K, Zhao S, Long J et al (2020) A novel chalcone derivative has antitumor activity in melanoma by inducing DNA damage through the upregulation of ROS products. Cancer Cell Int 20:36. 10.1186/s12935-020-1114-5<pub-id pub-id-type="pmid">32021565</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12935-020-1114-5</pub-id><pub-id pub-id-type="pmcid">PMC6993520</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR145"><label>145.</label><citation-alternatives><element-citation id="ec-CR145" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Manica</surname><given-names>D</given-names></name><name name-style="western"><surname>da Silva</surname><given-names>GB</given-names></name><name name-style="western"><surname>da Silva</surname><given-names>AP</given-names></name><etal/></person-group><article-title>Curcumin promotes apoptosis of human melanoma cells by caspase 3</article-title><source>Cell Biochem Funct</source><year>2023</year><volume>41</volume><fpage>1295</fpage><lpage>1304</lpage><pub-id pub-id-type="doi">10.1002/cbf.3863</pub-id><pub-id pub-id-type="pmid">37792322</pub-id></element-citation><mixed-citation id="mc-CR145" publication-type="journal">Manica D, da Silva GB, da Silva AP et al (2023) Curcumin promotes apoptosis of human melanoma cells by caspase 3. Cell Biochem Funct 41:1295&#8211;1304. 10.1002/cbf.3863<pub-id pub-id-type="pmid">37792322</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cbf.3863</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR146"><label>146.</label><citation-alternatives><element-citation id="ec-CR146" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ali</surname><given-names>ML</given-names></name><name name-style="western"><surname>Roky</surname><given-names>AH</given-names></name><name name-style="western"><surname>Azad</surname><given-names>SMAK</given-names></name><etal/></person-group><article-title>Autophagy as a targeted therapeutic approach for skin cancer: evaluating natural and synthetic molecular interventions</article-title><source>Cancer Pathog Ther</source><year>2024</year><volume>2</volume><fpage>231</fpage><lpage>245</lpage><pub-id pub-id-type="doi">10.1016/j.cpt.2024.01.002</pub-id><pub-id pub-id-type="pmid">39371094</pub-id><pub-id pub-id-type="pmcid">PMC11447340</pub-id></element-citation><mixed-citation id="mc-CR146" publication-type="journal">Ali ML, Roky AH, Azad SMAK et al (2024) Autophagy as a targeted therapeutic approach for skin cancer: evaluating natural and synthetic molecular interventions. Cancer Pathog Ther 2:231&#8211;245. 10.1016/j.cpt.2024.01.002<pub-id pub-id-type="pmid">39371094</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cpt.2024.01.002</pub-id><pub-id pub-id-type="pmcid">PMC11447340</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR147"><label>147.</label><citation-alternatives><element-citation id="ec-CR147" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kudo</surname><given-names>T</given-names></name><name name-style="western"><surname>Takeuchi</surname><given-names>K</given-names></name><name name-style="western"><surname>Ebina</surname><given-names>Y</given-names></name><name name-style="western"><surname>Nakazawa</surname><given-names>M</given-names></name></person-group><article-title>Inhibitory effects of trehalose on malignant melanoma cell growth: implications for a novel topical anticancer agent on the ocular surface</article-title><source>ISRN Ophthalmol</source><year>2012</year><volume>2012</volume><fpage>1</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.5402/2012/968493</pub-id><pub-id pub-id-type="pmcid">PMC3914279</pub-id><pub-id pub-id-type="pmid">24558596</pub-id></element-citation><mixed-citation id="mc-CR147" publication-type="journal">Kudo T, Takeuchi K, Ebina Y, Nakazawa M (2012) Inhibitory effects of trehalose on malignant melanoma cell growth: implications for a novel topical anticancer agent on the ocular surface. ISRN Ophthalmol 2012:1&#8211;9. 10.5402/2012/968493<pub-id pub-id-type="doi" assigning-authority="pmc">10.5402/2012/968493</pub-id><pub-id pub-id-type="pmcid">PMC3914279</pub-id><pub-id pub-id-type="pmid">24558596</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR148"><label>148.</label><citation-alternatives><element-citation id="ec-CR148" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lakhter</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Sahu</surname><given-names>RP</given-names></name><name name-style="western"><surname>Sun</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Chloroquine promotes apoptosis in melanoma cells by inhibiting BH3 domain-mediated PUMA degradation</article-title><source>J Invest Dermatol</source><year>2013</year><volume>133</volume><fpage>2247</fpage><lpage>2254</lpage><pub-id pub-id-type="doi">10.1038/jid.2013.56</pub-id><pub-id pub-id-type="pmid">23370537</pub-id><pub-id pub-id-type="pmcid">PMC3675185</pub-id></element-citation><mixed-citation id="mc-CR148" publication-type="journal">Lakhter AJ, Sahu RP, Sun Y et al (2013) Chloroquine promotes apoptosis in melanoma cells by inhibiting BH3 domain-mediated PUMA degradation. J Invest Dermatol 133:2247&#8211;2254. 10.1038/jid.2013.56<pub-id pub-id-type="pmid">23370537</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/jid.2013.56</pub-id><pub-id pub-id-type="pmcid">PMC3675185</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR149"><label>149.</label><citation-alternatives><element-citation id="ec-CR149" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Egger</surname><given-names>ME</given-names></name><name name-style="western"><surname>Huang</surname><given-names>JS</given-names></name><name name-style="western"><surname>Yin</surname><given-names>W</given-names></name><etal/></person-group><article-title>Inhibition of autophagy with chloroquine is effective in melanoma</article-title><source>J Surg Res</source><year>2013</year><volume>184</volume><fpage>274</fpage><lpage>281</lpage><pub-id pub-id-type="doi">10.1016/j.jss.2013.04.055</pub-id><pub-id pub-id-type="pmid">23706562</pub-id></element-citation><mixed-citation id="mc-CR149" publication-type="journal">Egger ME, Huang JS, Yin W et al (2013) Inhibition of autophagy with chloroquine is effective in melanoma. J Surg Res 184:274&#8211;281. 10.1016/j.jss.2013.04.055<pub-id pub-id-type="pmid">23706562</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jss.2013.04.055</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR150"><label>150.</label><citation-alternatives><element-citation id="ec-CR150" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>L</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Q</given-names></name><name name-style="western"><surname>Deng</surname><given-names>G</given-names></name><etal/></person-group><article-title>AMPK activation by GSK621 inhibits human melanoma cells in vitro and in vivo</article-title><source>Biochem Biophys Res Commun</source><year>2016</year><volume>480</volume><fpage>515</fpage><lpage>521</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2016.10.040</pub-id><pub-id pub-id-type="pmid">27751856</pub-id></element-citation><mixed-citation id="mc-CR150" publication-type="journal">Chen L, Chen Q, Deng G et al (2016) AMPK activation by GSK621 inhibits human melanoma cells in vitro and in vivo. Biochem Biophys Res Commun 480:515&#8211;521. 10.1016/j.bbrc.2016.10.040<pub-id pub-id-type="pmid">27751856</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bbrc.2016.10.040</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR151"><label>151.</label><citation-alternatives><element-citation id="ec-CR151" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vera Aguilera</surname><given-names>J</given-names></name><name name-style="western"><surname>Rao</surname><given-names>RD</given-names></name><name name-style="western"><surname>Allred</surname><given-names>JB</given-names></name><etal/></person-group><article-title>Phase II study of everolimus in metastatic malignant melanoma (NCCTG-N0377, alliance)</article-title><source>Oncologist</source><year>2018</year><volume>23</volume><fpage>887</fpage><lpage>e94</lpage><pub-id pub-id-type="doi">10.1634/theoncologist.2018-0100</pub-id><pub-id pub-id-type="pmid">29666297</pub-id><pub-id pub-id-type="pmcid">PMC6156180</pub-id></element-citation><mixed-citation id="mc-CR151" publication-type="journal">Vera Aguilera J, Rao RD, Allred JB et al (2018) Phase II study of everolimus in metastatic malignant melanoma (NCCTG-N0377, alliance). Oncologist 23:887-e94. 10.1634/theoncologist.2018-0100<pub-id pub-id-type="pmid">29666297</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1634/theoncologist.2018-0100</pub-id><pub-id pub-id-type="pmcid">PMC6156180</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR152"><label>152.</label><citation-alternatives><element-citation id="ec-CR152" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Allavena</surname><given-names>G</given-names></name><name name-style="western"><surname>Del Bello</surname><given-names>B</given-names></name><name name-style="western"><surname>Tini</surname><given-names>P</given-names></name><etal/></person-group><article-title>Trehalose inhibits cell proliferation and amplifies long-term temozolomide- and radiation-induced cytotoxicity in melanoma cells: a role for autophagy and premature senescence</article-title><source>J Cell Physiol</source><year>2019</year><volume>234</volume><fpage>11708</fpage><lpage>11721</lpage><pub-id pub-id-type="doi">10.1002/jcp.27838</pub-id><pub-id pub-id-type="pmid">30488547</pub-id></element-citation><mixed-citation id="mc-CR152" publication-type="journal">Allavena G, Del Bello B, Tini P et al (2019) Trehalose inhibits cell proliferation and amplifies long-term temozolomide- and radiation-induced cytotoxicity in melanoma cells: a role for autophagy and premature senescence. J Cell Physiol 234:11708&#8211;11721. 10.1002/jcp.27838<pub-id pub-id-type="pmid">30488547</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jcp.27838</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR153"><label>153.</label><citation-alternatives><element-citation id="ec-CR153" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bao</surname><given-names>Y</given-names></name><name name-style="western"><surname>Ding</surname><given-names>Z</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>P</given-names></name><etal/></person-group><article-title>Autophagy inhibition potentiates the anti-EMT effects of alteronol through TGF-&#946;/Smad3 signaling in melanoma cells</article-title><source>Cell Death Dis</source><year>2020</year><volume>11</volume><fpage>223</fpage><pub-id pub-id-type="doi">10.1038/s41419-020-2419-y</pub-id><pub-id pub-id-type="pmid">32265437</pub-id><pub-id pub-id-type="pmcid">PMC7138813</pub-id></element-citation><mixed-citation id="mc-CR153" publication-type="journal">Bao Y, Ding Z, Zhao P et al (2020) Autophagy inhibition potentiates the anti-EMT effects of alteronol through TGF-&#946;/Smad3 signaling in melanoma cells. Cell Death Dis 11:223. 10.1038/s41419-020-2419-y<pub-id pub-id-type="pmid">32265437</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41419-020-2419-y</pub-id><pub-id pub-id-type="pmcid">PMC7138813</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR154"><label>154.</label><citation-alternatives><element-citation id="ec-CR154" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Strasberg Rieber</surname><given-names>M</given-names></name><name name-style="western"><surname>Zangemeister-Wittke</surname><given-names>U</given-names></name><name name-style="western"><surname>Rieber</surname><given-names>M</given-names></name></person-group><article-title>P53-independent induction of apoptosis in human melanoma cells by a bcl-2/bcl-xL bispecific antisense oligonucleotide</article-title><source>Clin Cancer Res</source><year>2001</year><volume>7</volume><fpage>1446</fpage><lpage>51</lpage><pub-id pub-id-type="pmid">11350916</pub-id></element-citation><mixed-citation id="mc-CR154" publication-type="journal">Strasberg Rieber M, Zangemeister-Wittke U, Rieber M (2001) P53-independent induction of apoptosis in human melanoma cells by a bcl-2/bcl-xL bispecific antisense oligonucleotide. Clin Cancer Res 7:1446&#8211;51<pub-id pub-id-type="pmid">11350916</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR155"><label>155.</label><citation-alternatives><element-citation id="ec-CR155" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bufalo</surname><given-names>DD</given-names></name><name name-style="western"><surname>Trisciuoglio</surname><given-names>D</given-names></name><name name-style="western"><surname>Scarsella</surname><given-names>M</given-names></name><etal/></person-group><article-title>Treatment of melanoma cells with a bcl-2/bcl-xL antisense oligonucleotide induces antiangiogenic activity</article-title><source>Oncogene</source><year>2003</year><volume>22</volume><fpage>8441</fpage><lpage>8447</lpage><pub-id pub-id-type="doi">10.1038/sj.onc.1206999</pub-id><pub-id pub-id-type="pmid">14627985</pub-id></element-citation><mixed-citation id="mc-CR155" publication-type="journal">Bufalo DD, Trisciuoglio D, Scarsella M et al (2003) Treatment of melanoma cells with a bcl-2/bcl-xL antisense oligonucleotide induces antiangiogenic activity. Oncogene 22:8441&#8211;8447. 10.1038/sj.onc.1206999<pub-id pub-id-type="pmid">14627985</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/sj.onc.1206999</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR156"><label>156.</label><citation-alternatives><element-citation id="ec-CR156" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jiang</surname><given-names>CC</given-names></name><name name-style="western"><surname>Wroblewski</surname><given-names>D</given-names></name><name name-style="western"><surname>Yang</surname><given-names>F</given-names></name><etal/></person-group><article-title>Human melanoma cells under endoplasmic reticulum stress are more susceptible to apoptosis induced by the BH3 mimetic obatoclax</article-title><source>Neoplasia</source><year>2009</year><volume>11</volume><fpage>945</fpage><lpage>955</lpage><pub-id pub-id-type="doi">10.1593/neo.09692</pub-id><pub-id pub-id-type="pmid">19724688</pub-id><pub-id pub-id-type="pmcid">PMC2735806</pub-id></element-citation><mixed-citation id="mc-CR156" publication-type="journal">Jiang CC, Wroblewski D, Yang F et al (2009) Human melanoma cells under endoplasmic reticulum stress are more susceptible to apoptosis induced by the BH3 mimetic obatoclax. Neoplasia 11:945&#8211;955. 10.1593/neo.09692<pub-id pub-id-type="pmid">19724688</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1593/neo.09692</pub-id><pub-id pub-id-type="pmcid">PMC2735806</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR157"><label>157.</label><citation-alternatives><element-citation id="ec-CR157" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Karpel-Massler</surname><given-names>G</given-names></name><name name-style="western"><surname>Ishida</surname><given-names>CT</given-names></name><name name-style="western"><surname>Bianchetti</surname><given-names>E</given-names></name><etal/></person-group><article-title>Inhibition of Mitochondrial Matrix Chaperones and Antiapoptotic Bcl-2 Family Proteins Empower Antitumor Therapeutic Responses</article-title><source>Cancer Res</source><year>2017</year><volume>77</volume><fpage>3513</fpage><lpage>3526</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-16-3424</pub-id><pub-id pub-id-type="pmid">28522750</pub-id><pub-id pub-id-type="pmcid">PMC5503474</pub-id></element-citation><mixed-citation id="mc-CR157" publication-type="journal">Karpel-Massler G, Ishida CT, Bianchetti E et al (2017) Inhibition of Mitochondrial Matrix Chaperones and Antiapoptotic Bcl-2 Family Proteins Empower Antitumor Therapeutic Responses. Cancer Res 77:3513&#8211;3526. 10.1158/0008-5472.CAN-16-3424<pub-id pub-id-type="pmid">28522750</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/0008-5472.CAN-16-3424</pub-id><pub-id pub-id-type="pmcid">PMC5503474</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR158"><label>158.</label><citation-alternatives><element-citation id="ec-CR158" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yu</surname><given-names>X</given-names></name><name name-style="western"><surname>Dobrikov</surname><given-names>M</given-names></name><name name-style="western"><surname>Keir</surname><given-names>ST</given-names></name><etal/></person-group><article-title>Synergistic antitumor effects of 9.2.27-PE38KDEL and ABT-737 in primary and metastatic brain tumors</article-title><source>PLoS ONE</source><year>2019</year><volume>14</volume><fpage>e0210608</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0210608</pub-id><pub-id pub-id-type="pmid">30625226</pub-id><pub-id pub-id-type="pmcid">PMC6326518</pub-id></element-citation><mixed-citation id="mc-CR158" publication-type="journal">Yu X, Dobrikov M, Keir ST et al (2019) Synergistic antitumor effects of 9.2.27-PE38KDEL and ABT-737 in primary and metastatic brain tumors. PLoS ONE 14:e0210608. 10.1371/journal.pone.0210608<pub-id pub-id-type="pmid">30625226</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0210608</pub-id><pub-id pub-id-type="pmcid">PMC6326518</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR159"><label>159.</label><citation-alternatives><element-citation id="ec-CR159" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>Y-J</given-names></name><name name-style="western"><surname>Tsang</surname><given-names>T</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>GR</given-names></name><etal/></person-group><article-title>Inhibition of BCL2 family members increases the efficacy of copper chelation in BRAFV600E-driven melanoma</article-title><source>Cancer Res</source><year>2020</year><volume>80</volume><fpage>1387</fpage><lpage>1400</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-19-1784</pub-id><pub-id pub-id-type="pmid">32005716</pub-id><pub-id pub-id-type="pmcid">PMC7127963</pub-id></element-citation><mixed-citation id="mc-CR159" publication-type="journal">Kim Y-J, Tsang T, Anderson GR et al (2020) Inhibition of BCL2 family members increases the efficacy of copper chelation in BRAFV600E-driven melanoma. Cancer Res 80:1387&#8211;1400. 10.1158/0008-5472.CAN-19-1784<pub-id pub-id-type="pmid">32005716</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/0008-5472.CAN-19-1784</pub-id><pub-id pub-id-type="pmcid">PMC7127963</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR160"><label>160.</label><citation-alternatives><element-citation id="ec-CR160" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mukherjee</surname><given-names>N</given-names></name><name name-style="western"><surname>Lu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Almeida</surname><given-names>A</given-names></name><etal/></person-group><article-title>Use of a MCL-1 inhibitor alone to de-bulk melanoma and in combination to kill melanoma initiating cells</article-title><source>Oncotarget</source><year>2017</year><volume>8</volume><fpage>46801</fpage><lpage>46817</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.8695</pub-id><pub-id pub-id-type="pmid">27086916</pub-id><pub-id pub-id-type="pmcid">PMC5564524</pub-id></element-citation><mixed-citation id="mc-CR160" publication-type="journal">Mukherjee N, Lu Y, Almeida A et al (2017) Use of a MCL-1 inhibitor alone to de-bulk melanoma and in combination to kill melanoma initiating cells. Oncotarget 8:46801&#8211;46817. 10.18632/oncotarget.8695<pub-id pub-id-type="pmid">27086916</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.18632/oncotarget.8695</pub-id><pub-id pub-id-type="pmcid">PMC5564524</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR161"><label>161.</label><citation-alternatives><element-citation id="ec-CR161" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mukherjee</surname><given-names>N</given-names></name><name name-style="western"><surname>Skees</surname><given-names>J</given-names></name><name name-style="western"><surname>Todd</surname><given-names>KJ</given-names></name><etal/></person-group><article-title>MCL1 inhibitors S63845/MIK665 plus Navitoclax synergistically kill difficult-to-treat melanoma cells</article-title><source>Cell Death Dis</source><year>2020</year><volume>11</volume><fpage>443</fpage><pub-id pub-id-type="doi">10.1038/s41419-020-2646-2</pub-id><pub-id pub-id-type="pmid">32513939</pub-id><pub-id pub-id-type="pmcid">PMC7280535</pub-id></element-citation><mixed-citation id="mc-CR161" publication-type="journal">Mukherjee N, Skees J, Todd KJ et al (2020) MCL1 inhibitors S63845/MIK665 plus Navitoclax synergistically kill difficult-to-treat melanoma cells. Cell Death Dis 11:443. 10.1038/s41419-020-2646-2<pub-id pub-id-type="pmid">32513939</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41419-020-2646-2</pub-id><pub-id pub-id-type="pmcid">PMC7280535</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR162"><label>162.</label><citation-alternatives><element-citation id="ec-CR162" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Serasinghe</surname><given-names>MN</given-names></name><name name-style="western"><surname>Missert</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Asciolla</surname><given-names>JJ</given-names></name><etal/></person-group><article-title>Anti-apoptotic BCL-2 proteins govern cellular outcome following B-RAFV600E inhibition and can be targeted to reduce resistance</article-title><source>Oncogene</source><year>2015</year><volume>34</volume><fpage>857</fpage><lpage>867</lpage><pub-id pub-id-type="doi">10.1038/onc.2014.21</pub-id><pub-id pub-id-type="pmid">24608435</pub-id><pub-id pub-id-type="pmcid">PMC4160434</pub-id></element-citation><mixed-citation id="mc-CR162" publication-type="journal">Serasinghe MN, Missert DJ, Asciolla JJ et al (2015) Anti-apoptotic BCL-2 proteins govern cellular outcome following B-RAFV600E inhibition and can be targeted to reduce resistance. Oncogene 34:857&#8211;867. 10.1038/onc.2014.21<pub-id pub-id-type="pmid">24608435</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/onc.2014.21</pub-id><pub-id pub-id-type="pmcid">PMC4160434</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR163"><label>163.</label><mixed-citation publication-type="other">Fontana F, Raimondi M, Marzagalli M, et al (2020) The emerging role of paraptosis in tumor cell biology: Perspectives for cancer prevention and therapy with natural compounds. Biochim Biophys Acta Rev Cancer<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bbcan.2020.188338</pub-id><pub-id pub-id-type="pmid">31904399</pub-id></mixed-citation></ref><ref id="CR164"><label>164.</label><citation-alternatives><element-citation id="ec-CR164" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Meng</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Q</given-names></name><name name-style="western"><surname>Dian</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Ferroptosis: a targetable vulnerability for melanoma treatment</article-title><source>J Invest Dermatol</source><year>2025</year><pub-id pub-id-type="doi">10.1016/j.jid.2024.11.007</pub-id><pub-id pub-id-type="pmid">39797894</pub-id></element-citation><mixed-citation id="mc-CR164" publication-type="journal">Meng Y, Zhou Q, Dian Y et al (2025) Ferroptosis: a targetable vulnerability for melanoma treatment. J Invest Dermatol. 10.1016/j.jid.2024.11.007<pub-id pub-id-type="pmid">39797894</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jid.2024.11.007</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR165"><label>165.</label><citation-alternatives><element-citation id="ec-CR165" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Singh</surname><given-names>D</given-names></name></person-group><article-title>Revolutionizing cellular energy: the convergence of mitochondrial dynamics and delivery technologies</article-title><source>Mitochondrion</source><year>2024</year><volume>76</volume><fpage>101873</fpage><pub-id pub-id-type="doi">10.1016/j.mito.2024.101873</pub-id><pub-id pub-id-type="pmid">38503363</pub-id></element-citation><mixed-citation id="mc-CR165" publication-type="journal">Singh D (2024) Revolutionizing cellular energy: the convergence of mitochondrial dynamics and delivery technologies. Mitochondrion 76:101873. 10.1016/j.mito.2024.101873<pub-id pub-id-type="pmid">38503363</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.mito.2024.101873</pub-id></mixed-citation></citation-alternatives></ref></ref-list></back></article></pmc-articleset>